Comprising Volume 25 (2004) - European Heart Journal

PII:S0195-668X(04)00818-8 

Comprising 

Volume 25 (2004) 

and European Heart Journal Supplements 

Volume 6 (2004) 

Downloaded from 

http://eurheartj.oxfordjournals.org/ by guest on December 30, 2012

European Heart Journal (2004) 25, i–xxix 

PII:S0195-668X(04)00818-8 

In the following indexes, numbers preceded by a bold letter refer to page numbers in 

European Heart Journal Supplements, Volume 6 2004 (Suppls A–I). 

A-to-Z Investigators see de Lemos, J.A. 1688 

Aarnoudse, W. see Barbato, E. 219, 2034 

Abashidze, S. see George, J. 1003 

Abdellhadi, R.H., Chung, M.K. and Van Wagoner, D.R. New hope 

for the prevention of recurrent atrial fibrillation 1089 

Abdo, A. see Yousufuddin, M. 377 

Abedini, S. see Sajadieh, A. 363 

Abizaid, A., Costa, M.A., Albertal, M., Blanchard, D., 

Eltchaninoff, H., Guagliumi, G., Geert-Jan, L., Abizaid, 

A.S., Sousa, A.G.M.R., Wuelfert, E., Wietze, L., Sousa, J.E., 

Serruys, P.W. and Morice, M.-C. on behalf of the Ravel 

investigators Sirolimus-eluting stents inhibit neointimal 

hyperplasia in diabetic patients. Insights from the RAVEL 

Trial 107 

Abizaid, A. see Degertekin, M. 32 

Abizaid, A.S. see Abizaid, A. 107 

Abraham, W.T. see Javaheri, S. 260 

Acharya, J. see Dhamrat, S.S. 468 

Achilli, F. see Giannattasio, C. F30 

Adam, M. see Goldenberg, I. 212 

Adams, L. see Rosen, S.D. 952 

Adamson, P.B. see Vanoli, E., F7 

Adgey, J. see Taneja, A.K. 2013 

Adler, Y. see Maisch, 587 

Aegerter, P. see Milleron, O. 728 

Aengevaeren, W.R. see Barbato, E. 219 

Agardh, C.-D. see Gustavsson, C.G. 2120 

Agema, W.R.P., Monraats, P.S., Zwinderman, A.H., de Winter, 

R.J., Tio, R.A., Doevendans, P.A.F.M., Waltenberger, J., de 

Maat, M.P.M., Frants, R.R., Atsma, D.E., van der Laarse, A., 

van der Wall, E.E. and Jukema, J.W. Current PTCA practice 

and clinical outcomes in The Netherlands: the real world in 

the pre-drug-eluting stent era 1163 

Agnoletti, L., Curello, S., Malacarne, F., Airò, P., Cargnoni. A., 

Valgimigli, M. and Ferrari, R. Immune activation in severe 

heart failure. Does etiology pay a role? F22 

Agranat, O. see Goldenberg, I. 212 

Ahl, R. see Friberg, P. 987 

Ahlström, H. see Steuer, J. 1293 

Aicher, F. see Reisinger, J. 1318 

Aiello, V.D. see Soares, A.M. 1927 

Aihara, N. see Noda, T. 2149 

Airò, P.see Agnoletti, L. F22 

Airoldi, F. see Briguori, C. 1822 

Aizawa, T. see Sahara, M. 2026 

Akaishi, M. see Baba, A. 1108 

Akkerhuis, K.M. see Roe, M.T. 313 

Akoudad, H. see Iung, B. 701 

Al-Saadi, N. see Giang, T.H. 1657 

Albanes, D. see Törnwall, M.E. 1171 

Albertal, M. see Abizaid, A. 107 

Alberti, A. see Covolo, L. 1534 

Alboni, P. see Brignole, M. 2054 

Aldama, G. see Arroyo-Espliguero, R. 401 

Alexander, J.H. see Roe, M.T. 313 

Alfonso, F., Melgares, R., Mainar, V., Lezaún, R., Vázquez, N., 

Tascón, J., Pomar, F., Cequier, A., Angel, J., Pérez- 

Vizcayno, M.-J., Sabaté, M., Bañuelos, C., Fernández, C. 

Index of authors 

iii 

and Garcia, J.M., for the Restenosis Intra-stent: Balloon 

angioplasty versus elective Stenting (RIBS) investigators 

Therapeutic implications of in-stent restenosis located at 

the stent edge. Insights from the Restenosis Intra-stent 

Balloon angioplasty versus elective Stenting (RIBS) 

randomized trial 1829 

Alfonso, F. see Angiolillo, D.J. 1903 

Algra, A. see Olijhoek, J.K. 342 

Aliot, E., Moss, A. and Erdman, E. Foreward to Supplement I 

(2003) I1 (2003) 

Aliot, E. see Zannad, F. I105 (2003) 

Allansdotter-Johnsson, A˚. see Friberg, P. 987 

Allikmets, K. see Weber, 623 

Alloni, A. see Rinaldi, M. F81 

Almeria, C. see Zamorano, J. 2086 

Alonso, C. see Cazeau, S. I83 (2003) 

Amado, L.C. see Azevedo, C. 1419 

Amann, W. see Kaiser, C. 1036 

Ambring, A. see Friberg, P. 987 

Amighi, J. see Schillinger, M. 742 

Ammirati, F. see Colivicchi, F. 1749 

Amouyel, P. 

see Imhof, A. 2092 

see Mizon-Gérard, F. 688 

see Ruidavets, J.-B. 1153 

Anand, I. see Latini, R. 292 

Anderson, T.J. see Verma, S. 1754 

Andersson, P., Rydberg, E. and Willenheimer, R. Primary 

hyperparathyroidism and heart disease – a review 1776 

Andrade, J.L. see Soares, A.M. 1927 

André-Fouët, X.see Argaud, L. 2019 

Andrén, B. see Ärnlöv, J. 2220 

Angel, J. see Alfonso, F. 1829 

Angelini, G. see Martin, J. 1568 

Angelini, G.D. 

see Ascione, R. 765 

see Murphy, G.J. 2077 

Angermann, C.E., Störk, S., Costard-Jöckle, A., Dengler, T.J., 

Siebert, U., Tenderich, G., Rahmel, A., Schwarz, E.R., 

Nägele, H., Wagner, F.M., Haaff, B. and Pethig, K. 

Reduction of cyclosporine after introduction of 

mycophenolate mofetil improves chronic renal dysfunction 

in heart transplant recipients – The IMPROVED multi-centre 

study 1626 

Angiolillo, D.J., Fernández-Ortiz, A., Bernardo, E., Ramírez. C., 

Sabaté, M., Bañuelos, C., Hernández-Antolin, R., Escaned, J., 

Moreno, R., Alfonso, F. and Macava, C. High clopidogrel 

loading dose during coronary stenting: effects of drug 

response and interindividual variability 1903 

Anker, S.D. see Sharma, R. 1021 

Antman, E.M. 

see Gibson, C.M. 1001, 1998 

see Kashani, A. 1702 

see Morrow, D.A. 1139 

see Verheugt, F.W.A. B1 

Antman, E.M. The re-emergence of anticoagulation in coronary 

disease B2 

Antolin, R.H. see Zamorano, J. 2086 



Author index 

Antoniades, L. see Basso, C. 531 

Antzelvitch, C. see Belardinelli, L. I3 

Aoki, J. see Serruys, P.W. E2 

Arbeitgemeinschaft Leitende Kardiologische Krankenhausärzte 

(ALKK) 

see Zahn, R. 1550 

see Zeymer, U. 322 

Arbustini, E. 

see Repetto, A. F54 

see Tavazzi, L. F1 

Arbustini, E., Repetto, A., Pasotti, M., Azan, G., Opasich, C., 

Campana, C., Gavazzi, A., Ferrari, R. and Tavazzi, L. 

Cardiomylogy: an attempt to link structural cardiac and 

skeletal muscle damage in patients with dilated 

cardiomyopathy F40 

Argaud, L., Rioufol, G., Lièvre, M., Bontemps, L., Legalery, P., 

Stumpf, M., Finet, G., Itti, R., André-Fouët, X. and Ovize, M. 

Preconditioning during coronary angioplasty: no influence of 

collateral perfusion or the size of the area at risk 2019 

Arheden, H. see Friberg, P. 987 

Armstrong, P. see Ottervanger, J.P. 1494 

Armstrong, P.W. 

see Roe, M.T. 313 

see Velazquez, E.J. 1911 

Ärnlöv, J., Ingelsson, E., Risérus, U., Andrén, B. and Lind, L. 

Myocardial performance index, a Doppler-derived index of 

global left ventricular function, predicts congestive heart 

failure in elderly men 2220 

Arnold, J.M.O.see Gustafsson, F. 1596 

Arntz, H.R. see Priori, S.G. 437 

Arroyo-Espliguero, R., Avanzas, P., Cosín-Sales, J., Aldama, G., 

Pizzi, C. and Kaski, J.C. C-reactive protein elevation and 

disease activity in patients with coronary artery disease 401 

Arveiler, D. see Ruidavets, J.-B. 1153 

Asbury, E.A., Creed, F. and Collins, P. Distinct psychosocial 

differences between women with coronary heart diseases 

and cardiac syndrome X 1695 

Ascione, R., Reeves, B.C., Taylor, F.C., Seehra, H.K. and 

Angelini, G.D. Beating heart against cardioplegic arrest 

studies (BHACAS 1 and 2): quality of life at mid-term followup 

in two randomised controlled trials 765 

Ascione, R. see Murphy, G.J. 2077 

ASSENT-2 and ASSENT-PLUS study groups see Björklund, E. 113 

Assmann, S.F. see Morrow, D.A. 1139 

Atsma, D.E. see Agema, W.R.P. 1163 

Aufdemkampe, G. see Vanhees, L. 1120 

Auriacombe, L. see Ou, P. 1853 

Autschbach, R. see Ortlepp, J.R. 514 

Avanzas, P. see Arroyo-Espliguero, R. 401 

Avanzini, M. see Steger, C. 1734 

Avegliano, G. see Evangelista, A. 81 

Avrikan, M. see Greaves, K. 847 

Aylward, P.E. see Velazquez, E.J. 1911 

Azan, G. see Arbustini, E. F40 

Azevedo, C.F., Amado, L.C., Kraitchman, D.L., Gerber, B.L., 

Osman, N.F., Rochitte, C.E., Edvardson, T. and Lima, J.A.C. 

Persistent diastolic dysfunction despite complete systolic 

functional recovery after reperfused acute myocardial 

infarction demonstrated by tagged magnetic resonance 

imaging 1419 

Baba, A., Yoshikawa, T., Fukada, Y., Sugiyama, T., Shimada, M., 

Akaishi, M., Tsuchimoto, K., Ogawa, S. and Fu, M. 

Autoantobodies against M2-muscarine acetylcholine 

receptor: new upstream targets in atrial fibrillation in 

patients with dilated cardiomyopathy 1108 

Bacchini, S. see Vanoli, E., F7 

Bachetti, T., Comini, L., Pasini, E. and Ferrari, R. Anti-cytokine 

therapy in chronic heart failure: new approaches and unmet 

promises F16 

Bachleitner, T. see Reisinger, J. 1318 

Bachmann, F. see Patrono, C. 166 

iv 

Bacquer, D. see De Backer, G.G. 2183 

Badimon, J.J. see Viles-Gonzalez, J.F. 1197 

Bahit C. see Bazzino, O. 859 

Baigent, C. see Patrono, C. 166 

Bailey, S.R. see Patel, D.N. 1972 

Bakhai, A. see Hill, R.A. 902 

Bakhai, A. see Taneja, A.K. 2013 

Baldin, S. see Capomolla, S. F91 

Balestrieri, P. see Briguori, C. 206, 1822 

Baller, D., Vogt, J., Lindner, O., Lamp, B., Holzinger, J., 

Kammeier, A., Wielepp, P., Burchert, W. and Horstkotte, D. 

Myocardial oxygen consumption and perfusion before and 

after cardiac resynchronisation therapy: experimental 

observations and clinical implications D91 

Balleux, F. see Ou, P. 1853 

Ballo, P., Bernabò, D. and Faraguti, S.A. Heart rate is a predictor 

of success in the treatment of adults with symptomatic 

paroxysmal supraventricular tachycardia 1310 

Balmer, F. see Togni, M. 1208 

Banegas, J.R. see Gonseth, J. 1570 

Banga, J.-D. see Olijhoek, J.K. 342 

Bañuelos, C. 

see Alfonso, F. 1829 

see Angiolillo, D.J. 1903 

Banus, Y. see Gras, D. D98 

Barbato, E., Aarnoudse, W., Aengevaeren, W.R., Werner, G., 

Klauss, V., Bojara, W., Herzfeld, I., Oldroyd, K.G., Pijls, 

N.H.J. and De Bruyne, B. for the ’week 25 study’ group 

Validation of coronary flow reserve measurements by 

thermodilution in clinical practice 219 

Barbato, E., Bartunek, J., Aarnoudse, W., Vanderheyden, M., 

Staelens, F., Wijns, W., Heyndrickx, G.R., Pijls, N.H.J. and 

De Bruyne, B. Alpha-adrenergic receptor blockade and 

hyperaemic response in patients with intermediate coronary 

stenoses 2034 

Barendregt, J. see Mamun, A.A. 409 

Barengo, N.C., Hu, G., Lakka, T.A., Pekkarinen, H., Nissinen, A. 

and Tuomilehto, J. Low physical activity as a predictor for 

total and cardiovascular disease mortality in middle-aged 

men and women in Finland 2204 

Barengo, N.C. see Hu, G. 2212 

Barlera, S. see Latini, R. 292 

Barnathan, E.S. see Ottervanger, J.P. 1494 

Baron, G. see Iung, B. 701 

Barron, H.V. see Morrow, D.A. 1139 

Barst, R. see Galiè, N. 2243 

Barter, P. Is high density lipoprotein the protector of the 

cardiovascular system? A19 

Barter, P. see Colquhoun, D. 771 

Barthel, P. see Simões, M.V. 551 

Bartnik, M., Malmberg, K., Norhammar, A., Tenerz, Ä., Öhrvik, 

J. and Rydén, L. Newly detected abnormal glucose 

tolerance: an important predictor of long-term outcome 

after myocardial infarction 1990 

Bartunek, J. see Barbato, E. 2034 

Bassaert, L.L. see Priori, S.G. 437 

Bassand, J.-P., Tendera, M., Kappenberger, L. and Pinto, F. 

Major changes in the statutes of the European Society of 

Cardiology 804 

Basso, C. see Thiene, G. 1772 

Basso, C., Wichter, T., Danieli, G.A., Corrado, D., Czarnowska, 

E., Fontaine, G., McKenna, W.J., Nava, A., Protonotarios, N., 

Antoniades, L., Wlodarska, K., D’Alessi, F. and Thiene, G. 

Arrhythmogenic right ventricular cardiomyopathy: clinical 

registry and database, evaluation of therapies, pathology 

registry, DNA banking 531 

Bataille, V. see Ruidavets, J.-B. 1153 

Batin, P. see Channer, K.S. 144 

Batnick, M., Rydén, L., Ferrari, R., Malmberg, K., Pyörälä, K., 

Simoons, M., Standl, E., Soler-Soler, J. and Öhrvik, J., on 

behalf of the Euro Heart Survey Investigators The 

prevalence of abnormal glucose regulation in patients with 



coronary artery disease across Europe. The Euro Heart Survey 

on diabetes and the heart 1880 

Battler, A. see Rosengren, A. 663 

Bauer, P. 

see Fetsch, T. 1385 

see Patten, M. 1395 

Bauer, W. see Ertl, G. I44 (2003) 

Baumgartner, H. 

see Mascherbauer, J. 787 

see Rosenhek, R. 199 

Bauters, C. 

see de Groote, P. 656 


Bax, J.J. 

see Steendijk, P. D35 

see Underwood, S.R. 815 

Bazzino, O., Fuselli, J.J., Botto, F., Perez de Arenaza, D., Bahit 

C. and Dadone, J. for the PACS group of investigators Relative 

value of N-terminal probrain natriuretic peptide, TIMI risk 

score, ACC/AHA prognostic classification and other risk 

markers in patients with non-ST-elevation acute coronary 

syndromes 859 

Becherini, F. see Mariotti, R. F87 

Beckers, P. see Conraads, V.M. 1797 

Beer, J.-C. see Zeller, M. 308 

Behar, S. see Rosengren, A. 663 

Belardinelli, L., Antzelvitch, C. and Fraser, H. Inhibition of 

late (sustained/persistent) sodium current: apotential drug 

target to reduce intracellular sodium-dependent calcium 

overload and its detrimental effects on cardiomyocyte 

function I3 

Bella, P.D., Riva, S., Fassini, G., Giraldi, F., Berti, M., Klersy, C. 

and Trevisi, N. Incidence and significance of pleomorphism in 

patients with postmyocardial infarction ventricular 

tachycardia. Acute and long-term outcome of 

radiofrequency catheter ablation 1127 

Belletti, S. see Lombardi, F. 1242 

Bellows, W.H. see Leung, J.M. 1836 

Ben-Haim, S. see Stix, G. 650 

Benditt, D.G. see Brignole, M. 2054 

Bengel, F.M. see Simões, M.V. 551 

Bengel, F.M., Ueberfuhr, P., Karja, J., Schreiber, K., Nekolla, 

S.G., Reichart, B. and Schwaiger, M. Sympathetic 

reinnervation, exercise performance and effects of ßadrenergic 

blockade in cardiac transplant recipients 1726 

Bengtsson, B. see Kragelund, C. 1891 

Benjamin, E.J. see Sundström, J. 523, 1509 

Bennet, A.M. see Edfeldt, 1447 

Benzer, W. see Gyöngyösi, M. 2125 

Berdeaux, A.iseei Monnet, X. 579 

Berger, J. see Rössig, L. 1620 

Berger, R. see Nuhr, M.J. 136 

Bergfeldt, L. see Brignole, M. 2054 

Berglund, G. see Öhlin, B. 867 

Berman, D.S. see Zellweger, M.J. 543 

Bernabò, D. see Ballo, P. 1310 

Bernardo, E. see Angiolillo, D.J. 1903 

Berti, M. see Bella, P.D. 1127 

Bertoletti, A. see Repetto, A. F54 

Betteridge, D.J. see Erhardt, L. G1 

Betteridge, D.J. The interplay of cardiovascular risk factors in 

the metabolic syndrome and type 2 diabetes G3 

Betteridge, D.J. Treating dyslipidaemia in the patient with type 

2 diabetes C28 

Bewton-Cheh, C. see Kathiresan, S. 1378 

Biamino, G. see Scheinert, D. 694 

Bianchi, S. see Puglisi, A. 1063 

Bierhuizen, M.F.A. see Teunissen, B.E.J. 1979 

Bigi, R., Cortigiani, L., Gregori, D., De Chiara, B. and Fiorentini, 

C. Exercise versus recovery electrocardiography in predicting 

mortality in patients with uncomplicated myocardial 

infarction 558 

v 

Author index 

Bijnens, B. 

see Breithardt, O.A. D16 

see Goodman, N. 1382 

see Turschner, O. 794 

Bilheimer, D.W. see de Lemos, J.A. 1688 

Billinger, M., Meier, B. and Hess, O.M. Prevention of contrastindiced 

renal dysfunction by N-acetylcysteine. Truth ot 

Myth? 188 

Billinger, M., Raeber, L., Seiler, C., Windecker, S., Neier, B. and 

Hess, O.M. Coronary collateral perfusion in patients with 

coronary artery disease: effect of metoprolol 565 

Billinger, M. see Torti, S.R. 1014 

Binder, T. see Rosenhek, R. 199 

Bingham, A. see Ruidavets, J.-B. 1153 

Birchall, A. see Channer, K.S. 144 

Bjerner, T. see Steuer, J. 1293 

Björklund, E., Lindahl, B., Johanson, P., Jernberg, T., Svensson, 

A.-M., Venge, P., Wallentin, L. and Dellborg, M., the ASSENT- 

2 and ASSENT-PLUS study groups Admission Troponin T and 

measurement of ST-segment resolution at 60 min improves 

early risk stratification in ST-elevation myocardial infarction 

113 

Bjornholt, J.V. see Erikssen, G. 978 

Blanc, J.-J. see Brignole, M. 2054 

Blanchard, D. see Abizaid, A. 107 

Blann, A.D. see Makin, A.J. 371 

Blazing, M.A. see de Lemos, J.A. 1688 

Bleasdale, R.A. see Steendijk, P. D35 

Bleumink, G.S., Knetsch, A.M., Sturkenboom, M.C.J.M., Straus, 

S.M.J.M., Hofman, A., Deckers, J.W., Witteman, J.C.M. and 

Stricker, B.H.Ch. Quantifying the heart failure epidemic: 

prevalence, incidence rate, lifetime risk and prognosis of 

heart failure. The Rotterdam Study 1614 

Bleumink, G.S. see Schut, A.F.C. 2143 

Blindt, R. see Vogt, F. 1330 

Blot, S. see Chetboul, V. 1934 

Blue, L. see Nielsen, O.W. 1718 

Blumenfeld, A. see Pollak, A. 240 

Böcker, D. see Stix, G. 650 

Boczor, S. see Cappato, R. 642 

Bode, C. 

see Brunner, M. 88 

see Patrono, C. 166 

see Tschöpe, D. 1969 

Bode, C. Recent trials in atrial fibrillation: lessons learned 

beyond rate and thythm B15 

Bodegard, J. see Erikssen, G. 978 

Boden, W.E. see Elkoustaf, R.A. 1559 

Boehm, B.O. see März, W. 2109 

Boehmer, J.P. CRT only or CRT plus ICD? D83 

Boersma, E. 

see Lenzen, M.J. 1214 

see Ottervanger, J.P. 1494 

see van’t Hof, A.W.J. 837 

Bogdan, see Voigt, J.-U. 1517 

Bogers, A.J.J.C. 

see Roos-Hesselink, J.W. 1057, 1264 

see van Rijen, E.H.M. 1605 

Böhm, M., Kilter, H. and Kindermann, M. Mechanisms 

contributing to the progression of left ventricular 

dysfunction to end-stage heart failure I14 (2003) 

Bojara, W. see Barbato, E. 219 

Boland, B. and Goderis, G. Statins in patients at high risk of 

cardiovascular disease presenting with peripheral artery 

disease 712 

Bonhoeffer, P. see Martin, J. 1568 

Bonizzoni, E. see Briguori, C. 206, 1822 

Bonner, G. see Gyöngyösi, M. 2125 

Bonnet, D. 

see Ou, P. 1853 

see Villain, E. 1405 

Bonneux, L. see Mamun, A.A. 409 



Author index 

Bonser, R. see Pitt, M. 500 

Bontemps, L. see Argaud, L. 2019 

Bonzel, T. see Zeymer, U. 322 

Bordachar, P., Reuter, S., Garrique, S., Caï, X., Hocini, M., Jaïs, 

P., Haïssaguerre, M. and Clementy, J. Incidence, clinical 

implications and prognosis of atrial arrhythmias in Brugada 

syndrome 879 

Borggrefe, M. see Stix, G. 650 

Boriani, G. see Leone, O. 1237 

Bos, E. see Roos-Hesselink, J.W. 1264 

Bosch, J. see Östergren, J. 17 

Boscheri, A. see Braun, M. 424 

Bosker, H.A. see Hagens, V.E. 1542 

Bosserhoff, A.-K. see Vogt, F. 1330 

Botto, F. see Bazzino, O. 859 

Bottoni, N. see Solano, A. 1116 

Brady, W.E. see de Lemos, J.A. 1688 

Brandt, R.R., Sperzel, J., Pitschner, H.F. and Hamm, C.W. 

Echocardiographic assessment of mitral regurgitation in 

patients with heart failure D25 

Braschi, A. see Mojoli, E. F74 

Braun, M., Gliech, V., Boscheri, A., Schoen, S., Gahn, G., 

Reichmann, H., Haass, M., Schraeder, R. and Strasser, R.H. 

Transcatheter closure of patent foramen ovale (PFO) in 

patients with paradoxical embolism. Periprocedural safety 

and mid-term follow-up results of three diffferent device 

occluder systems 424 

Braund, P.S. see Tobin, M.D. 459 

Bräunlich, S. see Scheinert, D. 694 

Braunwald, E. 

see de Lemos, J.A. 1688 

see Gibson, C.M. 1998 

see Givertz, M.M. 281 



Breithardt, G. 


see Rydén, 611 

see Vahlhaus, C. 151 

Breithardt, O.A., Claus, P. and Sutherland, G.R. Do we 

understand who benefits from resynchronisation therapy? 535 

Breithardt, O.A., Herbots, L., D’Hooge, J., Claus, P., Bijnens, 

B., Stellbrink, C., Franke, A. and Sutherland, G.R. Strain 

rate imaging in CRT candidates D16 

Breithardt, O.A. see Stellbrink, C. D43, D101 

Brendberg, R. see Troseid, M. 349 

Brenner, H. see Twardella, D. 2101 

Brett, W. see Kaiser, C. 1036 

Breuer, S. see Fichtlscherer, S. 1412 

Brignole, M. 

see Raviele, A. 1741 

see Solano, A. 1116 

Brignole, M., Alboni, P., Benditt, D.G., Bergfeldt, L., Blanc, J.- 

J., Thomsen, P.E.B., van Dijk, J.G., Fitzpatrick, A., 

Hohnloser, S., Janousek, J., Kapoor, W., Kenny, R.A., 

Kulakowski, P., Masotti, G., Moya, A., Raviele, A., Sutton, 

R., Theodorakis, G., Ungar, A., Wieling, W. Guidelines on 

Management (Diagnosis and Treatment) of syncope – 

Update 2004 2054 

Briguori, C., Colombo, A., Airoldi, F., Violante, A., Focaccio, A., 

Balestrieri, P., Elia, P.P., Golia, B., Lepore, S., Riviezzo, G., 

Scarpato, P., Librera, M., Bonizzoni, E. and Ricciardelli, B. 

Statin administration before percutaneous coronary 

intervention: impact on periprocedural myocardial 


Briguori, C., Colombo, A., Violante, A., Balestrieri, P., 

Manganelli, F., Elia, P.P., Golia, B., Lepore, S., Riviezzo, 

G., Scarpato, P., Focaccio, A., Librera, M., Bonizzoni, E. 

and Ricciardelli, B. Standard vs double dose of Nacetylcysteine 

to prevent contrast agent associated 

nephrotoxicity 206 

Brindisi, M.-C. see Zeller, M. 308 

vi 

Brochet, E. see Iung, B. 701 

Brooksby, W.P. see Channer, K.S. 144 

Brown, C. see Javaheri, S. 260 

Brown, W.V. Managing dyslipidaemia – multiple patients and 

mltiple approaches: metabolic syndrome, familial 

hypercholesterolaemia and hypertension A23 

Brucker, L. see Steg, P.G. 2187 

Brugada, P. see Rivero-Ayerza, M. I97 (2003) 

Brunel, P. see Gras, D. D98 

Brunner, M., Olschewski, M., Geibel, A., Bode, C. and Zehender, 

M. Long-term survival after pacemaker implantation. 

Prognostic importance of gender and baseline patient 

characteristics 88 

Bruns, H.-J. see Vahlhaus, C. 151 

Bruyne, B. see Barbato, E. 219 

Buch, P. see Gustafsson, F. 129 

Bucher, H.C. see Nordmann, A.J. 69 

Budts, W. see Post, M.C. 1651 

Bugiardini, R. see Manfrini, O. 1502 

Buithieu, J. see Verma, S. 1754 

Buller, C.E. see Segev, A. 1029 

Bundkirchen, A. and Schwinger, R.H.G. Epidemiology and 

economic burden of chronic heart failure D57 

Bunt, T. see van’t Hof, A.W.J. 837 

Burchardt, H. see Gustafsson, F. 129, 1711 

Burchert, W. see Baller, D. D91 

Burkhoff, D. see Stix, G. 650 

Burton, P.R. see Tobin, M.D. 459 

Buschler, H. see Vogt, J. D47 

Buser, P. see Kaiser, C. 1036 

Buser, T. see Claude, J. 2195 

Butter, C., Winbeck, G., Schlegl. M., Seifert, M., Wagner, A., 

Wellnhofer, E. and Fleck, E. Management of atrial 

fibrillation in cardiac resynchronisation therapy. Clinical 

practice of CRT: how to improve the success rate D106 

Büttner, H.J. and Neumann, F.-J. Tirofban for catheter 

intervention in acute myocardial infarction? 807 

Cagatay, M. see Hanefield, M. 10 

Caï, X.see Bordachar, P. 879 

Califf, R.M. 




Calverley, P.M.A. see Coughlin, S.R. 735 

Camici, P. see Pitt, M. 500 

Camici, P.G. see Rosen, S.D. 952 

Camm, A.J. Heart failure and sudden death: future use of 

antiarrhythmic drugs and devices I108 (2003) 

Camm, A.J.see Katritsis, D.G. 1093 

Campana, C. 

see Arbustini, E. F40 

see Ghio, S. 571, F35 

see Mojoli, E. F74 


Campana, C., Pasotti, M., Monti, L., Revera, M., Serio, A., 

Nespoli, L., Magrini, G., Scelsi, L., Ghio, S. and Tavazzi, L. 

The evaluation of right ventricular performance in different 

clinical models of heart failure F61 

can den Beld, J. see Vanhees, L. 1120 

Canadian Acute Coronary Syndrome (ACS) Registry Investigators 

see Yan, A.T. 2006 

Candelli, M. see Gabrielli, M. 64 

Cannon, C.P. 



Cannon, C.P. Revascularisation for everyone? 1471 

Capomolla, S., Pinna, G.D., La Rovere, M.T., Maestri, R., 

Ceresa, M., Ferrari, M., Febo, O., Caporotondi, A., 

Guazzotti, G., Lenta, F., Baldin, S., Mortara, A. and Cobelli, 

F. Heart failure case disease management program: a pilot 

study of home telemonitoring versus usual care F91 



Caporotondi, A. see Capomolla, S. F91 

Cappato, R., Boczor, S. and Kuck, K.-H. on behalf of the CASH 

investigators Response to programmed ventricular 

stimulation and clinical outcome in cardiac arrest survivors 

receiving randomised assignment to implantable 

cardioverter defibrillator or antiarrhythmic drug therapy 642 

Capra, A. see Giannattasio, C. F30 

Capucci, A. see Priori, S.G. 437 

Carayon, A. 

see Gackowski, A. 1788 

see Lim, P. 2048 

Cargnoni. A. see Agnoletti, L. F22 

Carlsen, J. see Kragelund, C. 1891 

Carrié, D.see Steg, P.G. 2187 

CASH investigators see Cappato, R. 642 

Caslake, M. see Chapman, M.J. A43 

Casscells, S.W. see Schaar, J.A. 1077 

Castell, J. see Cortadellas, J. 224 

Castrogiovanni, F. see Mariotti, R. F87 

Cazaux, P. see Steg, P.G. 2187 

Cazeau, S., Ritter, P., Jauvert, G., Alonso, C. and Lazarus, A. 

Cardiac resynchronisation therapy: technical issues I83 (2003) 

Cebron, J.P. see Gras, D. D98 

Celutkiene, J., Sutherland, G.R., Laucevicius, A., Zakarkaite, 

D., Rudys, A. and Grabauskiene, V. Is post-systolic motion 

the optimal ultrasound parameter to detect induced 

ischaemia during dobutamine stress echocardiography? 932 

Cenacchi, G. see Leone, O. 1237 

Cequier, A. see Alfonso, F. 1829 

Ceresa, M. see Capomolla, S. F91 

Chamberlain, D.A. see Priori, S.G. 437 

Champagne, S. see Steg, P.G. 2187 

Channer, K. see Tobin, M.D. 459 

Channer, K.S., Birchall, A., Steeds, R.P., Walters, S.J., Yeo, 

W.W., West, J.N., Muthusamy, R., Rhoden, W.E., Saeed, 

B.T., Batin, P., Brooksby, W.P., Wilson, I. and Grant, S. A 

randomized placebo-controlled trial of pre-treatment and 

short- or long-term maintenance therapy with amiodarone 

supporting DC cardioversion for persistent atrial fibrillation 

144 

Channon, K.M. and Watkins, H. Coronary artery disease 

genetics: bigger is better 900 

Chapman, M.J. and Caslake, M. Non-high-density lipoprotein 

cholesterol as a risk factor – addressing risk associated with 

alipoprotein B-containing lipoproteins A43 

Chapman, M.J. Are the effects of statins on HDL-cholesterol 

clinically relevant? C58 

Charbonneau, F. see Verma, S. 1754 

Charbonnier, B. see Patrono, C. 166 

Chastang, C. see Steg, P.G. 2187 

Chau, L.-Y. see Chen, Y.-H. 39 

Chen, J.-W. see Chen, Y.H. 39 

Chen, L.-C. see Chen, Y.-H. 39 

Chen, Y.-H., Chau, L.-Y., Lin, M.-W., Chen, L.-C., Yo, M.-H., 

Chen, J.-W. and Lin, S.J. Heme oxygenase-1 gene promoter 

microsatellite polymorphism is associated with angiographic 

restenosis after coronary stenting 39 

Cheng, S. see Tobin, M.D. 459 

Chester, A.H. see Mikhail, G.W. 431 

Chetboul, V., Escriou, C., Tessier, D., Richard, V., Pouchelon, 

J.-L., Thibault, H., Lallemand, F., Thuillez, C., Blot, S. and 

Derumeaux, G. Tissue Doppler imaging detects early 

asymptomatic myocardial abnormalities in a dog model of 

Duchenne’s cardiomyopathy 1934 

Cheung, M.M.H., Smallhorn, J.F., Redington, A.N. and Vogel, M. 

The effects of changes in loading conditions and modulation 

of inotropic state on the myocardial performance index: 

comparison with conductance catheter measurements 2238 

Chevret, S. see Steg, P.G. 2187 

Chiappini, B. see Leone, O. 1237 

Chlouverakis, G.I. see Simantirakis, E.N. 1070 

Chow, C.-M. see Yan, A.T. 2006 

vii 

Author index 

Christ, T. see Dobrev, D. 1091 

Christodoulou, G. see Panagiotakos, D.B. 492 

Chrysohoou, C. see Panagiotakos, D.B. 492 

Chrysostomakis, S.I. see Simantirakis, E.N. 1070 

Chung, M.K. see Abdellhadi, R.H. 1089 

Chung, N.A.Y. see Makin, A.J. 371 

Cicconi, V. see Gabrielli, M. 64 

Claude, J., Schindler, C., Kuster, G.M., Schwenkglenks, M., 

Szucs, T., Buser, T., Osswald, S., Kaiser, C., Grädel, C., 

Estlinbaum, W., Rickenbacher, P., Pfisterer, M., for the 

Trial of Invasive versus Medical therapy in the Elderly 

(TIME) Investigators Cost-effectiveness of invasive versus 

medical management of elderly patients with chronic angina 

(TIME) 2195 

Claudi, T. see Troseid, M. 349 

Claus, P. 

see Breithardt, O.A. 535, D16 


Clayton, T.C., Pocock, S.J., Henderson, R.A., Poole-Wilson, 

P.A., Shaw, T.R.D., Knight, R. and Fox, K.A.A. Do men 

benefit more than women from an interventional strategy in 

patients with unstable angina or non-ST-elevation 

myocardial infarction? The impact of gender on the RITA 2 

trial 1641 

Cleland, J. see Lenzen, M.J. 1214 

Clementy, J. 

see Bordachar, P. 879 

see Scavée, C. 963 

Coats, A.J.S. 

see Rosen, S.D. 952 

see Scott, A.C. 1806 

see Sharma, R. 1021 

Cobbe, S. Electrophysiological perspectibes – what has 

ranolazine taught us? I9 

Cobelli, F. see Capomolla, S. F91 

Coccheri, S. see Serneri, G.G.N. 1845 

Cohen, A. see Steg, P.G. 2187 

Cohen, E.A. see Segev, A. 1029 

Cohen, M. Progress with diabetic patients undergoing 

percutaneous coronary intervention 99 

Cohn, J.N. see Latini, R. 292 

Coisne, D. see Steg, P.G. 2187 

Cokkinos, D. see De Bacquer, D. 121 

Colagiuri, S. The prevalence of abnormal glucose regulation in 

patients with coronary artery disease across Europe 1861 

Colella, A. see Padeletti, L. D79 

Colin, P. see Monnet, X. 579 

Colivicchi, F., Ammirati, F. and Santini, M. Epidemiology and 

prognostic implications of syncope in young competing 

athletes 1749 

Collins, P. see Asbury, E.A. 1695 

Collinson, J. see Taneja, A.K. 2013 

Colombo, A. 

see Briguori, C. 206, 1822 

see Schaar, J.A. 1077 

see Toutouzas, K. 1679 

Colombo, A. and Iakovoub, I. Drug-eluting stents: the new 

gold standard for percutaneous coronary revascularisation 

895 

Colombo, F. see Lombardi, F. 1242 

Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, J., 

Glasziou, P., White, H., Barter, P. and Tonkin, A. for the 

LIPID Study Investigators Effects of pravastatin on coronary 

events in 2073 patients with low levels of both low-density 

lipoprotein cholesterol and high density lipoprotein 

cholesterol: results from the LIPID study 771 

Colucci, W.S. see Sundström, J. 1509 

Comini, L. see Bachetti, T. F16 

Committees and the Investigators of the Drug Evaluation in 

Atherosclerotic Vascular Disease in Diabetics (DAVID) Study 

Group see Serneri, G.G.N. 1845 

Connelly, P.W. see Segev, A. 1029 



Author index 

Conraads, V.M., Beckers, P., Vaes, J., Martin, M., Van Hoof, V., 

De Maeyer, C., Possemiers, N., Wuyts, F.L. and Vrints, C.J. 

Combined endurance/resistance training reduces NT-proBNP 

levels in patients with chronic heart failure 1797 

Constantin, C. see Ghio, S. 571 

Cook, D.J. see Yousufuddin, M. 377 

Cooper, J.A. see Dhamrat, S.S. 468 

Cooper, J.S. see Ottervanger, J.P. 1494 

Cordeiro, P. see Zamorano, J. 2086 

Cormier, B. see Iung, B. 701 

Cornelussen, R.N. see Pescher, M. D61 

Corrado, D 

see Thiene, G. 1772 

Corrado, D. 

see Basso, C. 531 

Corsi, D. see Giannattasio, C. F30 

Cortadellas, J., Figueras, J., Missorici, M., Domingo, E., Rodés, 

J., Castell, J. and Soler-Soler, J. ST segment elevation at 72 

hours in patients with a first anterior myocardial infarction 

best correlates with pre-discharge and 1-year regional 

contractility and ventricular dilatation 224 

Cortese, B. see Mariotti, R. F87 

Cortigiani, L. see Bigi, R. 558 

Cosín-Sales, J. see Arroyo-Espliguero, R. 401 

Costa, M.A. see Abizaid, A. 107 

Costard-Jöckle, A. see Angermann, C.E. 1626 

Cottin, Y. see Zeller, M. 308 

Coughlin, S.R., Mawdsley, L., Mugarza, J.A., Calverley, P.M.A. 

and Wilding, J.P.H. Obstructive sleep apnoea is 

independently associated with an increased prevalence of 

metabolic syndrome 735 

Coulden, R. see Giang, T.H. 1657 

Covolo, L., Gelatti, U., Metra, M., Nodari, S., Piccichè, A., 

Pezzali, N., Zani, C., Alberti, A., Donato, F., Nardi, G. and 

Dei Cas, L. Role of ß1- and ß2-adrenoceptor polymorphisms 

in heart failure: a case-control study 1534 

Cowburn, P. see Nielsen, O.W. 1718 

Cracowski, J.-L. and Ormezzano, O. isoprostanes, emerging 

biomarkers and potential mediators in cardiovascular 

diseases 1675 

Creed, F. see Asbury, E.A. 1695 

Cremonini, F. see Gabrielli, M. 64 

Crevenna, R. see Nuhr, M.J. 136 

Crijns, H.J.G.M. see Hagens, V.E. 1542 

Croci, F. see Solano, A. 1116 

Cunningham, V. see Rosen, S.D. 952 

Curello, S. see Agnoletti, L. F22 

Czarnowska, E. see Basso, C. 531 

Czerny, M. see Mascherbauer, J. 787 

Dadone, J. see Bazzino, O. 859 

Dagenais, G. see Östergren, J. 17 

D’Agostino, R.B. see Sundström, J. 523 

Dahlöf, B. Implications of recent end-point trials on future 

management of hypertension and dyslipidaemia G13 

D’Alessi, F. see Basso, C. 531 

Dallongeville, J. 


see Ruidavets, J.-B. 1153 

Dama˚s, J.K. see Troseid, M. 349 

Dambrink, J.-H.E. 

see De Luca, G. 1009 

see Elsman, P. 854 


Danesh, J. 

see Lowe, G.D.O. 252 

see Wheeler, J.G. 1287 

Daniel, W. see Voigt, J.-U. 1517 

Danieli, G.A. see Basso, C. 531 

Danisa, K. see Östergren, J. 17 

Dargie, H. 

see Nielsen, O.W. 1718 

viii 

Dargie, H. see Mortara, A. F99 

Dargle, H. 

see Lópex-Sendón, J. 1341, 1454 

Dartevelle, P. see Galiè, N. 2243 

Davies, L.C. see Scott, A.C. 1806 

Davos, C.H. see Scott, A.C. 1806 

de Arenaza, D.P. see Taneja, A.K. 2013 

De Backer, G. see De Bacquer, D. 121 

De Backer, G.G. and Bacquer, D. Be physically active: the best 

buy in promoting heart health 2183 

De Backer, T. see Rivero-Ayerza, M. I97 (2003) 

De Bacquer, D., De Backer, G., Cokkinos, D., Keil, U., Montaye, 

M., Östör, E., Pyörälä, K. and Sans, S., for the EUROASPIRE II 

study group Overweight and obesity in patients with 

established coronary heart disease: Are we meeting the 

challenge? 121 

de Boer, M.-J. 



see Timmer, J.R. 926 


De Bruyne, B. see Barbato, E. 2034 

de Buyzere, M.L. see Gillebert, T.C. 2185 

De Caterina, R. see Patrono, C. 166 

De Chiara, B. see Bigi, R. 558 

de Faire, U. see Edfeldt, 1447 

de Feyter, P.J. see Degertekin, M. 32 

de Groote, P., Lamblin, N., Mouquet, F., Plichon, D., McFadden, 

E., Van Belle, E. and Bauters, C. Impact of diabetes mellitus 

on long-term survival in patients with congestive heart 

failure 656 

de Groote, P. see Mizon-Gérard, F. 688 

de Lemos, J.A., Blazing, M.A., Wiviott, S.D., Brady, W.E., 

White, H.D., Fox, K.A.A., Palmisano, K.E., Ramsey, D.W., 

Bilheimer, D.W., Lewis, E.F., Pfeffer, M., Califf, R.M. and 

Braunwald, E. for the A to Z investigators Enoxaparin versus 

unfractionated heparin in patients treated with tirofiban, 

aspirin and an early conservative initial management 

strategy: results from the A phase of the A-to-Z trial 1688 

de Lemos, J.A. see Gibson, C.M. 1001 

De Luca, G., van’t Hof, A.W.J., de Boer, M.-J., Ottervanger, 

J.P., Hoorntje, J.C.A., Gosselink, A.T.M., Dambrink, J.- 

H.E., Zijlstra, F. and Suryapranata, H. Time-to-treatment 

significantly affects the extent of ST-segment resolution and 

myocardial blush in patients with acute myocardial 

infarction treated by primary angioplasty 1009 

de Maat, M.P.M. see Agema, W.R.P. 1163 

De Maeyer, C. see Conraads, V.M. 1797 

De Meyer, G.R.Y. see Verheye, S. 158 

De Ponti, R. see Tritto, M. 2155 

de Roquefeuil, F. see Milleron, O. 728 

De Scheerder, I. see Turschner, O. 794 

De Sutter, J. see Gillebert, T.C. 2185 

de Winter, R. see van’t Hof, A.W.J. 837 

de Winter, R.J. see Agema, W.R.P. 1163 

de Zutter, M. see Rivero-Ayerza, M. I97 (2003) 

Deanfield, J.E. see Derrick, G. 1863 

Deckers, J.W. 

see Bleumink, G.S. 1614 

see Schut, A.F.C. 2143 

DECOPI investigators see Steg, P.G. 2187 

Deedwania, P.C., Gottlieb, S., Ghali, J.K., Waagstein, F. and 

Wikstrand, J.C.M. for the MERIT-HT Study Group Efficacy, 

safety and tolerability of ß-adrenergic blockade with 

metroprolol CR/XL in elderly patients with heart failure 1300 

Defoor, J. see Vanhees, L. 1120 

Degertekin, M., Lemos, P.A., Lee, C.H., Tanabe, K., Sousa, J.E., 

Abizaid, A., Regar, E., Sianos, G., van der Giessen, W.J., de 

Feyter, P.J., Wuelfert, E., Popma, J.J. and Serruys, P.W. 

Intravascular ultrasound evaluation after sirolimus eluting 

stent implantation for de novo and in-stent restenosis 

lesions 32 



Dei Cas, L. see Covolo, L. 1534 

Deinum, J. see Schut, A.F.C. 2143 

Deisenhofer, I. see Zrenner, B. 2226 

D’Eliseo, A. see Martuscelli, E. 1043 

Dellborg, M. see Björklund, E. 113 

Dengler, T.J. see Angermann, C.E. 1626 

Denjoy, I. see Villain, E. 1405 

Dentan, G. see Zeller, M. 308 

Dernellis, J. and Panaretou, M. Relationship betweem Creactive 

protein concentrations during glucocorticoid 

therapy and recurrent atrial fibrillation 1100 

Derrick, G. and Deanfield, J.E. Decline in ventricular function 

and clinical condition after Mustard repair 1863 

Derumeaux, G. see Chetboul, V. 1934 

Derumeaux, G.A. Assessment of reperfusion-induced myocardial 

injury by echocardiography 714 

Deutsch, V. see George, J. 1003 

Dhamrat, S.S., Stephens, J.W., Cooper, J.A., Acharya, J., Mani, 

A,.R., Moore, K., Miller, G.J., Humphries, S.E., Hurel, S.J. 

and Montgomery, H.E. Cardiovascular risk in healthy men 

and markers of oxidative stress in diabetic men are 

associated with common variation in the gene for 

uncoupling protein 2 468 

D’Hooge, J. 



Di Matteo, A. see Ghio, S. F35 

DIAMOND study group see Gustafsson, F. 129, 1711 

Diaz, R. see Velazquez, E.J. 1911 

Dickson, R. see Hill, R.A. 902 

Dickstein, K. 

see Larsen, A.I. 104, 1284 

see Pocock, S. 1974 

Dickstein, K. Appearances can deceive: even brave hearts can 

fail 1181 

Dieta, R. Current implementation of proven therapy in heart 

failure H43 

Dimmeler, S. 

see Fichtlscherer, S. 1412 

see Rössig, L. 1620 

Dirksen, M.T., Laarman, G., van’t Hof, A.W.J., Guagliumi, G., 

Tonino, W.A.L., Tavazzi, L., Duncker, D.J.G.M. and 

Simoons, M.L. on behalf of the PARI-MI investigators 

(Protect Against Reperfusion Injury with ITF-1697 in acute 

myocardial infarction) The effect of ITF-1697 on reperfusion 

in patients undergoing primary angioplasty. Safety and 

efficacy of a novel tetrapeptide, ITF-1697 392 

Dixon, S.R. see Greaves, K. 847 

Dluzniewski, M. see Patten, M. 1395 

Dobrev, D., Christ, T. and Ravens, U. Muscarine subtype-2 

receptor autoantibodies: actors or bystanders in human 

atrial fibrillation 1091 

Doering, A. see Imhof, A. 2092 

Doevendans, P.A. see Stella, P.R. 898 

Doevendans, P.A.F.M. see Agema, W.R.P. 1163 

Domanovits, H. see Gyöngyösi, M. 2125 

Domingo, E. see Cortadellas, J. 224 

Dominguez, R. see Evangelista, A. 81 

Dommke, C. see Turschner, O. 794 

Donateo, P. see Solano, A. 1116 

Donato, F. see Covolo, L. 1534 

Dong, J. see Zrenner, B. 2226 

Dresner Pollak, R. see Pollak, A. 240 

Dronskowski, R. see Ortlepp, J.R. 514 

Duboc, D. see van Berio, J.H. 812 

Dubourg, O. see Milleron, O. 728 

Ducimetière, P. see Ruidavets, J.-B. 1153 

Dumaine, R.L. see Gibson, C.M. 1998 

Duncker, D.J.G.M. see Dirksen, M.T. 392 

Dundar, Y. see Hill, R.A. 902 

Duprez, D. HOPE brings hope for the use of the ankle-brachial 

index as cardiovascular risk marker 1 

ix 

Durand-Zaleski, I. see Steg, P.G. 2187 

Dutka, D. see Pitt, M. 500 

Duvernoy, O. see Steuer, J. 1293 

Dzau, V.J. 

see Melo, L.G. E24 

see Ylä-Herttuala, S. E1 

Author index 

Ebrahim, S. see Emberson, J. 484 

Edfeldt, K., Bennet, A.M., Eriksson, P., Frostega˚rd, J., Wiman, 

B., Hamsten, A., Hansson, G.K., de Faire, U. and Yan, Z.-Q. 

Association of hypo-responsive toll-like receptor 4 variants 

with risk of myocardial infarction 1447 

Edvardson, T. see Azevedo, C. 1419 

Edworthy, S. see Verma, S. 1754 

Eisserer, G. see Reisinger, J. 1318 

Elia, P.P. 

see Briguori, C. 206, 1822 

Elian, D. see Goldenberg, I. 212 

Elkoustaf, R.A. and Boden, W.E. Is there a gender paradox in the 

early invasive strategy for non ST-segment elevation acute 

coronary syndromes? 1559 

Ellery, S.M. and Paul, V.E. Complications of biventricular pacing 

D117 

Elsman, P. see Stella, P.R. 898 

Elsman, P., van’t Hof, A.W.J., de Boer, M.J., Hoorntje, J.C.A., 

Suryapranata, H., Dambrink, J.H.E. and Zijlstra, F. on behalf 

of of the Zwolle Myocardial Infarction Study Group Role of 

collateral circulation in the acute phase of ST-segmentelevation 

myocardial infarction treated with primary 

coronary intervention 854 

Eltchaninoff, H. see Abizaid, A. 107 

Emberson, J., Whincup, P., Morris, R., Walker, M. and Ebrahim, 

S. Evaluating the impact of population and high-risk strategies 

for the primary prevention of cardiovascular disease 484 

Emdin, M., Marini, C., Passino, C., Giuggioli, D., Formichi, B., 

Ferri, C., Khabirinejad, J., Poletti, R., Prontera, C., Iervasi, 

A. and L’Abbate, A. Right ventricular overload and 

cardiovascular neuroendocrine derangement in systemic 

sclerosis F68 

Engberding, R. see Fetsch, T. 1385 

Erbel, R. see Maisch, 587 

Erdman, E. see Aliot, E. I1 (2003) 

Erdmann, E. Pharmacotherapy for chronic heart failure: when to 

use which drug and at what dose? I64 (2003) 

Erhardt, L. and Betteridge, D.J. Editorial G1 

Erhardt, L. see Herlitz, J. 232 

Erikssen, G., Bodegard, J., Bj¢rnholt, J.V., Liest¢l, K., Thelle, 

D.S. and Erikssen, J. Exercise capacity of healthy men in a 

new perspective: from diagnosis to prognosis 978 

Erikssen, J. see Erikssen, G. 978 

Eriksson, A.-L., Skrtic, S., Niklason, A., Hultén, L.M., Wiklund, 

O., Hedner, T. and Ohlsson, C. Association between the low 

activity genotype of catechol-O-methyltransferase and 

myocardial infarction in a hypertensive population 386 

Eriksson, P. Long-term clopidogrel therapy after percutaneous 

coronary intervention in PCI-CURE and CREDO: the 

‘‘Emperor’s New Clothes’’ revisited 720 

Eriksson, P. see Edfeldt, 1447 

Erne, P. see Kaiser, C. 1036 

Ernst, N. see van’t Hof, A.W.J. 837 

Ertl, G. and Bauer, W. Advances in managing heart failure and 

sudden death: reverse remodelling by drugs? I44 (2003) 

Ertl, G. see Velazquez, E.J. 1911 

Escaned, J. see Angiolillo, D.J. 1903 

Escriou, C. see Chetboul, V. 1934 

Essop, M.F. and Opie, L.H. Metabolic therapy for heart failure 

1765 

Estlinbaum, W. see Claude, J. 2195 

Estner, H. see Zrenner, B. 2226 

Euro Heart Survey Investigators see Batnick, M. 1880 

EUROASPIRE II study group see De Bacquer, D. 121 

Evander, M.H. see Herlitz, J. 232 



Author index 

Evangelista, A., Dominguez, R., Sebastia, C., Salas, A., 

Permanyer-Miralda, G., Avegliano, G., Gomez-Bosh, Z., 

Gonzalez-Alujas, T., Garcia del Castillo, H. and Soler-Soler, 

J. Prognostic value of clinical and morphologic findings in 

short-term evolution of aortic intramural haematoma. 

Therapeutic implications 81 

Evans, J.C. see Sundström, J. 1509 

Evans, T.W. see Mikhail, G.W. 431 

Exner, B. see Voigt, J.-U. 1517 

Exner, M. see Schillinger, M. 742 

Faber, L. 

see Lamp, B. D128 

see Vogt, J. D122 

Faber, L., Lamp, B., Vogt, J. and Horstkotte, D. Tissue Doppler 

imaging in patients with congestive heart failure and 

conduction disorders D10 

Faergeman, O. Evolution of statin therapy: an ongoing story A3 

Fagard, R. see Vanhees, L. 1120 

Failla, M. see Giannattasio, C. F30 

Falk, E. see Schaar, J.A. 1077 

Faraguti, S.A. see Ballo, P. 1310 

Farré, J. and Wellens, H.J. Obituary to: Philippe Coumel – A 

founding father of modern arrhythmology 1083 

Farwell, D.J., Freemantle, N. and Sulke, A.N. Use of implantable 

loop recorders in the diagnosis and management of syncope 

1257 

Fassini, G. see Bella, P.D. 1127 

FATE investigators see Verma, S. 1754 

Febo, O. see Capomolla, S. F91 

Feccia, M. see Puglisi, A. 1063 

Fejka, M.J. see Greaves, K. 847 

Feldman, T. see Zamorano, J. 2086 

Fernández, C. see Alfonso, F. 1829 

Fernández-Ortiz, A. see Angiolillo, D.J. 1903 

Ferrari, M. see Capomolla, S. F91 

Ferrari, R. 

see Agnoletti, L. F22 


see Bachetti, T. F16 

see Batnick, M. 1880 

Ferri, C. see Emdin, M. F68 

Ferrièes, J. see Ruidavets, J.-B. 1153 

Fetsch, T., Bauer, P., Engberding, R., Koch, H.P., Lukl, J., 

Meinertz, T., Oeff, M., Seipel, L., Trappe, H..J., Treese, N. 

and Breithardt, G. for The Prevention of Atrial Fibrillation 

after Cardioversion Investigators Prevention of atrial 

fibrillation after cardioversion: results of the PAFAC trial 1385 

Fialka-Moser, V. see Nuhr, M.J. 136 

Fichtlscherer, S., Breuer, S., Schächinger, V., Dimmeler, S. and 

Zeither, A.M. C-reactive protein levels determine systemic 

nitric oxide bioavailability in patients with coronary artery 

disease 1412 

Fichtlscherer, S. see Rössig, L. 1620 

Figueras, J. see Cortadellas, J. 224 

Finet, G. see Argaud, L. 2019 

Fini, M. see Vitale, C. 1814 

Finkelstein, A. see George, J. 1003 

Fiorentini, C. 

see Bigi, R. 558 

see Lombardi, F. 1242 

Fitchett, D. see Yan, A.T. 2006 

Fitzgerald, D. see Patrono, C. 166 

Fitzpatrick, A. see Brignole, M. 2054 

Flachskampf, F.A. see Voigt, J.-U. 1517 

Flamm, S.D. High-dose dobutamine stress cardiac magnetic 

resonance imaging – has its time come? 1183 

Flather, M.D. see Taneja, A.K. 2013 

Fleck, E. 

see Butter, C. D106 

see Wahl, A 1230 

Fleury, S. see Simeoni, E. 1438 

x 

Flugelman, M.Y. and Lewis, B.S. The promise of myocardial 

repair – towards a better understanding 1483 

Focaccio, A. see Briguori, C. 206, 1822 

Foell, D. see Wahl, A 1230 

Follath, F. 

see Horstkotte, D. 267 


Fondard, O. see Iung, B. 701 

Fontaine, G. see Basso, C. 531 

Fontana, A. 

see Ghio, S. 571 


Fontana, F. see Manfrini, O. 1502 

Formichi, B. see Emdin, M. F68 

Foucher, A. see Milleron, O. 728 

Fox, K.A.A. 

see Clayton, T.C. 1641 


see Taneja, A.K. 2013 

Framme, J. see Friberg, P. 987 

Francis, D.P. 

see Scott, A.C. 1806 


Francis, G. see Pocock, S. 1974 

Francis, G.S. see Velazquez, E.J. 1911 

Franke, A. 


see Radke, P.W. 920 

Frankel, S. see Martin, R.M. 778 

Frants, R.R. see Agema, W.R.P. 1163 

Fraser, H. see Belardinelli, L. I3 

Freemantle, N. see Farwell, D.J. 1257 

Frenneaux, M. see Lee, L. 634 

Friberg, P., Allansdotter-Johnsson, A˚., Ambring, A., Ahl, R., 

Arheden, H., Framme, J., Johansson, A˚., Holmgren, D., 

Wa˚hlander, H. and Ma˚rild, S. Increased left ventricular mass 

in obese adolescents 987 

Friedman, J.D. see Zellweger, M.J. 543 

Friedrich, M. see Giang, T.H. 1657 

Frikke-Schmidt, R., Nordestgaard, B.G., Schnohr, P. and 

Tybærg-Hansen, A. Single nucleotide polymorphism in the 

low-density lipoprotein receptor is associated with a threefold 

risk of stroke. A case-control and prospective study 943 

Frostega˚rd, J. see Edfeldt, 1447 

Fu, M. see Baba, A. 1108 

Fujii, K. see Iwakura, K. 1526 

Fukada, Y. see Baba, A. 1108 

Fung, M. see Verma, S. 1754 

Fuselli, J.J. see Bazzino, O. 859 

Fuster, V. 


see Viles-Gonzalez, J.F. 1197 

Gabriel, H. see Rosenhek, R. 199 

Gabrielli, M., Santoliquido, A., Cremonini, F., Cicconi, V., 

Candelli, M., Serricchio, M., Tondi, P., Pola, R., Gasbarrini, 

G., Pola, P. and Gasbarrini, A. CagA-positive cytotoxic H. 

pylori strains as a link between plaque instability and 

atherosclerosic stroke 64 

Gackowski, A., Isnard, R., Golmard, J.-L., Pousset, F., Carayon, 

A., Montalescot, G., Hulot, J.-S., Thomas, D., Piwowarska, W. 

and Komajda, M. Comparison of echocardiography and plasma 

ß-type natriuretic peptide for monitoring the response to 

treatment in acute heart failure 1788 

Gahn, G. see Braun, M. 424 

Galiè, N., Torbicki, A., Barst, R., Dartevelle, P., Plessy- 

Robinson, Le, Haworth, S., Higenbottam, T., Olschewski, 

H., Peacock, A., Pietra, G., Rubin, L.J. and Simonneau, G. 

Guidelines on diagnosis and treatment of pulmonary arterial 

hypertension. The Task Force of Diagnosis and Treatment of 

Pulmonary Arterial Hypertension of the European Society of 




Galiñanes, M. see Hadjinikolaou, L. 508 

Gami, A.S. and Somers, V.K. Obstructive sleep apnoea, 

metabolic syndrome, and cardiovascular outcomes 709 

Garbarz, E. 

see Iung, B. 701 

see Steg, P.G. 2187 

Garcia, J.M. see Alfonso, F. 1829 

Garcia del Castillo, H. see Evangelista, A. 81 

Garot, J. see Lim, P. 2048 

Garot, J. The study of diastole by tagged MRI: are we nearly 

there yet? 1376 

Garrique, S. see Bordachar, P. 879 

Gasbarrini, A. see Gabrielli, M. 64 

Gasbarrini, G. see Gabrielli, M. 64 

Gasparini, G. see Raviele, A. 1741 

Gasparini, M. Case study: a stepwise approach in a patient with 

ischaemic cardiomyopathy and incessant ventricular 

tachycardia I102 (2003) 

Gatterer, E. see Reisinger, J. 1318 

Gatzoulis, M.A. see Mikhail, G.W. 431 

Gaul, G. see Gyöngyösi, M. 2125 

Gavazzi, A. see Arbustini, E. F40 

Gawaz, M. see Gorchakova, O. 1898 

Gazzoli, F. see Rinaldi, M. F81 

Gebara, O. see Vitale, C. 1814 

Gebker, R. see Wahl, A 1230 

Geelen, P. see Rivero-Ayerza, M. I97 (2003) 

Geert-Jan, L. see Abizaid, A. 107 

Geibel, A. see Brunner, M. 88 

Gelatti, U. see Covolo, L. 1534 

Gelfand, E.V. see Gibson, C.M. 1998 

Gentile, G. see Giannattasio, C. F30 

George, J., Goldstein, E., Abashidze, S., Deutsch, V., 

Shmilovich, H., Finkelstein, A., Herz, I., Miller, H. and 

Keren, G. Circulating endothelial progenitor cells in patients 

with unstable angina: association with systemic 

inflammation 1003 

Georgiadou, P. see Scott, A.C. 1806 

Gerber, B.L. see Azevedo, C. 1419 

Germano, G. see Zellweger, M.J. 543 

Gersh, B.J. see Mathew, V. 2177 

Gerszten, R.E. see Kathiresan, S. 1378 

Ghaleh, B. see Monnet, X. 579 

Ghali, J.K. see Deedwania, P.C. 1300 

Ghio, S. 

see Campana, C. F61 


Ghio, S., Constantin, C., Klersy, C., Serio, A., Fontana, A., 

Campana, C. and Tavazzi, L. Interventricular and 

intraventricular dyssunchrony are common in heart failure 

patients regardless of duration 571 

Ghio, S., Di Matteo, A., Scelsi, L., Klersy, C., Orsolini, P., Monti, 

L., Campana, C., Minoli, L. and Tavazzi, L. Plasma brain 

natriuretic peptide is a marker of right ventricular overload 

in pulmonary hypertension associated to HIV infection F35 

Giaccardi, M. see Padeletti, L. D79 

Giada, F. see Raviele, A. 1741 

Giang, T.H., Nanz, D., Coulden, R., Friedrich, M., Graves, M., 

Al-Saadi, N., Lüscher, T.F., von Schulthness, G.K. and 

Schwitter, J. Detection of coronary artery disease by 

magnetic resonance myocardial perfusion imaging with 

various contrast medium doses: first European multi-centre 

experience 1657 

Giannattasio, C., Achilli, F., Failla, M., Capra, A., Vincenzi, A., 

Gentile, G., Corsi, D., Zazzeron, C., Turolo, L., Morganti, A. 

and Mancia, G. Arterial stiffness in heart failure patients: 

dependence on diastolic dysfunction and plasma aldosterone 

levels F30 

Gibbs, J.S.R. see Mikhail, G.W. 431 

Gibson, C.M. 



xi 

Author index 

Gibson, C.M., de Lemos, J.A. and Antman, E.M. from the TIMI 

Study Group Time is muscle in primary PCI: the strength of 

the evidence grows 1001 

Gibson, C.M., Dumaine, R.L., Gelfand, E.V., Murphy, S.A., 

Morrow, D.A., Wiviott, S.D., Giugliano, R.P., Cannon, C.P., 

Antman, E.M. and Braunwald, E. for the TIMI Study Group 

Association of glomerular filtration rate on presentation 

with subsequent mortality in non-ST-segment elevation 

acute coronary syndrome: observations in 13307 patients in 

five TIMI trials 1998 

Giesting, R. see Javaheri, S. 260 

Gillebert, T.C., Van de Veire, N., de Buyzere, M.L. and De 

Sutter, J. Time intervals and global cardiac function. Use 

and limitations 2185 

Gillum, R.F. see Wheeler, J.G. 1287 

Giraldi, F. see Bella, P.D. 1127 

Gitt, A.K. see Rosengren, A. 663 

Giudicelli, J.F. see Monnet, X. 579 

Giuggioli, D. see Emdin, M. F68 

Giugliano, R.P. 




Givertz, M.M. and Braunwald, E. Neurohormones in heart 

failure: predicting outcomes, optimizing care 281 

Glasziou, P. see Colquhoun, D. 771 

Gliech, V. see Braun, M. 424 

Glogar, D. see Gyöngyösi, M. 2125 

Gnecchi, M. see Melo, L.G. E24 

Goderis, G.see Boland, B. 712 

Goethals, M. see Rivero-Ayerza, M. I97 (2003) 

Goette, A. and Röcken, C. Atrial amyloidosis and atrial 

fibrillation: a gender-dependent "arrhythmoggenic 

substrate"? 1185 

Goetze, J.P., Yongzhong, W., Rehfeld, J.F., Jorgensen, E. and 

Kastrup, J. Coronary angiography transiently increases 

plasma pro-B-type natriuetic peptide 759 

Goldenberg, I., Schechter, M., Matezky, S., Jonas, M., Adam, 

M., Pres, H., Elian, D., Agranat, O. and Schwammenthal, E. 

Oral acetylcysteine as an adjunct to saline hydration for the 

prevention of contrast-induced nephropathy following 

coronary angiography. A randomized controlled trial and 

review of the current literature 212 

Goldstein, E. see George, J. 1003 

Golia, B. see Briguori, C. 206, 1822 

Gollesch, A. see Wahl, A 1230 

Golmard, J.-L. see Gackowski, A. 1788 

Gomez-Bosh, Z. see Evangelista, A. 81 

Gonseth, J., Gualler-Castillón, J., Banegas, J.R. and Rodríguez- 

Artalejo, F. The effectiveness of disease management 

programmes in reducing hospital re-admission in older 

patients with heart failure: a systemic review and metaanalysis 

of published reports 1570 

Gonzalez-Alujas, T. see Evangelista, A. 81 

Goodman, N., Bijnens, B. and Van de Werf, F. The European 

Heart Journal: a European journal with a global impact in 

cardiovascular medicine 1382 

Goodman, S.G. see Yan, A.T. 2006 

Gorchakova, O., von Beckerath, N., Gawaz, M., Mocz, A., 

Joost, A., Schömig, A. and Kastrati, A. Antiplatelet effects 

of a 600 mg loading dose of clopidogrel are not 

attenuated in patients receiving atorvastatin or 

simvastatin for at least 4 weeks prior to coronary artery 

stenting 1898 

Gosselink, A.T.M. see De Luca, G. 1009 

Gottlieb, S. see Deedwania, P.C. 1300 

Gottwik, M. see Zeymer, U. 322 

Gourabi, B.M. see Verheye, S. 158 

Grabauskiene, V. see Celutkiene, J. 932 

Grädel, C. see Claude, J. 2195 

Grander, W. see Reisinger, J. 1318 

Granger, C. see O’Meara, E. 1920 



Author index 

Granger, C.B. Importance of CHARM in relation to other heart 

failure trials with ARBs H55 

Granger, C.B. see Roe, M.T. 313 

Grant, S. see Channer, K.S. 144 

Gras, D., Cebron, J.P., Brunel, P., Leurent, B. and Banus, Y. The 

selection of patients for cardiac resynchronisation therapy 

D98 

Graves, M. see Giang, T.H. 1657 

Greaves, K., Dixon, S.R., O’Brian Coker, I., Mallet, A.I., Avrikan, 

M., Shattock, M., Fejka, M.J., O’Neill, W.W., Senior, R., 

Redwood, S. and Marber, M.S. Influence of isoprostane F2a - 

III on reflow after myocardial infarction 847 

Gregori, D. see Bigi, R. 558 

Gresele, P. and Migliacci, R. Picotamide versus aspirin in 

diabetic patients with peripheral arterial disease: has David 

defeated Goliath? 1769 

Grines, C.L. The AGENT clinical trials programme E18 

Groenink, M. see Nollen, G.J. 1146 

Grube, E. see Radke, P.W. 920 

Guagliumi, G. 

see Abizaid, A. 107 

see Dirksen, M.T. 392 

Gualler-Castillón, J. see Gonseth, J. 1570 

Guan, K. see Höcht-Zeisberg, E. 749 

Guazzotti, G. see Capomolla, S. F91 

Gueldner, H. see Hansky, B. D53, D112 

Gueret, P. see Lim, P. 2048 

Guicheney, P. see Villain, E. 1405 

Güldner, H. see Vogt, J. D47, D122 

Gummert, J.F. see Scheinert, D. 694 

Gunnell, D. see Martin, R.M. 778 

Gurfinkel, E.P., Leon de la Fuente, R., Mendiz, O. and Mautner, 

B. Flu vaccination in acute coronary syndromes and planned 

percutaneous coronary interventions (FLUVACS) study 25 

Gustafsson, F. and Arnold, J.M.O. Heart failure clinics and 

outpatient management: review of the evidence and call for 

quality assurance 1596 

Gustafsson, F., Torp-Pedersen, C., Burchardt, H., Buch, P., 

Seibaek, M., Kj¢ller, E., Gustafsson, I. and K¢ber, L. for the 

DIAMOND study group Female sex is associated with a better 

long-term survival in patients hospitalized with congestive 

heart failure 129 

Gustafsson, F., Torp-Pedersen, C., Seibæk, M., Burchardt, H., 

K¢ber, L. for the DIAMOND study group Effect of age on 

short and long-term mortality in patients admitted to 

hospital with congestive heart failure 1711 

Gustafsson, I. see Gustafsson, F. 129 

Gustavsson, C.G. and Agardh, C.-D. Markers of inflammation in 

patients with coronary artery disease are also associated 

with glycosylated haemoglobin A1c within the normal range 

2120 

GUSTO IV-ASC Investigators see Ottervanger, J.P. 1494 

Gutschik, E. see Horstkotte, D. 267 

Gyöngyösi, M., Domanovits, H., Benzer, W., Haugk, M., 

Heinisch, B., Sodeck, G., Hödl, E., Gaul, G., Bonner, G., 

Wojta, J., Laggner, A., Glogar, D. and Huber, K., for the 

ReoPro-BRIDGING Study Group Use of abciximab prior to 

primary angioplasty in STEMI results in early recanalization 

of the infarct-related artery and improved myocardial tissue 

reperfusion – results of the Austrian multi-centre 

randomized RepPro-BRIDGING Study 2125 

Haaff, B. see Angermann, C.E. 1626 

Haass, M. see Braun, M. 424 

Hachamovitch, R. see Zellweger, M.J. 543 

Hadjinikolaou, L., Kotidis, K. and Galiñanes, M. Relationship 

between reduced elasticity of extracardiac vessels and left 

main stem coronary artery disease 508 

Haerten, K. see Zahn, R. 1550 

Hagens, V.E., Vermeulen, K.M., TenVergert, E.M., Van 

Veldhuisen, D.J., Bosker, H.A., Kamp, O., Kingma, J.H., 

Tijssen, J.G.P., Crijns, H.J.G.M. and Van Gelder, I.C., for 

xii 

the RAte Control versus Electrical cardioversion for 

persistend atrial fibrillation study group Rate control is more 

cost-effective than rhythm control for patients with 

persistent atrial fibrillation – results from the RAte Control 

versus Electrical cardioversion (RACE) study 1542 

Haghighat, T. see Iung, B. 701 

Hahmann, H. see Twardella, D. 2101 

Hainque, B. see Villain, E. 1405 

Haïssaguerre, M. 



Haji, S. see Yousufuddin, M. 377 

Halinen, M.O. see Koukkunen, H. 329 

Hall, C. see Hole, T. 416 

Hamm, C. Unmet needs in chronic angina: the burden of disease 

and current management options I1 

Hamm, C.W. see Brandt, R.R. D25 

Hamsten, A. see Edfeldt, 1447 

Hanefield, M., Cagatay, M., Petrowitsch, T., Neuser, D., 

Petzina, D. and Rupp, M. Acarbose reduces the risk for 

myocardial infarction in type 2 diabetic patients: metaanalysis 

of seven long-term studies 10 

Hanrath, P. 

see Ortlepp, J.R. 514 


see Stellbrink, C. D43, D101 

see Vogt, F. 1330 

Hansen, J.F. see Sajadieh, A. 363 

Hansky, B. 


see Vogt, J. D29, D47, D122 

Hansky, B., Schulte-Eistrup, S., Vogt, J., Gueldner, H., 

Horstkotte, D. and Koerfer, R. Implantation of systems for 

cardiac resynchronisation: tips and tricks – the cardiac 

surgeon’s view D53 

Hansky, B., Schulte-Eistrup, S., Vogt, J., Gueldner, H., Minami, 

K., Horstkotte, D. and Koerfer, R. Lead selection and 

implantation technique for biventricular pacing D112 

Hansson, G.K. see Edfeldt, 1447 

Hara, H. see Sahara, M. 2026 

Harding, S.E. see Sato, M. 537 

Harr, T. see Nordmann, A.J. 69 

Harrington, R.A. see Roe, M.T. 313 

Hasdai, D. see Rosengren, A. 663 

Hasenfuss, G. see Höcht-Zeisberg, E. 749 

Hatala, E. see Patten, M. 1395 

Hau, W.K. Fractional flow reserve and complex coronary 

pathologic conditions 723 

Haugk, M. see Gyöngyösi, M. 2125 

Hauptmann, K.E. see Zahn, R. 1550 

Haworth, S. see Galiè, N. 2243 

Hayes, S.W. see Zellweger, M.J. 543 

Heagerty, A.M. Effect of AT 1-receptor blockade on 

cardiovascular structure and function H17 

Hedner, T. see Eriksson, A.-L. 386 

Heeschen, C. see Rössig, L. 1620 

Heger, M. see Rosenhek, R. 199 

Heidbüchel, H. see Vanhees, L. 1120 

Heikklä, J.see Lepäntalo, A. 476 

Hein, H.O. see Sajadieh, A. 363 

Heinisch, B. see Gyöngyösi, M. 2125 

Heintze, J. see Vogt, J. D29, D47, D122 

Heinze, G. see Reisinger, J. 1318 

Helbecque, N. 



Heliö, T.see Märkkäinen, S. 885 

Hemmerlein, B. see Höcht-Zeisberg, E. 749 

Henderson, R.A. see Clayton, T.C. 1641 

Henein, M.Y. see Underwood, S.R. 815 

Hengstler, P. see Nordmann, A.J. 69 

Henis, M. see Velazquez, E.J. 1911 



Herbots, L. see Breithardt, O.A. D16 

Herlitz, J., Holm, J., Peterson, M., Karlson, B.W., Evander, M.H. 

and Erhardt, L., for the LoWASA study group Effect of fixed 

low-dose warfarin added to aspirin in the long-term after 

acute myocardial infarction 232 

Hermant, X. see Mizon-Gérard, F. 688 

Hernández-Antolin, R. see Angiolillo, D.J. 1903 

Herrmann, J., Higano, S.T., Lenon, R.J., Rihal, C.S. and Lerman, 

A. Myocardial bridging is associated with alteration in 

coronary vasoreactivity 2134 

Herz, I. see George, J. 1003 

Herzfeld, I. see Barbato, E. 219 

Hess, O.M. see Billinger, M. 188, 565 

Hester, A. see Latini, R. 292 

Heyndrickx, G.R. see Barbato, E. 2034 

HHH investigators see Mortara, A. F99 

Higano, S.T. see Herrmann, J. 2134 

Higenbottam, T. see Galiè, N. 2243 

Higgins, C.B. see Pennell, D.J. 1940 

Hill, R.A., Dundar, Y., Bakhai, A., Dickson, R. and Walley, T. 

Drug-eluting stents: an early systematic review to inform 

policy 902 

Himbert, D. see Steg, P.G. 2187 

Hindricks, G. see Stix, G. 650 

Hirashiki, A. see Murase, Y. 970 

Hirsh, J. see Patrono, C. 166 

Hittinger, L. 


see Monnet, X. 579 

Hobbs, F.D.R. Guidelines and management of global risk: the 

European perspective C5 

Höcht-Zeisberg, E., Kahnert, H., Guan, K., Wulf, G., 

Hemmerlein, B., Schlott, T., Tenderich, G., Körfer, R., 

Raute-Kreinsen, U. and Hasenfuss, G. Cellular repopulation 

of myocardial infarction in patients with sex-mismatched 

heart transplantation 749 

Hocini, M. 



Hödl, E. see Gyöngyösi, M. 2125 

Hoffmann, M. see Willems. S. 1249 

Hoffmann, M.M. 

see März, W. 2109 

see Simeoni, E. 1438 

Hoffmann, R. 




Hofman, A. 


see Oei, H.-H. 48 


Hogg, K. and McMurray, J.J.V. Treatment of heart failure with 

preserved systolic function: a review of the evidence H61 

Hohnloser, S. see Brignole, M. 2054 

Hojberg, S. see Kragelund, C. 1891 

Hole, T., Hall, C. and Skjærpe, T. N-terminal proatrial 

natriuretic peptide predicts two-year remodelling in 

patients with acute transmural myocardial infarction 416 

Hollak, F. see van’t Hof, A.W.J. 837 

Holm, J. see Herlitz, J. 232 

Holmgren, D. see Friberg, P. 987 

Holzinger, J. see Baller, D. D91 

Hoorntje, J.C.A. 





HOPE study investigators see Östergren, J. 17 

Hoppmann, P., Koch, W., Schömig, A. and Kastrati, A. The 5A/ 

6A polymorphism of the stromelysin-1 gene and restenosis 

after percutaneous coronary interventions 335 

xiii 

Author index 

Hori, M. see Yamamoto, K. 1221 

Horowitz, J. see Lee, L. 634 

Horstkotte, D. 

see Baller, D. D91 

see Faber, L. D10 

see Hansky, B. D53, D112 

see Lamp, B. D5, D128 

see Vogt, J. D29, D47, D122 

Hsu, L.-F. see Scavée, C. 963 

Hu, G. see Barengo, N.C. 2204 

Hu, G., Tuomilehto, J., Silventoinen, K., Barengo, N.C. and 

Jousilahti, P. Joint effects of physical activity, body mass 

index, waist circumference and waist-to-hip ratio with the 

risk of cardiovascular disease among in middle-aged Finnish 

men and women 2212 

Huber, K. see Gyöngyösi, M. 2125 

Huelsman, M. see Nuhr, M.J. 136 

Huikuri, H.V. see Junttila, M.J. 874 

Hulot, J.-S. see Gackowski, A. 1788 

Hultén, L.M. see Eriksson, A.-L. 386 

Humphries, S.E. see Dhamrat, S.S. 468 

Hunt, D. see Colquhoun, D. 771 

Hurel, S.J. see Dhamrat, S.S. 468 

Husted, S. see Patrono, C. 166 

Huster, J. see Ortlepp, J.R. 514 

Huttunen, J.K. see Törnwall, M.E. 1171 

Iakovoub, I.see Colombo, A. 895 

Ichijhara, S. see Murase, Y. 970 

Iervasi, A. see Emdin, M. F68 

Imhof, A., Woodward, M., Doering, A., Helbecque, N., Loewel, 

H., Amouyel, P., Lowe, G.D.O. and Koenig, W. Overall 

alcohol intake, beer, wine, and systemic markers of 

inflammation in Western Europe: results from three MONICA 

samples (Augsburg, Glasgow, Lille) 2092 

Ingelsson, E. see Ärnlöv, J. 2220 

Ino, H. see Konno, T. 246 

Inoue, S. see Yamamoto, K. 1221 

Inoue, Y. see Yokoyams, I. 671 

Ischinger, T. see Zahn, R. 1550 

Isnard, R. see Gackowski, A. 1788 

Ito, H. see Iwakura, K. 1526 

Itti, R. see Argaud, L. 2019 

Iung, B., Nicoud-Houel, A., Fondard, O., Akoudad, H., 

Haghighat, T., Brochet, E., Garbarz, E., Cormier, B., Baron, 

G., Luxereau, P. and Vahanian, A. Temporal trends in 

percutaneous mitral commissurotomy over a 15-year period 

701 

Iwakura, K., Ito, H., Kawano, S., Okamura, A., Tanaka, K., 

Nishida, Y., Maekawa, Y. and Fujii, K. Assessing myocardial 

perfusion with the transthoracic Doppler technique in 

patients with reperfused anterior myocardial infarction: 

comparison with angiographic, enzymatic and 

electrocardiographic indices 1526 

Jacques, P.F. see Sundström, J. 523 

Jaïs, P. 



James, S., Lindahl, B., Johnston, N., Stridsberg, M., Venge, P. 

and Wallentin, L. Jernberg, T. 1486 

James, S. see Ottervanger, J.P. 1494 

Janin-Manificat, L. see Zeller, M. 308 

Janousek, J., Kapoor, W., Kenny, R.A., Kulakowski, P., Masotti, 

G., Moya, A., Raviele, A., Sutton, R., Theodorakis, G., Ungar, 

A., Wieling, W. Brignole, M. 2054 

Janousek, J. see Brignole, M. 2054 

Janssen, F. see Vahlhaus, C. 151 

Janssens, S. see Post, M.C. 1651 

Jap, W. see van’t Hof, A.W.J. 837 

Jauvert, G. see Cazeau, S. I83 (2003) 



Author index 

Javaheri, S., Abraham, W.T., Brown, C., Nishiyama, H., 

Giesting, R. and Wagoner, L.E. Prevalence of obstructive 

sleep apnoea and periodic limb movements in 45 subjects 

with heart transplantation 260 

Jernberg, T., James, S., Lindahl, B., Johnston, N., Stridsberg, 

M., Venge, P. and Wallentin, L. Natriuetic peptides in 

unstable coronary artery disease 1486 

Jernberg, T. see Björklund, E. 113 

Jidéus, L. see Steuer, J. 1293 

Johanson, P. see Björklund, E. 113 

Johansson, A˚. see Friberg, P. 987 

Johansson, L. see Steuer, J. 1293 

Johnson, P. see Mortara, A. F99 

Jonas, M. see Goldenberg, I. 212 

Jondeau, G. see Milleron, O. 728 

Jongsma, H.J. see Teunissen, B.E.J. 1979 

Joost, A. see Gorchakova, O. 1898 

Jordaens, L.J. see Kimman, G.P. 2232 

Jorgensen, E. see Goetze, J.P. 759 

Jousilahti, P. see Hu, G. 2212 

Judd, D. see Latini, R. 292 

Jukema, J.W. see Agema, W.R.P. 1163 

Juliard, J.-M. see Steg, P.G. 1667 

Junttila, M.J., Raattikainen, M.J.P., Karjalainen, J., Kauma, H., 

Kesäniemi, Y.A. and Huikuri, H.V. Prevalence and prognosis of 

subjects with Brugada-type ECG pattern in a young and 

middle-aged Finnish population 874 

Kaartinen, M. see Märkkäinen, S. 885 

Kahnert, H. see Höcht-Zeisberg, E. 749 

Kaiser, A. see Radke, P.W. 920 

Kaiser, C., Kuster, G., Erne, P., Amann, W., Naegeli, B., 

Osswald, S., Buser, P., Schlaüpfer, H., Brett, W., Zerkowski, 

H.-R., Schindler, C. and Pfisterer, M. and the TIME 

investigators Risks and benefits of optimised medical and 

revascularisation therapy in elderly patients with angina – 

on-treatment analysis of the TIME trial 1036 

Kaiser, C. see Claude, J. 2195 

Kajita, L.J. see Soares, A.M. 1927 

Kalpakos, D. see Rivero-Ayerza, M. I97 (2003) 

Kamakura, S. see Noda, T. 2149 

Kammeier, A. see Baller, D. D91 

Kamp, O. 

see Hagens, V.E. 1542 

see Mannaerts, H.F.J. 680, 2073 

Kanaganayagam, G. see Perera, D. 999 

Kanda, H. see Murase, Y. 970 

Kaneda, T. see Konno, T. 246 

Kang, X. see Zellweger, M.J. 543 

Kapoor, W. see Brignole, M. 2054 

Kappenberger, L. 

see Bassand, J.-P. 804 


Karch, M. see Zrenner, B. 2226 

Karja, J. see Bengel, F.M. 1726 

Karjalainen, J. see Junttila, M.J. 874 

Karlson, B.W. see Herlitz, J. 232 

Karnik, S.S. see Yousufuddin, M. 377 

Kasam, S. see Segev, A. 1029 

Kashani, A., Giugliano, R.P., Antman, E.M., Morrow, D.A., 

Gibson, C.M., Murphy, S.A. and Braunwald, E. Severity 

of heart failure, treatments, and outcomes after 

fibrinolysis in patients with ST-elevation myocardial 


Kaski, J.C. see Arroyo-Espliguero, R. 401 

Kasper, W. see Zahn, R. 1550 

Kass, D.A. Ventricular remodelling: chamber dyssynchrony and 

effects of cardiac resynchronisation I54 (2003) 

Kastrati, A. 

see Gorchakova, O. 1898 

see Hoppmann, P. 335 

see Ndrepepa, G. 1635 

xiv 

Kastrati, A., Schömig, A. and Schömig, E. Are we making 

efficient use of clopidogrel? 454 

Kastrup, J. see Goetze, J.P. 759 

Kathiresan, S., Bewton-Cheh, C. and Gerszten, R.E. On the 

interpretation of genetic association studies 1378 

Katritsis, D.G. and Camm, A.J. Nonsustained ventricular 

tachycardia: where do we stand? 1093 

Kauma, H. see Junttila, M.J. 874 

Kaurer, G. see Mascherbauer, J. 787 

Kawano, S. see Iwakura, K. 1526 

Kearney, M.T. and Marber, M. Trends in incidence and prognosis 

of heart failure. You always pass failure on the way to success 

283 

Keech, A. see Colquhoun, D. 771 

Keil, U. see De Bacquer, D. 121 

Kenny, R.A. see Brignole, M. 2054 

Keren, G. see George, J. 1003 

Kesäniemi, Y.A. see Junttila, M.J. 874 

Kesteloot, H. Alcohol intake and markers of inflammation 2075 

Khabirinejad, J. see Emdin, M. F68 

Khalifé, K.see Steg, P.G. 2187 

Khan, I.A. Pharmacological cardioversion of recent onset atrial 

fibrillation 1274 

Khan, M. see Mikhail, G.W. 431 

Khush, K.K. see Waters, D.D. C49 

Kilaru, R. 



Kilter, H. see Böhm, M I14 (2003) 

Kimman, G.P., Theuns, D.A.M.J., Szili-Torok, T., Scholten, 

M.F., Res, J.C. and Jordaens, L.J. CRAVT: a prospective, 

randomized study comparing transvenous cryothermal and 

radiofrequency ablation in atrioventricular nodal re-entrant 

tachycardia 2232 

Kindermann, M. see Böhm, M I14 (2003) 

Kingma, J.H. see Hagens, V.E. 1542 

Kirigaya, H. see Sahara, M. 2026 

Kjærgaard, J.-J. see Kragelund, C. 1891 

Kjekshus, J. see Lópex-Sendón, J. 1341, 1454 

Kjoller, E. see Gustafsson, F. 129 

Klaar, U. see Rosenhek, R. 199 

Klapsinos, N.C. see Simantirakis, E.N. 1070 

Klauss, V. see Barbato, E. 219 

Kleber, F.X. The predictive value of cardiorespiratory fitness 

1374 

Kleber, F.X., Waurick, P. and Winterhalter, M. CPET in heart 

failure D1 

Klein, C. see Wahl, A 1230 

Klein, H.U. Device therapy for congestive heart failure: which 

devices are indicated? I75 (2003) 

Klersy, C. 

see Bella, P.D. 1127 


Klersy, C. see Ghio, S. F35 

Kluft, C. Identifying patients at risk of coronary vascular 

disease: the potential role of inflammatory markers C21 

Knaapen, M.W.M. see Verheye, S. 158 

Knetsch, A.M. see Bleumink, G.S. 1614 

Knight, R. see Clayton, T.C. 1641 

Kobella, S. see Radke, P.W. 920 

Kober, L. 

see Gustafsson, F. 129, 1711 

see Kragelund, C. 1891 

Koch, H.P. see Fetsch, T. 1385 

Koch, W. see Hoppmann, P. 335 

Kockx, M.M. see Verheye, S. 158 

Koenig, W. see Imhof, A. 2092 

Komajda, M. 



Konno, T., Shimizu, M., Ino, H., Yamaguchi, M., Terai, H., 

Uchiyama, K., Oe, K., Mabuchi, T., Kaneda, T. and Mabuchi, 



H. Diagnostic value of abnormal Q waves for identification of 

preclinical carriers of hypertrophic cardiomyopathy based on 

a molecular genetic diagnosis 246 

Körfer, R. 


see Höcht-Zeisberg, E. 749 


see Vogt, J. D122 

Korhonen, P.A. see Törnwall, M.E. 1171 

Kornaat, M. see Vanhees, L. 1120 

Kornfeld, G. see Weber, 623 

Köster, M. see Schaufelberger, M. 300 

Koster, R.W. see Priori, S.G. 437 

Kotidis, K. see Hadjinikolaou, L. 508 

Kottkamp, H. see Stix, G. 650 

Koukkunen, H., Pyörälä, K. and Halinen, M.O. Low-risk patients 

with chest pain and without evidence of myocardial infarction 

may be safely discharged from emergency department 329 

Kragelund, C., Snorgaard, O., Kober, L., Bengtsson, B., Ottesen, 

M., Hojberg, S., Olesen, C., Kjærgaard, J.-J., Carlsen, J. and 

Torp-Petersen, C, on behalf of the TRACE Study Group 

Hyperinsulinaemia is associated with increased long-term 

mortality following acute myocardial infarction in nondiabetic 

patients 1891 

Kraitchman, D.L. see Azevedo, C. 1419 

Krakor, R. see Scheinert, D. 694 

Krams, R. see Verheye, S. 158 

Krankenberg, H. see Scheinert, D. 694 

Kritharides, L. Reducing low-density lipoprotein cholesterol and 

treating to target and meeting A12 

Krott, N. see Vogt, F. 1330 

Krum, H. Clinical decision making in managing the ’difficult’ 

patient with chronic heart failure I88 (2003) 

Kuck, K.-H. see Cappato, R. 642 

Kühn, P. see Reisinger, J. 1318 

Kulakowski, P. see Brignole, M. 2054 

Küpper-Nybelen, J. see Twardella, D. 2101 

Kurita, T. see Noda, T. 2149 

Kurl, S. see Laukkanen, J.A. 1428 

Kuster, G. see Kaiser, C. 1036 

Kuster, G.M. see Claude, J. 2195 

Kuusisto, J. see Märkkäinen, S. 885 

Kuwert, T. see Voigt, J.-U. 1517 

Kvasnicka, J. see Patrono, C. 166 

La Rovere, M.T. 

see Capomolla, S. F91 

see Mortara, A. F99 

Laakso, M. see Märkkäinen, S. 885 

Laarman, G. see Dirksen, M.T. 392 

L’Abbate, A. see Emdin, M. F68 

Laggner, A. see Gyöngyösi, M. 2125 

Lakka, T.A. see Barengo, N.C. 2204 

Lallemand, F. see Chetboul, V. 1934 

Lamblin, N. 

see de Groote, P. 656 


Lamp, B. 



see Vogt, J. D29, D122 

Lamp, B., Vogt, J., Faber, L., Hansky, B., Körfer, R. and 

Horstfotte, D. Extended indications for cardiac 

resynchronisation therapy? D128 

Lamp, B., Vogt, J., Schmidt, H. and Horstkotte, D. Impact of 

cardiopulmonary exercise testing on patient selection for 

cardiac resynchronisation therapy D5 

Lang, R.M. see Zamorano, J. 2086 

Lang, W. see Reisinger, J. 1318 

Langebartels, G. see Ortlepp, J.R. 514 

Langer, A. see Yan, A.T. 2006 

Langewitz, WQ. see Zellweger, M.J. 3 

xv 

Author index 

Langreck, H. see Wahl, A 1230 

Lanzotti, M. see Tritto, M. 2155 

Lappega˚rd, K.T. see Tr¢seid, M. 349 

LaRosa, J.C. and Pedersen, T.R. Forward to Supplement C 

C1 

Larsen, A.I. and Dickstein, K. BNP in acute coronary syndromes: 

the heart expresses its suffering 1284 

Larsen, A.I. and Dickstein, K. Can sedentary patients with heart 

failure achieve the neneficial effect of exercise training 

without moving? 104 

Larson, M.G. see Sundström, J. 1509 

Lassila, R. see Lepäntalo, A. 476 

Latini, R., Masson, S., Anand, I., Salio, M., Hester, A., Judd, D., 

Barlera, S., Maggioni, A.P., Tognoni, G. and Cohn, J.N., for 

the Val-HeFT investigators The comparitive prognostic value 

of plasma neurohormones at baseline in patients with heart 

failure enrolled in Val-HeFT 292 

Lau, H.K. see Segev, A. 1029 

Laucevicius, A. see Celutkiene, J. 932 

Laukkanen, J.A., Kurl, S., Salonen, R., Rauramaa, R. and 

Salonen, J.T. The predictive value of cardiorespiratory 

fitness for cardiovascular events in men with various 

risk profiles: a prospective population-based cohort study 

1428 

Laurent, Y. see Zeller, M. 308 

Lazarus, A. see Cazeau, S. I83 (2003) 

Lechat, P. see Lópex-Sendón, J. 1341, 1454 

Lechat, P. Therapeutic strategies in heart failure: what is the 

optimal sequence of drug therapy? I69 (2003) 

Lee, C.H. see Degertekin, M. 32 

Lee, L., Horowitz, J. and Frenneaux, M. Metabolic manipulation 

in ischaemic heart disease, a novel approach to treatment 634 

Leff, A.P. see Rosen, S.D. 952 

Legalery, P. see Argaud, L. 2019 

Leimenstoll, B.M. see Nordmann, A.J. 69 

Lemos, P.A. see Degertekin, M. 32 

Lengyel, M. see Horstkotte, D. 267 

Lennon, L. see Lowe, G.D.O. 252 

Lenon, R.J. see Herrmann, J. 2134 

Lenta, F. see Capomolla, S. F91 

Lenzen, M.J., Scholte op Reimer, W.J.M., Boersma, E., 

Vantrimpont, P.J.M.J., Follath, F., Swedberg, K., Cleland, 

J. and Komajda, M. Differences between patients with a 

preserved and a depressed left ventricular function: a 

report from the EuroHeart Failure Survey 1214 

Leon de la Fuente, R. see Gurfinkel, E.P. 25 

Leone, O., Boriani, G., Chiappini, B., Pacini, D., Cenacchi, G., 

Suarez, S.M., Rapezzi, C., Reggiani, M.L.B. and Marinelli, G. 

Amyloid deposition as a cause of atrial remodelling in 

persistent valular atrial fibrillation 1237 

Lepäntalo, A., Virtanen, K.S., Heikklä, J., Wartiovaara, U. and 

Lassila, R. Limited early antiplatelet effect of 300 mg 

clopidogrel in patients with aspirin therapy undergoing 

percutaneous coronary interventions 476 

Lepore, S. see Briguori, C. 206, 1822 

Lerman, A. see Herrmann, J. 2134 

Leung, J.M., Bellows, W.H. and Schiller, N.B. Impairment of left 

atrial function predicts post-operative atrial fibrillation after 

coronary artery bypass graft surgery 1836 

Leurent, B. see Gras, D. D98 

Levy, D. see Sundström, J. 523, 1509 

Lewington, S. see Lowe, G.D.O. 252 

Lewis, B.S.see Flugelman, M.Y. 1483 

Lewis, E.F. see de Lemos, J.A. 1688 

Lezaún, R. see Alfonso, F. 1829 

L’Huillier, I. see Zeller, M. 308 

Li, W. see Mikhail, G.W. 431 

Librera, M. see Briguori, C. 206, 1822 

Liestol, K. see Erikssen, G. 978 

Lièvre, M. see Argaud, L. 2019 

Lim, P., Monin, J.L., Monchi, M., Garot, J., Pasquet, A., 

Hittinger, L., Vanoverschelde, J.L., Carayon, A. and Gueret, 



Author index 

P. Predictors of outcome in patients with severe aortic 

stenosis and normal left ventricular function: role of B-type 

natriuretic peptide 2048 

Lima, J.A.C. see Azevedo, C. 1419 

Limbourg, P. see Zahn, R. 1550 

Lin, M.-W. see Chen, Y.-H. 39 

Lin, S.J. see Chen Y.-H. 39 

Lincoff, A.M. see Roe, M.T. 313 

Lind, L. see Ärnlöv, J. 2220 

Lindahl, B. 

see Björklund, E. 113 

see Steuer, J. 1293 

Lindemans, F. see Rydén, 611 

Lindholm, L.H. and Samuelsson, O. Clinical relevance of glucose 

metabolism disturbances induced by antihypertensive drugs 

H31 

Lindner, O. see Baller, D. D91 

Lindpaintner, K. see Tobin, M.D. 459 

Lip, G.Y.H. see Makin, A.J. 371 

LIPID Study Investigators see Colquhoun, D. 771 

Lipsic, E. see van der Meer, P. 285 

Lita, T. Coronary heart disease risk in Japan – an East/West 

divide? A8 

Loewel, H. see Imhof, A. 2092 

Logeart, D. see Steg, P.G. 2187 

Lolli, G. see Solano, A. 1116 

lombardi, F. Sympathetic activation and sub-clinical 

inflammation: a new combination to identify high risk 

subjects 359 

Lombardi, F., Tarricone, D., Tundo, F., Colombo, F., Belletti, S. 

and Fiorentini, C. Autonomic nervous system and paroxysmal 

atrial fibrillation: a study based on the analysis of RR interval 

changes before, during and after paroxysmal atrial fibrillation 

1242 

Lonn, E. see Verma, S. 1754 

Lopes, A.A.B. see Soares, A.M. 1927 

Lópex-Sendón, J., Swedberg, K., McMurray, J., Tamargo, 

J., Maggioni, A.P., Dargle, H., Tendera, M., Waagstein, 

F., Kjekshus, J., Lechat, P. and Torp-Pedersen, C. 

Expert consensus document on angiotensin converting 

enzyme inhibitors in cardiovascular disease. The Task 

Force on ACE-inhibitors of the European Society of 


Lópex-Sendón, J., Swedberg, K., McMurray, J., Tamargo, J., 

Maggioni, A.P., Dargle, H., Tendera, M., Waagstein, F., 

Kjekshus, J., Lechat, P. and Torp-Pedersen, C. Expert 

consensus document on ß-adrenergic receptor blockers. The 

Task Force on Beta-Blockers of the European Society of 


Lopez-Palop, R., Pinar, E., Lozano, Í., Saura, D., Picó, F. and 

Valdés, M. Utilty of the fractional flow reserve in the 

evaluation of angiographically moderate in-stent restenosis 

2040 

LoWASA study group see Herlitz, J. 232 

Lowe, G.D.O. 


see Yarnell, J.W.G. 1049 

Lowe, G.D.O., Danesh, J., Lewington, S., Walker, M., Lennon, 

L., Thomson, A., Rumley, A. and Whincup, P.H. Tissue 

plasminogen activator antigen and coronary heart disease. 

Prospective study and meta-analysis 252 

Lozano, Í. see Lopez-Palop, R. 2040 

Luani, B. see Zrenner, B. 2226 

Lucet, V. see Villain, E. 1405 

Lüdertz, B. see Patten, M. 1395 

Lukl, J. see Fetsch, T. 1385 

Lunati, M. see Puglisi, A. 1063 

Lupoglazoff, J.M. see Villain, E. 1405 

Lüscher, T. Future directions in the management of chronic 

angina and ACS – the MERLIN-TIMI 36 trial I17 

Lüscher, T.F. see Giang, T.H. 1657 

Luxereau, P. see Iung, B. 701 

xvi 

Maarout, N. and Rowland, E. What makes patients vulnerable to 

ventricular tachycardia or fibrillation? I22 (2003) 

Maarout, N. see Rowland, E. I22 (2003) 

Maas, R. see Patten, M. 1395 

Mabuchi, H. see Konno, T. 246 

Mabuchi, T. see Konno, T. 246 

Macaya, C. 


see Zamorano, J. 2086 

McCabe, C.H. see Morrow, D.A. 1139 

McCarthy, P.M. see Yousufuddin, M. 377 

McDonagh, T. see Nielsen, O.W. 1718 

McFadden, E. see de Groote, P. 656 

McGhie, J. see Roos-Hesselink, J.W. 1264 

McKelvie, R. Haemodynamic and neurohormonal effects of AT 1receptor 

blockers H49 

McKenna, W.J. see Basso, C. 531 

Macle, L. see Scavée, C. 963 

McMurray, J. 


see O’Meara, E. 1920 

McMurray, J.J. see Stewart, S. I3 (2003) 

McMurray, J.J.V. 

see Hogg, K. H61 

see Swedberg, K. 357 


McMurray, J.J.V. and Stewart, S. The burden of heart failure I3 

(2003) 

Maekawa, Y. see Iwakura, K. 1526 

Maestri, R. see Capomolla, S. F91 

Magera, M.J. see Svatikova, A. 1325 

Maggi, R. see Solano, A. 1116 

Maggioni, A.P. 

see Latini, R. 292 



Maggioni, A.P. Overview of recent drug studies in chronic heart 

failure I28 (2003) 

Magrini, G. 



Mahaffey, K.W. see Roe, M.T. 313 

Maier, W. see Togni, M. 1208 

Mainar, V. see Alfonso, F. 1829 

Makin, A.J., Blann, A.D., Chung, N.A.Y., Silverman, S.H. and Lip, 

G.Y.H. Assessment of endothelial damage in atherosclerosic 

vascular disease by quantification of circulating endothelial 

cells. Relationship with von Willebrand factor and tissue 

factor 371 

Makki, H. see Zeller, M. 308 

Malacarne, F. see Agnoletti, L. F22 

Mallet, A.I. see Greaves, K. 847 

Malmberg, K. see Bartnik, M. 1880, 1990 

Mamun, A.A., Peeters, A., Barendregt, J., Willekens, F., 

Nusselder, W. and Bonneux, L. Smoking decreases the 

duration of life lived with and without cardiovascular 

disease: a life course analysis of the Framingham Heart 

study 409 

Mancia, G. see Giannattasio, C. F30 

Manfrini, O., Morgagni, G., Pizzi, C., Fontana, F. and Bugiardini, 

R. Changes in autonomic nervous system activity: 

spontaneous versus balloon-induced myocardial ischaemia 

1502 

Manganelli, F. see Briguori, C. 206 

Mangtani, P. see Martin, R.M. 778 

Mani, A,.R. see Dhamrat, S.S. 468 

Mannaerts, H.F.J., Kamp, O. and Visser, C.A. Should mitral valve 

area assessment in patients with mitral stenosis be based on 

anatomical or on functional evaluation? A plea for 3D 

echocardiography as the new clinical standard 2073 

Mannaerts, H.F.J., van der Heide, J.A., Kamp, O., Stoel, M.G., 

Twisk, J. and Visser, C.A. Early identification of left 



ventricular remodelling after myocardial infarction, assessed 

by transthoracic 3D echocardiography 680 

Manning, W.J. see Pennell, D.J. 1940 

Mano, T. see Yamamoto, K. 1221 

Marazzi, R. see Tritto, M. 2155 

Marber, M. 

see Kearney, M.T. 283 

see Perera, D. 999 

Marber, M.S. see Greaves, K. 847 

Marcel Gosselink, A.T. see van’t Hof, A.W.J. 837 

Mariani, M. see Mariotti, R. F87 

Ma˚rild, S. see Friberg, P. 987 

Marinelli, G. see Leone, O. 1237 

Marini, C. see Emdin, M. F68 

Mariotti, R., Castrogiovanni, F., Becherini, F., Cortese, B., 

Rondinini, L. and Mariani, M. Obesity, weight loss and heart 

failure F87 

Mark, B. see Zahn, R. 1550 

Marketou, M.E. see Simantirakis, E.N. 1070 

Märkkäinen, S., Heliö, T., Miettinen, R., Tuomainen, P., Peltola, 

P., Rummukainen, J., Ylitalo, K., Kaartinen, M., Kuusisto, J., 

Toivonen, L., Nieminen, M.S., Laakso, M. and Peuhkurinen, K. 

A novel mutation, Ser143Pro, in the lamin A/C gene is 

common in Finnish patients with familial dilated 

cardiomyopathy 885 

Marschner, I. see Colquhoun, D. 771 

Martin, J., Bonhoeffer, P. and Angelini, G. Continental doctors 

take leadership in British medicine 1568 

Martin, M. see Conraads, V.M. 1797 

Martin, R.M., Smith, G.D., Mangtani, P., Tilling, K., Frankel, S. 

and Gunnell, D. Breastfeeding and cardiovascular mortality: 

the Boyd Orr cohort and a systematic review with metaanalysis 

778 

Martinek-Bregel, M. see Steger, C. 1734 

Martuscelli, E., Romagnoli, A., D’Eliseo, A., Razzini, C., 

Tomassini, M., Sperandio, M., Simonetti, G. and Romeo, F. 

Accuracy of thin-slice computed tomography in the 

detection of coronary stenosis 1043 

Marubini, E. see Serneri, G.G.N. 1845 

Marullo, A.G.M. see Puglisi, A. 1063 

März, W., Scharnagl, H., Hoffmann, M.M., Boehm, B.O. and 

WInkelmann, B.R. The apolipoprotein E polymorphism is 

associated with circulating C-reactive protein (the 

Ludwigshafen risk and cardiovascular health study) 2109 

März, W. see Simeoni, E. 1438 

Mascherbauer, J., Schima, H., Rosenhek, R., Czerny, M., Kaurer, 

G. and Baumgartner, H. Value and limitations of aortic valve 

resistance with particular consideration of low flow – 

lowgradient aortic stenosis: an in vitro study 787 

Maseri, A. see Schaar, J.A. 1077 

Masotti, G. see Brignole, M. 2054 

Masoudi, F.A.see Rumsfeld, J.S. 101, 1565 

Masson, S. see Latini, R. 292 

Masuyama, T. see Yamamoto, K. 1221 

Matezky, S. see Goldenberg, I. 212 

Mathew, V. and Gersh, B.J. To open or not to open: that remains 

the question 2177 

Mathias, W.Jr see Soares, A.M. 1927 

Matsunari, see Simões, M.V. 551 

Matsuzawa, Y. see Shepherd, J. A1 

Maurer, G. see Rosenhek, R. 199 

Mautner, B. see Gurfinkel, E.P., 25 

Mawdsley, L. see Coughlin, S.R. 735 

Mediani, S. see Mojoli, E. F74 

Mehilli, J. see Ndrepepa, G. 1635 

Meier, B. see Billinger, M. 188 

Meijboom, F.J. see Roos-Hesselink, J.W. 1057, 1264 

Meijboom, F.J. see van Rijen, E.H.M. 1605 

Meinertz, T. 


see Patten, M. 1395 

see Willems. S. 1249 

xvii 

Author index 

Melgares, R. see Alfonso, F. 1829 

Melo, L.G., Gnecchi, M., Pachori, A.S., Wang, K. and Dzau, V.J. 

Gene- and cell-based therapies for cardiovascular diseases: 

current status and future directions E24 

Mendiz, O. see Gurfinkel, E.P., 25 

Menozzi, C. 


see Solano, A. 1116 

Meredith, P. and Swedberg, K. Introduction H1 

Meredith, P. Modern strategies in hypertension management 

H23 

MERIT-HT Study Group see Deedwania, P.C. 1300 

Merli, E. and Sutherland, G.R. Can we quantify ischaemia 

during dobutamine stress echocardiography in clinical 

practice? 1477 

Messerli, F.H. TIMPs, MMPs and cardiovascular disease 1475 

Metra, M. see Covolo, L. 1534 

Mevissen, V. see Ortlepp, J.R. 514 

Michaeli, W. see Vogt, F. 1330 

Michelson, E. see O’Meara, E. 1920 

Michelucci, A. see Padeletti, L. D79 

Miekusch, W. see Schillinger, M. 742 

Miettinen, R. see Märkkäinen, S. 885 

Migliacci, R. see Gresele, P. 1769 

Mika, Y. see Stix, G. 650 

Mikhail, G.W., Prasad, S.K., Li, W., Rogers, P., Chester, A.H., 

Stephens, D., Khan, M., Gibbs, J.S.R., Evans, T.W., Mitchell, 

A., Yacoub, M.H. and Gatzoulis, M.A. Clinical and 

haemodynamic effects of sildenafil in pulmonary 

hypertension: acute and mid-term effects 431 

Miller, G.J. see 4Dhamrat, S.S. 468 

Miller, H. see George, J. 1003 

Milleron, O., Pillière, R., Foucher, A., de Roquefeuil, F., 

Aegerter, P., Jondeau, G., Raffestin, B.G. and Dubourg, O. 

Benefits of obstructive sleep apnoea treatment in coronary 

artery disease: a long-term follow-up study 728 

Milwa, T. see Yamamoto, K. 1221 

Minami, K. see Hansky, B. D112 

Minar, E. see Schillinger, M. 742 

Minoli, L. see Ghio, S. F35 

Missorici, M. see Cortadellas, J. 224 

Mitchell, A. see Mikhail, G.W. 431 

Mizon-Gérard, F., de Groote, P., Lamblin, N., Hermant, X., 

Dallongeville, J., Amouyel, P., Bauters, C. and Helbecque, 

N. Prognostic impact of matrix metalloproteinase gene 

polymorphism in patients with heart failure according to the 

aetiology of left ventricular systolic dysfunction 688 

Mocz, A. see Gorchakova, O. 1898 

Mohr, F.W. see Scheinert, D. 694 

Mojoli, E., Monti, L., Zanierato, M., Campana, C., Mediani, S., 

Tavazzi, L. and Braschi, A. Respiratory fatigue in patients 

with acute cardiogenic pulmonary edema F74 

Moliterno, D.J. see Roe, M.T. 313 

Mollnes, T.E. see Tr¢seid, M. 349 

Monchi, M. see Lim, P. 2048 

Monin, J.L. see Lim, P. 2048 

Monnet, X., Colin, P., Ghaleh, B., Hittinger, L., Giudicelli, J.F. 

and Berdeaux, A. Heart rate reduction during exerciseinduced 

myocardial ischaemia and stunning 579 

Monraats, P.S. see Agema, W.R.P. 1163 

Monsieurs, K.G. see Priori, S.G. 437 

Montalescot, G. 



Montalscot, G. Glycoprotein IIb/IIIa inhibition and long-term 

benefit: the stuff of dreams? 1562 

Montaye, M. see De Bacquer, D. 121 

Montély, J.-M. see Steg, P.G. 2187 

Montgomery, H.E. see Dhamrat, S.S. 468 

Monti, L. 


see Ghio, S. F35 



Author index 



Moore, K. see Dhamrat, S.S. 468 

Moreno, P.R. see Schaar, J.A. 1077 

Moreno, R. see Angiolillo, D.J. 1903 

Moretti, R. see Tritto, M. 2155 

Morgagni, G. see Manfrini, O. 1502 

Morganti, A. see Giannattasio, C. F30 

Morhy, S.S. see Soares, A.M. 1927 

Morice, M.-C. see Abizaid, A. 107 

Moritan, T. see Yokoyams, I. 671 

Morkrid, L. see Tr¢seid, M. 349 

Morris, R. see Emberson, J. 484 

Morrison, D.A. Cardiac revascularization of the medicallty 

refractory elderly patient: it is TIME to pay the piper 2180 

Morrow, D.A. 



Morrow, D.A., Antman, E.M., Murphy, S.A., Assmann, S.F., 

Giugliono, R.P., Cannon, C.P., Gibson, C.M., McCabe, C.H., 

Barron, H.V., Ven de Werf, F. and Braunwald, E. The Risk 

Score Profile: a novel approach to characterising the risk of 

populations enrolled in clinical studies 1139 

Mortara, A., Pinna, G.D., Johnson, P., Dargie, H., La Rovere, 

M.T., Ponikowski, P., Tavazzi, L. and Sleight, P. on behalf 

of HHH investigators A multi-country randomised trial of the 

role of a new telemonitoring system in CHF: the HHH study 

(Home or Hospital in Heart failure). Rational, study design 

and protocol F99 

Mortara, A. see Capomolla, S. F91 

Moser, P. see Nuhr, M.J. 136 

Moss, A. see Aliot, E. I1 (2003) 

Moss, A.J. Findings from MADIT-II substudies I34 (2003) 

Mouquet, F. see de Groote, P. 656 

Mousseaux, E. see Ou, P. 1853 

Moya, A. see Brignole, M. 2054 

Muellner, M. see Schillinger, M. 742 

Mugarza, J.A. see Coughlin, S.R. 735 

Mulder, B.J.M. see Nollen, G.J. 1146 

Müller, H.-W. see Patten, M. 1395 

Muller, J.E. see Schaar, J.A. 1077 

Murase, Y., Yamada, Y., Hirashiki, A., Ichij=hara, S., Kanda, H., 

Watarai, M., Takatsu, F., Murohara, T. and Yokata, M. Genetic 

risk and gene-environment interaction in coronary artery 

spasm in Japanese men and women 970 

Murohara, T. see Murase, Y. 970 

Murphy, G.J., Ascione, R. and Angelini, G.D. Coronary artery 

bypass grafting on the beating heart: surgical 

revascularization for the next decade? 2077 

Murphy, K. see Rosen, S.D. 952 

Murphy, S.A. 




Musilli, N. see Padeletti, L. D79 

Mussolino, M.E. see Wheeler, J.G. 1287 

Musumeci, F. see Puglisi, A. 1063 

Muthusamy, R. see Channer, K.S. 144 

Naegeli, B. see Kaiser, C. 1036 

Nagai, R. see Yokoyams, I. 671 

Nagashima, K. see Sahara, M. 2026 

Nagel, E. see Wahl, A 1230 

Nägele, H. see Angermann, C.E. 1626 

Nagueh, S.F. Tissue Doppler imaging for the pre-clinical 

diagnosis of cardiomyopathy 1865 

Nanz, D. see Giang, T.H. 1657 

Napolitano, C. see Priori, S.G. 437 

Nardi, G. see Covolo, L. 1534 

Natarajan, M.K. see Segev, A. 1029 

Nava, A. see Basso, C. 531 

xviii 

Ndrepepa, G., Kastrati, A., Neumann, F.-J., Schmitt, C., Mehilli, 

J. and Schömig, A. Five-year outcome of patients with acute 

myocardial infarction enrolled in a randomised trial 

assessing the value of abciximab during coronary stenting 

1635 

Neier, B. 

see Billinger, M. 565 

see Togni, M. 1208 

Nekolla, S.G. 

see Bengel, F.M. 1726 

see Simões, M.V. 551 

Nespoli, L. see Campana, C. F61 

Neuhaus, K.-L. see Zeymer, U. 322 

Neumann, F.-J. 

see Büttner, H.J. 807 


Neuser, D. see Hanefield, M. 10 

Nickenig, G. see Wassmann, S. H3 

Nicoud-Houel, A. see Iung, B. 701 

Niedermaier, N. see Zahn, R. 1550 

Nielsen, O.W., McDonagh, T., Cowburn, P., Blue, L., Robb, S.D. 

and Dargie, H. Patient differences related to management in 

general practice and the hospital: a cross-sectional study of 

heart failure in the community 1718 

Nielsen, O.W. see Sajadieh, A. 363 

Niemeth, C. see Reisinger, J. 1318 

Nieminen, M.S. see Märkkäinen, S. 885 

Niklason, A. see Eriksson, A.-L. 386 

Nilsson, J.-A˚. see Öhlin, B. 867 

Nilsson, P.M. see Öhlin, B. 867 

Nippert, M. see Zannad, F. I105 (2003) 

Nishida, Y. see Iwakura, K. 1526 

Nishikawa, N. see Yamamoto, K. 1221 

Nishiyama, H. see Javaheri, S. 260 

Nissen, S.E. Identifying patients at risk: novel diagnostic 

techniques C15 

Nissinen, A. see Barengo, N.C. 2204 

Nitzsche, S. see Scheinert, D. 694 

Nixdorff, U. see Voigt, J.-U. 1517 

Noda, T., Shimizu, W., Satomi, K., Suyama, K., Kurita, T., 

Aihara, N. and Kamakura, S. Classification and mechanism of 

Torsade de pointes initiation in patients with congenital 

long QT syndrome 2149 

Nodari, S. see Covolo, L. 1534 

Nollen, G.J., Groenink, M., Tijssen, J.G.P., van der Wall, E.E. 

and Mulder, B.J.M. Aortic stiffness and diameter predict 

progressive aortic dilatation in patients with Marfan 

syndrome 1146 

Nordestgaard, B.G. see Frikke-Schmidt, R. 943 

Nordmann, A.J., Hengstler, P., Leimenstoll, B.M., Harr, T., 

Young, J. and Bucher, H.C. Clinical outcomes of stents 

versus balloon angioplasty in non-acute coronary artery 

disease. A meta-analysis of randomized controlled trials 69 

Norhammar, A. see Bartnik, M. 1990 

Nuhr, M.J., Pette, D., Berger, R., Quittan, M., Crevenna, R., 

Huelsman, M., Wiesinger, G.F., Moser, P., Fialka-Moser, V. 

and Pacher, R. Beneficial effects of chronic low-frequency 

stimulation of thigh muscles in patients with advanced 

chronic heart failure 136 

Nusselder, W. see Mamun, A.A. 409 

O’Brian Coker, I. see Greaves, K. 847 

O’Connor, C.M. see Velazquez, E.J. 1911 

Oddone, D. see Solano, A. 1116 

Oe, K. see Konno, T. 246 

Oeff, M. see Fetsch, T. 1385 

Oei, H.-H., Vliegenthart, R., Hofman, A., Oudkerk, M. and 

Witteman, J.C.M. Risk factors for coronary calcification in 

older subjects. The Rotterdam Coronary Calcification Study 48 

Ogasawara, K. see Sahara, M. 2026 

Ogawa, S. see Baba, A. 1108 



Öhlin, B., Nilsson, P.M., Nilsson, J.-A˚. and Berglund, G. Chronic 

psycosocial stress predicts long-term cardiovascular morbidity 

and mortality in middle-aged men 867 

Ohlsson, C. see Eriksson, A.-L. 386 

Ohman, E.M. 



Öhrvik, J. 

see Bartnik, M. 1990 


Ohtomo, K. see Yokoyams, I. 671 

Oikawa, Y. see Sahara, M. 2026 

Oishi, Y. see Yamamoto, K. 1221 

Okamura, A. see Iwakura, K. 1526 

Oldroyd, K.G. see Barbato, E. 219 

Olesen, C. see Kragelund, C. 1891 

Olijhoek, J.K., van der Graaf, Y., Banga, J.-D., Algra, A., 

Rabelink, T.J. and Visseren, F.L.J., for the SMART study 

group The metabolic syndrome is associated with advanced 

vascular damage in patients with coronary heart disease, 

stroke, peripheral arterial disease or abdominal aortic 

aneurysm 342 

Olofsson, B. see O’Meara, E. 1920 

Olschewski, H. see Galiè, N. 2243 

Olschewski, M. see Brunner, M. 88 

Olsson, S.B. New advances in stroke prevention in atrial 

fibrillation: ximelagatran and direct thrombin inhibition B20 

O’Meara, E., Solomon, S., McMurray, J., Pfeffer, M., Yusuf, S., 

Michelson, E., Granger, C., Olofsson, B., Young, J.B. and 

Swedberg, K. Effect of candesartan on New York Heart 

Association functional class. Results of the Candesartan in 

heart failure: Assessment of Reduction in Mortality and 

morbidity (CHARM) programme 1920 

On-TIME study group see van’t Hof, A.W.J. 837 

O’Neill, W.W. see Greaves, K. 847 

Opasich, C. see Arbustini, E. F40 

Opie, L.H. see Essop, M.F. 1765 

Opolski, G. see Patten, M. 1395 

Orazi, S. see Raviele, A. 1741 

Ormezzano, O. see Cracowski, J.-L. 1675 

Orsolini, P. see Ghio, S. F35 

Orth-Gomér, K. see Rosengren, A. 56 

Ortlepp, J.R., Schmitz, F., Mevissen, V., Weiß, S., Huster, J., 

Dronskowski, R., Langebartels, G., Autschbach, R., Zerres, 

K., Weber, C., Hanrath, P. and Hoffmann, R. The amount of 

calcium-deficient hexagonal hydroxyapatite in aortic valves 

is influenced by gender and associated with genetic 

polymorphisms in patients with severe aortic stenosis 514 

Osman, N.F. see Azevedo, C. 1419 

Osswald, S. 

see Claude, J. 2195 

see Kaiser, C. 1036 

Östergren, J., Sleight, P., Dagenais, G., Danisa, K., Bosch, J., 

Qilong, Y. and Yusuf, S. for the HOPE study investigators 

Impact of ramipril in patients with evidence of clinical or 

subclinical peripheral arterial disease 17 

Osterwalder, R.H. see Zellweger, M.J. 3 

Östör, E. see De Bacquer, D. 121 

Oto, A. Brugada sign: a normal variant or a bad omen? Insights 

for risk stratification and prognostication 810 

Oto, A. see Horstkotte, D. 267 

Ottervanger, J.P. 



Ottervanger, J.P., Armstrong, P., Barnathan, E.S., Boersma, E., 

Cooper, J.S., Ohman, E.M., James, S., Wallentin, L. and 

Simoons, M.L., for the GUSTO IV-ASC Investigators 

Association of revascularisation with low mortality in non-ST 

elevation acute coronary syndrome, a report from GUSTTO 

IV-ACS 1494 

Ottesen, M. see Kragelund, C. 1891 

Otto, C.M. Aortic stenosis: even mild disease is significant 185 

xix 

Author index 

Ou, P., Bonnet, D., Auriacombe, L., Pedroni, E., Balleux, F., 

Sidi, D. and Mousseaux, E. Late systematic hypertension and 

aortic arch geometry after successful repair of coarctation 

of the aorta 1853 

Oudkerk, M. see Oei, H.-H. 48 

Ovize, M. see Argaud, L. 2019 

Pacher, R. see Nuhr, M.J. 136 

Pachori, A.S. see Melo, L.G. E24 

Pacini, D. see Leone, O. 1237 

Packard, C, Improving outcomes through statin therapy – a 

review of ongoing trials A28 

PACS group of investigators see Bazzino, O. 859 

Padeletti, L., Giaccardi, M., Turreni, F., Musilli, N., Colella, A., 

Pieragnoli, P., Michelucci, A., Ricciardi, G. and Porciani, M.C. 

Influence of QRS prolongation on the natural history of CHF 

D79 

Paetsch, I. see Wahl, A 1230 

Pagani, F. see Rinaldi, M. F81 

Pagano, D. see Pitt, M. 500 

Palatini, P.see Winnicki, M. 1281 

Palmisano, J. see de Lemos, J.A. 1688 

Panagiotakos, D.B., Pitsavos, C., Chrysohoou, C., Tsetsekou, E., 

Papageorgiou, C., Christodoulou, G. and Stefanadis, C. 

Inflammation, coagulation, and depressive symptomatology 

in cardiovascular disease-free people; the ATTICA study 492 

Panaretou, M.see Dernellis, J. 1100 

Panigada, S. see Vanoli, E., F7 

Panteghini, M. Role and importance of biochemical markers in 

clinical cardiology 1187 

Papageorgiou, C. see Panagiotakos, D.B. 492 

PARI-MI investigators see Dirksen, M.T. 392 

Pasini, E. see Bachetti, T. F16 

Pasotti, M. 




Pasquet, A. see Lim, P. 2048 

Passino, C. see Emdin, M. F68 

Patel, D.N. and Bailey, S.R. Role of BNP in patients with severe 

asymptomatic aortic stenosis 1972 

Patten, M., Maas, R., Bauer, P., Lüdertz, B., Sonntag, F., 

Dluzniewski, M., Hatala, E., Opolski, G., Müller, H.-W., 

Meinertz, T. for the SOPAT Investigators Suppression of 

paroxysmal atrial tachyarrhythmias- results of the SOPAT 

trial 1395 

Patterson, C.C. see Yarnell, J.W.G. 1049 

Paul, V.E. see Ellery, S.M. D117 

Pavie, A. see Horstkotte, D. 267 

Peacock, A. see Galiè, N. 2243 

Pedersen, T.R. see LaRosa, J.C. C1 

Pedroni, E. see Ou, P. 1853 

Peeters, A. see Mamun, A.A. 409 

Pekkarinen, H. see Barengo, N.C. 2204 

Peltola, P. see Märkkäinen, S. 885 

Pennell, D.J., Sechtem, U.P., Higgins, C.B., Manning, W.J., 

Pohost, G.M., Rademakers, F.E., van Rossum, A.C., Shaw, 

L.J. and Yucel, E.K. Clinical indications for cardiovascular 

magnetic resonance (CMR): Consensus Panel Report 1940 

Pentimalli, F. see Vanoli, E., F7 

Perera, D., Kanaganayagam, G. and Marber, M. Stem cells in 

unstable angina: the dynamic duo 999 

Perez de Arenaza, D. see Bazzino, O. 859 

Perez de Isla, L. see Zamorano, J. 2086 

Pérez-Vizcayno, M.-J. see Alfonso, F. 1829 

Permanyer-Miralda, G. see Evangelista, A. 81 

Pescher, M., Vernooy, K., Cornelussen, R.N., Verbeek, X.A.A.M., 

Reneman, R.S., Vos, M.A. and Prinzen, F.W. Structural, 

electrical and mechanical remodeling of the canine heart in 

AV-block and LBBB D61 

Peterson, M. see Herlitz, J. 232 

Pethig, K. see Angermann, C.E. 1626 



Author index 

Petrie, M.C. and Zijlstra, F. Reflections on the Danish Revolution 

540 

Petronio, S. see van’t Hof, A.W.J. 837 

Petrowitsch, T. see Hanefield, M. 10 

Pette, D. see Nuhr, M.J. 136 

Petzina, D. see Hanefield, M. 10 

Peuhkurinen, K. see Märkkäinen, S. 885 

Pezzali, N. see Covolo, L. 1534 

Pfeffer, M. 



Pfeffer, M.A. see Velazquez, E.J. 1911 

Pfiffner, D. see Togni, M. 1208 

Pfisterer, M. 



Pfisterer, M.E. see Zellweger, M.J. 3, 543 

Phillips, B.G. see Svatikova, A. 1325 

Piccichè, A.see Covolo, L. 1534 

Picó, F.see Lopez-Palop, R. 2040 

Piepoli, M.F. see Scott, A.C. 1806 

Pieragnoli, P. see Padeletti, L. D79 

Pieske, B. Reverse remodeling in heart failure – fact or fiction? 

D66 

Pietra, G. see Galiè, N. 2243 

Pijls, N.H.J. see Barbato, E. 219, 2034 

Pijls, N.H.J. The interventionalist’s dilemma: innocent intimal 

hyperplasia or in-stent restenosis? 1970 

Pillière, R. see Milleron, O. 728 

Pinar, E. see Lopez-Palop, R. 2040 

Pinna, G.D. 

see Capomolla, S. F91 


Pinto, F. see Bassand, J.-P. 804 

Pinto, Y.M. see van Berio, J.H. 812 

Pitsavos, C. see Panagiotakos, D.B. 492 

Pitschner, H.F. see Brandt, R.R. D25 

Pitt, B. see Sharma, R. 1021 

Pitt, M., Dutka, D., Pagano, D., Camici, P. and Bonser, R. The 

natural history of myocardium awaiting revascularisation in 

patients with impaired left ventricular function 500 

Piwowarska, W. see Gackowski, A. 1788 

Pizzi, C. 

see Arroyo-Espliguero, R. 401 

see Manfrini, O. 1502 

Pizzuto, F. see Voci, P. 1480, 1867 

Platsch, G. see Voigt, J.-U. 1517 

Plessy-Robinson, Le see Galiè, N. 2243 

Plichon, D. see de Groote, P. 656 

Pocock, S., Wilhelmsen, L., Dickstein, K., Francis, G. and 

Wittes, J. The data monitoring experience in the MOXCON 

trial 1974 

Pocock, S.J. see Clayton, T.C. 1641 

Pohost, G.M. see Pennell, D.J. 1940 

Pola, P. see Gabrielli, M. 64 

Pola, R. see Gabrielli, M. 64 

Poletti, R. see Emdin, M. F68 

Pollak, A., Rokach, A., Blumenfeld, A., Rosen, L.J., Resnik, L. 

and Dresner Pollak, R. Association of oestrogen receptor 

alpha gene polymorphism with the angiographic extent of 

coronary artery disease 240 

Pols, H.A.P. see Schut, A.F.C. 2143 

Pomar, F. see Alfonso, F. 1829 

Ponikowski, P. see Mortara, A. F99 

Poole-WIlson, P.A. 


Poole-Wilson, P.A. 

see Clayton, T.C. 1641 

see Sato, M. 537 

Popma, J.J. see Degertekin, M. 32 

Porcher, R. see Steg, P.G. 2187 

Porciani, M.C. see Padeletti, L. D79 

xx 

Possemiers, N. see Conraads, V.M. 1797 

Post, M.C., Janssens, S., Van de Werf, F. and Budts, W. 

Responsiveness to inhaled nitric oxide is a predictor for midterm 

survival in adult patients with congenital heart defects 

and pulmonary arterial hypertension 1651 

Potgieter, A. see Rydén, 611 

Pouchelon, J.-L. see Chetboul, V. 1934 

Pousset, F. see Gackowski, A. 1788 

Prasad, S.K. see Mikhail, G.W. 431 

Pratter, A. see Steger, C. 1734 

Pres, H. see Goldenberg, I. 212 

Prevention of Atrial Fibrillation after Cardioversion Investigators 


Prinzen, F.W. see Pescher, M. D61 

Priori, S.G., Bassaert, L.L., Chamberlain, D.A., Napolitano, C., 

Arntz, H.R., Koster, R.W., Monsieurs, K.G., Capucci, A. and 

Wellens, H.J. ESC-ERC recommendations for the use of 

automated external defibrillators (AEDs) in Europe 437 

Prontera, C. see Emdin, M. F68 

Protonotarios, N. see Basso, C. 531 

Puggioni, E. see Solano, A. 1116 

Puglisi, A., Lunati, M., Marullo, A.G.M., Bianchi, S., Feccia, M., 

Sgreccia, F., Vicini, I., Valsecchi, S., Musumeci, F. and Vitali, 

E. Limited thoracatomy as a second choice alternative to 

transvenous implant for cardiac resynchronisation therapy 

delivery 1063 

Pyörälä, K. 


see De Bacquer, D. 121 

see Koukkunen, H. 329 

Qilong, Y. see Östergren, J. 17 

Quittan, M. see Nuhr, M.J. 136 

Raattikainen, M.J.P. see Junttila, M.J. 874 

Rabelink, T.J. see Olijhoek, J.K. 342 

Rademakers, F.E. see Pennell, D.J. 1940 

Radke, P.W., Kobella, S., Kaiser, A., Franke, A., Schubert, D., 

Grube, E., Hanrath, P. and Hoffmann, R. Treatment of instent 

restenosis using a paclitaxel-eluting stent: acute 

results and long-term follow-up of a matched-pair 

comparison with intracoronary ß-radiation therapy 920 

Raeber, L. see Billinger, M. 565 

Raffestin, B.G. see Milleron, O. 728 

Rahmel, A. see Angermann, C.E. 1626 

Ramires, J.A.F. see Soares, A.M. 1927 

Ramírez. C. see Angiolillo, D.J. 1903 

Ramsey, K.E. see de Lemos, J.A. 1688 

Rapezzi, C. see Leone, O. 1237 

Rasmussen, V. see Sajadieh, A. 363 

RAte Control versus Electrical cardioversion for persistend atrial 

fibrillation study group see Hagens, V.E. 1542 

Ratliff, N.B. see Yousufuddin, M. 377 

Rauramaa, R. see Laukkanen, J.A. 1428 

Raute-Kreinsen, U. see Höcht-Zeisberg, E. 749 

Ravel investigators see Abizaid, A. 107 

Ravens, U. see Dobrev, D. 1091 

Raviele, A., Giada, F., Menozzi, C., Speca, G., Orazi, S., 

Gasparini, G., Sutton, R. and bridnole, M. for the Vasovagal 

Syncope and Pacing trial Investigators A randomized, 

double-blind, placebo-controlled study of permanent cardiac 

pacing for the treatment of recurrent tilt-induced vasovagal 

syncope, The vasovagal syncope and pacing trial (SYNPACE) 

1741 

Raviele, A. see Brignole, M. 2054 

Raybaud, F. see Scavée, C. 963 

Razzini, C. see Martuscelli, E. 1043 

Redington, A.N. see Cheung, M.M.H. 2238 

Redwood, S. see Greaves, K. 847 

Reeves, B.C. see Ascione, R. 765 

Regar, E. see Degertekin, M. 32 

Reggiani, M.L.B. see Leone, O. 1237 



Rehfeld, J.F. see Goetze, J.P. 759 

Reichart, B. see Bengel, F.M. 1726 

Reichmann, H. see Braun, M. 424 

Reisinger, J., Gatterer, E., Lang, W., Vanicek, T., Eisserer, G., 

Bachleitner, T., Niemeth, C., Aicher, F., Grander, W., 

Heinze, G., Kühn, P. and Siostrzonek, P. Flecainide versus 

ibutilide for immediate cardioversion of atrial fibrillation of 

recent onset 1318 

Reithmann, C.see Steinbeck, G. 1277 

Reneman, R.S. see Pescher, M. D61 

ReoPro-BRIDGING Study Group see Gyöngyösi, M. 2125 

Repetto, A. see Arbustini, E. F40 

Repetto, A., Serio, A., Pasotti, M., Fontana, A., Bertoletti, A., 

Scelsi, L., Magrini, G. Monti, L., Campana, C., Ghio, S. 

Tavazzi, L and Arbustini, E. Rescreening of "healthy" 

relatives of patients with dilated cardiomyopathy identifies 

subgroups at risk of developing the disease F54 

Res, J.C. see Kimman, G.P. 2232 

Resnik, L. see Pollak, A. 240 

Restenosis Intra-stent: Balloon angioplasty versus elective 

Stenting (RIBS) investigators see Alfonso, F. 1829 

Rettemeier. G. see Vogt, F. 1330 

Reuter, S. see Bordachar, P. 879 

Revera, M. see Campana, C. F61 

Rhoden, W.E. see Channer, K.S. 144 

Ricci, D. see Rinaldi, M. F81 

Ricciardelli, B. see Briguori, C. 206, 1822 

Ricciardi, G. see Padeletti, L. D79 

Richard, V. see Chetboul, V. 1934 

Rickenbacher, P. see Claude, J. 2195 

RICO survey working group see Zeller, M. 308 

Rienmüller, R. see Maisch, 587 

Rihal, C.S. see Herrmann, J. 2134 

Rinaldi, M., Pagani, F., Gazzoli, F., Alloni, A., Ricci, D. and 

Vigano, M. Left ventricular assistance from bridge to 

transplantation to destination therapy. The Pavia 

experience F81 

Rioufol, G. see Argaud, L. 2019 

Risérus, U. see Ärnlöv, J. 2220 

Ristic, A.D. see Maisch, 587 

Risuis, T. see Willems. S. 1249 

Rittenhouse, L.M. see Velazquez, E.J. 1911 

Ritter, P. see Cazeau, S. I83 (2003) 

Riva, S. see Bella, P.D. 1127 

Rivero-Ayerza, M., De Backer, T., Vanderheyden, M., Geelen, 

P., Goethals, M., de Zutter, M., Kalpakos, D. and Brugada, 

P. Indications for cardiac resynchronisation therapy: should 

they be extended? I97 (2003) 

Riviezzo, G. see Briguori, C. 206, 1822 

Robb, S.D. see Nielsen, O.W. 1718 

Robertson, A.C. see Verma, S. 1754 

Rochitte, C.E. see Azevedo, C. 1419 

Röcken, C.see Goette, A. 1185 

Rodés, J. see Cortadellas, J. 224 

Rodrigo, J.L. see Zamorano, J. 2086 

Rodriguez, L.A.G. see Patrono, C. 166 

Rodríguez-Artalejo, F. see Gonseth, J. 1570 

Rodriquez, R.-M. see Steg, P.G. 2187 

Roe, M.T., Mahaffey, K.W., Kilaru, R., Alexander, J.H., 

Akkerhuis, K.M., Simoons, M.L., Harrington, R.A., Tardiff, 

B.E., Granger, C.B., Ohman, E.M., Moliterno, D.J., Lincoff, 

A.M., Armstrong, P.W., Van de Werf, F., Califf, R.M. and 

Topol, E.J. Creatine kinase-MS elevation after percutaneous 

coronary intervention predicts adverse outcomes in patients 

with acute coronary syndromes 313 

Roelandt, J.R.T.C. see van Rijen, E.H.M. 1605 

Roethemeyer, S. see Wahl, A 1230 

Roffi, M. and Topol, E.J. Percutaneous coronary intervention in 

diabetic patients with non-ST-segment elevation acute 

coronary syndromes 190 

Rogers, P. see Mikhail, G.W. 431 

Rokach, A. see Pollak, A. 240 

xxi 

Author index 

Romagnoli, A. see Martuscelli, E. 1043 

Romeo, F. 

see Martuscelli, E. 1043 

see Voci, P. 1480, 1867 

Rondinini, L. see Mariotti, R. F87 

Roos-Hesselink, J.W., Meijboom, F.J., Spitaels, S.E.C., van 

Domburg, R., van Rijen, E.H.M., Utens, E.M.W.J., Bogers, 

A.J.J.C. and Simoons, M.L. Outcome of patients after 

surgical closure of ventricular septal defect at young age: 

longitudinal follow-up of 22-34 years 1057 

Roos-Hesselink, J.W., Meijboom, F.J., Spitaels, S.E.C., van 

Domburg, R., van Rijen, E.M.W.J., Utens, J., McGhie, J., 

Bos, E., Bogers, A.J.J.C. and Simoons, M.L. Decline in 

ventricular function and clinical condition after mustard 

repair for the transposition of the great arteries (a 

prospective study of 22-29 years) 1264 

Roos-Hesselink, J.W. see van Rijen, E.H.M. 1605 

Rosano, G.M.C. see Vitale, C. 1814 

Rosen, L.J. see Pollak, A. 240 

Rosén, M. see Schaufelberger, M. 300 

Rosen, S.D. Hearts and minds: psychological factors and the 

chest pain of cardiac syndrome X 1672 

Rosen, S.D., Murphy, K., Leff, A.P., Cunningham, V., Wise, 

R.J.S., Adams, L., Coats, A.J.S. and Camici, P.G. Is central 

nervous system processing altered in patients with heart 

failure? 952 

Rosenberg, I.H. see Sundström, J. 523 

Rosengren, A. see Schaufelberger, M. 300 

Rosengren, A., Wallentin, L., Gitt, A.K., Behar, S., Battler, A. 

and Hasdai, D. Sex, age and clinical presentation of acute 

coronary syndromes 663 

Rosengren, A., Wilhelmsen, L. and Orth-Gomér, K. Coronary 

disease in relation to social support and social class in 

Swedish men. A 15 year follow-up in the study of men born 

in 1933 56 

Rosenhek, R., Klaar, U., Schemper, M., Scholten, C., Heger, M., 

Gabriel, H., Binder, T., Maurer, G. and Baumgartner, H. Mild 

and moderate aortic stenosis. Natural history and risk 

stratification by echocardiography 199 

Rosenhek, R. see Mascherbauer, J. 787 

Rössig, L., Fichtlscherer, S., Heeschen, C., Berger, J., 

Dimmeler, S. and Zeiher, A.M. The pro-apoptotic serum 

activity is an independent mortality predictor of patients 

with heart failure 1620 

Rossini, P. see Vitale, C. 1814 

Rostock, T. see Willems. S. 1249 

Rothenbacher, D. see Twardella, D. 2101 

Rouleau, J.-L. see Velazquez, E.J. 1911 

Rubanyi, G.M. The design and preclinical testing of Ad5FGF-4 to 

treat chronic myocardial ischaemia E12 

Rubin, L.J. see Galiè, N. 2243 

Rudys, A. see Celutkiene, J. 932 

Ruidavets, J.-B., Bataille, V., Dallongeville, J., Simon, C., 

Bingham, A., Amouyel, P., Arveiler, D., Ducimetière, P. and 

Ferrièes, J. Alcohol intake and diet in France, the 

prominent role of lifestyle 1153 

Ruiz, J. see Simeoni, E. 1438 

Rumley, A. see Lowe, G.D.O. 252 

Rummukainen, J. see Märkkäinen, S. 885 

Rumpold, H. see Schillinger, M. 742 

Rumsfeld, J.S. and Masoudi, F.A. Heart failure disease 

management wotks, but will it succeed? 1565 

Rumsfeld, J.S. and Masoudi, F.A. Sex differences: implications 

for heart failure care 101 

Rupp, M. see Hanefield, M. 10 

Rydberg, E. see Andersson, P. 1776 

Rydén, L. see Bartnik, M. 1880, 1990 

Rydén, L., Stokoe, G., Breithardt, G., Lindemans, F. and 

Potgieter, A. on behalf of Task Force 2 of the 

Cardiovascular Round Table of the European Society of 

Cardiology Patient access to medical technology across 

Europe 611 



Author index 

Saad, Y. see Yousufuddin, M. 377 

Sabaté, M. 

see Alfonso, F. 1829 


Sabeti, S. see Schillinger, M. 742 

Sacks, F.M. Do statins play a role in the early management of the 

acute coronary syndrome? A32 

Sadoul, N. see Zannad, F. I105 (2003) 

Saeed, B.T. see Channer, K.S. 144 

Sahara, M., Kirigaya, H., Oikawa, Y., Yajima, J., 

Nagashima, K., Hara, H., Ogasawara, K. and Aizawa, 

T. Soft plaque detected on intravascular ultrasound is 

the strongest predictor of in-stent restenosis: an 

intravascular ultrasound study 2026 

Sajadieh, A., Nielsen, O.W., Rasmussen, V.., Hein, H.O., 

Abedini, S. and Hansen, J.F. Increased heart rate and 

reduced heart-rate variability are associated with subclinical 

inflammation in middle-aged and elderly subjects with no 

apparent heart disease 363 

Sakata, Y. see Yamamoto, K. 1221 

Salas, A. see Evangelista, A. 81 

Salerno-Uriarte, J.A. see Tritto, M. 2155 

Salio, M. see Latini, R. 292 

Salonen, J.T. see Laukkanen, J.A. 1428 

Salonen, R. see Laukkanen, J.A. 1428 

Samani, N.J. see Tobin, M.D. 459 

Samuelsson, O. see Lindholm, L.H. H31 

Sanders, P. see Scavée, C. 963 

Sanderson, J.E. BNP or echocardiography for monitoring heart 

failure? 1763 

Sans, S. In search of the grail: the never-ending story of 

biomarkers for coronary risk prediction 1271 

Sans, S. see De Bacquer, D. 121 

Santini, M. see Colivicchi, F. 1749 

Santoliquido, A. see Gabrielli, M. 64 

Sato, M., Harding, S.E. and Poole-Wilson, P.A. ß-blockers, 

myocardial ischaemia and collateral circulation 537 

Satomi, K. see Noda, T. 2149 

Saura, D. see Lopez-Palop, R. 2040 

Sawyer, D.B. see Sundström, J. 1509 

Scarpato, P. see Briguori, C. 206, 1822 

Scavée, C., Jaïs, P., Hsu, L.-F., Sanders, P., Hocini, M., 

Weerasooriya, R., Macle, L., Raybaud, F., Clementy, J. and 

Haïssaguerre, M. Prospective randomised comparison of 

irrigated-tip and large-tip catheter ablation of cavotricuspid 

isthmus-dependent atrial flutter 963 

Scelsi, L. 


see Ghio, S. F35 


Schaar, J.A., Muller, J.E., Falk, E., Virmani, R., Fuster, V., 

Serruys, P.W., Colombo, A., Stefanadis, C., Casscells, S.W., 

Moreno, P.R., Maseri, A. and van der Steen, A.F.W. 

Terminology for high-risk and vulnerable coronary artery 

plaques. Report of a meeting on the Vulnerable Plaque, 

June 17 and 18, 2003, Santorin, Greece 1077 

Schächinger, V. see Fichtlscherer, S. 1412 

Schäfers, M. see Vahlhaus, C. 151 

Schalij, M.J. see Steendijk, P. D35 

Scharnagl, H. see März, W. 2109 

Schaufelberger, M., Swedberg, K., Köster, M., Rosén, M. and 

Rosengren, A. Decreasing one-year mortality and 

hospitalization rates for heart failure in Sweden. Data from 

the Swedish Hospital Discharge Registry 1988 to 2000 300 

Schechter, M. see Goldenberg, I. 212 

Scheinert, D., Krankenberg, H., Schmidt, A., Gummert, J.F., 

Nitzsche, S., Scheinert, S., Bräunlich, S., Sorge, I., Krakor, 

R., Biamino, G., Schuler, G. and Mohr, F.W. Endoluminal 

stent – graft replacement for acute rupture of the 

descending thoracic aorta 694 

Scheinert, S. see Scheinert, D. 694 

Scheld, H.H. see Vahlhaus, C. 151 

xxii 

Schellekens, S. and Verheugt, F.W.A. Hotline sessions of the 

26th European Society of Cardiology 2164 

Schemper, M. see Rosenhek, R. 199 

Schepers, D. see Vanhees, L. 1120 

Schiller, N.B. see Leung, J.M. 1836 

Schillinger, M., Exner, M., Miekusch, W., Amighi, J., Sabeti, S., 

Muellner, M., Rumpold, H., Wagner, O. and Minar, E. Statin 

therapy improves cardiovascular outcome of patients with 

peripheral artery disease 742 

Schima, H. see Mascherbauer, J. 787 

Schindler, C. 



Schiza, S.I. see Simantirakis, E.N. 1070 

Schlaüpfer, H. see Kaiser, C. 1036 

Schlegl. M. see Butter, C. D106 

Schlott, T. see Höcht-Zeisberg, E. 749 

Schmidinger, H. see Stix, G. 650 

Schmidt, A. see Scheinert, D. 694 

Schmidt, G. see Simões, M.V. 551 

Schmidt, H. see Lamp, B. D5 

Schmieddehausen, K. see Voigt, J.-U. 1517 

Schmitt, C. 


see Zrenner, B. 2226 

Schmitz, F. see Ortlepp, J.R. 514 

Schnohr, P. see Frikke-Schmidt, R. 943 

Schober, O. see Vahlhaus, C. 151 

Schoen, S. see Braun, M. 424 

Schoenhagen, P. The emerging role of delayed contrastenhanced 

magnetic resonance imaging in the peri-operative 

evaluation of patients undergoing coronary revascularisation 

1279 

Scholte op Reimer, W.J.M. see Lenzen, M.J. 1214 

Scholten, C. see Rosenhek, R. 199 

Scholten, M.F. see Kimman, G.P. 2232 

Schömig, A. 

see Gorchakova, O. 1898 

see Hoppmann, P. 335 

see Kastrati, A. 454 



Schömig, E. see Kastrati, A. 454 

Schraeder, R. see Braun, M. 424 

Schreiber, K. see Bengel, F.M. 1726 

Schreieck, J. see Zrenner, B. 2226 

Schubert, D. see Radke, P.W. 920 

Schuler, G. see Scheinert, D. 694 

Schulte-Eistrup, S. see Hansky, B. D53, D112 

Schut, A.F.C., Bleumink, G.S., Stricker, B.H. Ch., Hofman, A., 

Witteman, J.C.M., Pols, H.A.P., Deckers, J.W., Deinum, J. 

and van Duijn, C.M. Angiotensin converting enzyme 

insertion/deletion polymorphism and the risk of heart 

failure in hypertensive subjects 2143 

Schwaiger, M. 

see Bengel, F.M. 1726 


Schwammenthal, E. see Goldenberg, I. 212 

Schwarz, E.R. 

see Angermann, C.E. 1626 


Schwenkglenks, M. see Claude, J. 2195 

Schwerzmann, M. see Torti, S.R. 1014 

Schwinger, R.H.G. see Bundkirchen, A. D57 

Schwitter, J. see Giang, T.H. 1657 

Scott, A.C., Wensel, R., Davos, C.H., Georgiadou, P., Davies, 

L.C., Coats, A.J.S., Francis, D.P. and Piepoli, M.F. Putative 

contribution of prostaglandin and bradykinin to muscle 

hyperactivity in patients on ACE-inhibitor therapy for 

chronic heart failure 1806 

Sebastia, C. see Evangelista, A. 81 

Sechtem, U.P. see Pennell, D.J. 1940 



Seehra, H.K. see Ascione, R. 765 

Seferovic, P.M. see Maisch, 587 

Segev, A., Kasam, S., Buller, C.E., Lau, H.K., Sparkes, J.D., 

Connelly, P.W., Seidelin, P.H., Natarajan, M.K., Cohen, E.A. 

and Strauss, B.H. Pre-procedural plasma levels of C-reactive 

protein and interleukin-6 do not predict late coronary 

angiographic restenosis after elective stenting 1029 

Seibæk, M. see Gustafsson, F. 129, 1711 

Seidelin, P.H. see Segev, A. 1029 

Seifert, M. see Butter, C. D106 

Seiler, C. 


see Torti, S.R. 1014 

Seipel, L. see Fetsch, T. 1385 

Selhub, J. see Sundström, J. 523 

Senges, J. 



Senior, R. see Greaves, K. 847 

Serio, A. 




Serneri, G.G.N., Coccheri, S., Marubini, E. and Violi, F., for the 

Committees and the Investigators of the Drug Evaluation in 

Atherosclerotic Vascular Disease in Diabetics (DAVID) Study 

Group Picotamide, a combined inhibitor of thromboxane A2 

synthase and receptor, reduces 2-year mortality in diabetics 

with peripheral arterial disease: The DAVID study 1845 

Serricchio, M. see Gabrielli, M. 64 

Serruys, P.W. 


see Degertekin, M. 32 


see Verheye, S. 158 

Serruys, P.W. and Aoki, J. Therapeutic options for patients with 

chronic myocardial ischaemia E2 

Sgreccia, F. see Puglisi, A. 1063 

Shamsuzzaman, A.S. see Svatikova, A. 1325 

Sharma, R., Francis, D.P., Pitt, B., Poole-WIlson, P.A., Coats, 

A.J.S. and Anker, S.D. Haemoglobin predicts survival in 

patients with chronic heart failure: a substudy of the ELITE 

II trial 1021 

Shattock, M. see Greaves, K. 847 

Shaw, L.J. see Pennell, D.J. 1940 

Shaw, T.R.D. see Clayton, T.C. 1641 

Sheldon, R. Transient myocardial ischaemia: a new question 

about autonomic responses 1473 

Shenasa, M. see Willems. S. 1249 

Shepherd, J. and Matsuzawa, Y. Forward to Supplement A A1 

Shimada, M. see Baba, A. 1108 

Shimizu, M. see Konno, T. 246 

Shimizu, W. see Noda, T. 2149 

Shindler, D.M. Nonischaemic heart failure and diabetes mellitus 

629 

Shmilovich, H. see George, J. 1003 

Siafakas, N.S. see Simantirakis, E.N. 1070 

Sianos, G. see Degertekin, M. 32 

Sidi, D. see Ou, P. 1853 

Siebert, U. see Angermann, C.E. 1626 

Sievert, H. and Taaffe, M. Patent foramen ovale: the jury is still 

out 361 

Sillesen, H. What does the future hold for the patient with 

peripheral arterial disease? C43 

Silventoinen, K. see Hu, G. 2212 

Silverman, S.H. see Makin, A.J. 371 

Simantirakis, E.N., Schiza, S.I., Marketou, M.E., Chrysostomakis, 

S.I., Chlouverakis, G.I., Klapsinos, N.C., Siafakas, N.S. and 

Vardas, P.E. Severe bradyarrhythmias in patients with sleep 

apnoea: the effect of continuous positive airway pressure 

treatment. A long-term evaluation using an insertable loop 

recorder 1070 

xxiii 

Author index 

Simeoni, E., Winkelmann, B.R., Hoffmann, M.M., Fleury, S., 

Ruiz, J., Kappenberger, L., März, W. and Vassalli, G. 

Association of RANTES G-403A gene polymorphism with 

increased risk of coronary arteriosclerosis 1438 

Simes, J. see Colquhoun, D. 771 

Simões, M.V., Barthel, P., Matsunari, I., Nekolla, S.G., Schömig, 

A., Schwaiger, M., Schmidt, G. and Bengel, F.M. Presence of 

sympathetically denervated but variable myocardium and its 

electrophysiologic correlates after early revascularised 

acute myocardial infarction 551 

Simon, C. see Ruidavets, J.-B. 1153 

Simonetti, G. see Martuscelli, E. 1043 

Simonneau, G. see Galiè, N. 2243 

Simoons, M. see Batnick, M. 1880 

Simoons, M.L. 




see Roos-Hesselink, J.W. 1057, 1264 

Sinha, A.-M. see Stellbrink, C. D101 

Siostrzonek, P. see Reisinger, J. 1318 

Sipido, K.R.see Willems, R. 

Siwik, D.A. see Sundström, J. 1509 

Skjærpe, T. see Hole, T. 416 

Skrtic, S. see Eriksson, A.-L. 386 

Slama, M. see Steg, P.G. 2187 

Slany, J. see Steger, C. 1734 

Sleight, P. 


see Östergren, J. 17 

Smallhorn, J.F. see Cheung, M.M.H. 2238 

SMART study group see Olijhoek, J.K. 342 

Smith, G.D. see Martin, R.M. 778 

Snorgaard, O. see Kragelund, C. 1891 

Soares, A.M., Aiello, V.D., Andrade, J.L., Kajita, L.J., Soares, 

J.Jr, Morhy, S.S., Mathias, W.Jr, Lopes, A.A.B. and Ramires, 

J.A.F. Doppler flow evaluation can anticipate abnormal left 

lung perfusion after transcatheter closure of patent ductus 

arteriosus 1927 

Soares, J.Jr see Soares, A.M. 1927 

Sodeck, G. see Gyöngyösi, M. 2125 

Solano, A., Menozzi, C., Maggi, R., Donateo, P., Bottoni, N., 

Lolli, G., Tomasi, C., Croci, F., Oddone, D., Puggioni, E. 

and Brignole, M. Incidence, diagnostic yield and safety of 

the implantable loop-recorder to detect the mechanism of 

syncope in patients with and without structural heart 

disease 1116 

Soler-Soler, J. 


see Cortadellas, J. 224 

see Evangelista, A. 81 


Solomon, S. see O’Meara, E. 1920 

Somers, V.K. 

see Gami, A.S. 709 

see Svatikova, A. 1325 

Sonntag, F. see Patten, M. 1395 

SOPAT Investigators see Patten, M. 1395 

Sorge, I. see Scheinert, D. 694 

Sousa, A.G.M.R. see Abizaid, A. 107 

Sousa, J.E. 



Spac, J. see Velazquez, E.J. 1911 

Spadacini, G. see Tritto, M. 2155 

Sparkes, J.D. see Segev, A. 1029 

Spaulding, C. see Steg, P.G. 2187 

Speca, G. see Raviele, A. 1741 

Sperandio, M. see Martuscelli, E. 1043 

Sperzel, J. see Brandt, R.R. D25 

Spinale, F.G. Matrix metalloproteinase gene polymorphisms in 

heart failure: new pieces to the myocardial matrix puzzle 631 



Author index 

Spitaels, S.E.C. see Roos-Hesselink, J.W. 1057, 1264 

Sposato, B. see Vitale, C. 1814 

Sposito, A.C. Emerging insights into hypertension and 

dyslipidaemia synergies G8 

Staelens, F. see Barbato, E. 2034 

Sta˚hle, E. see Steuer, J. 1293 

Standl, E. see Batnick, M. 1880 

Stanton, E. see Yan, A.T. 2006 

Starling, R.C. see Yousufuddin, M. 377 

Steeds, R. see Tobin, M.D. 459 

Steeds, R.P. see Channer, K.S. 144 

Steendijk, P., Tulner, S.A.F., Wiener, M., Bleasdale, R.A., Bax, 

J.J., van der Wall, E.E., Vogt, J. and Schalij, M.J. Pressurevolume 

measurements by conductance catheter during 


Stefanadis, C. 

see Panagiotakos, D.B. 492 


Stefanidis, C. see Toutouzas, K. 1679 

Steg, P.G. and Juliard, J.-M. Enoxaparin in non-ST segment 

elevation acute coronary syndromes: duration of therapy is 

essential to benefit 1667 

Steg, P.G., Thuaire, C., Himbert, D., Carrié, D., Champagne, S., 

Coisne, D., Khalifé, K., Cazaux, P., Logeart, D., Slama, M., 

Spaulding, C., Cohen, A., Tirouvanziam, A., Montély, J.-M., 

Rodriquez, R.-M., Garbarz, E., Wijns, W., Durand-Zaleski, I., 

Porcher, R., Brucker,L., Chevret, S., Chastang, C. on behalf 

of the DECOPI investigators DECOPI (DEsobstruction 

COronaire en Post-Infarctus): a randomized multi-centre 

trial of occluded artery angioplasty after acute myocardial 


Steger, C., Pratter, A., Martinek-Bregel, M., Avanzini, M., 

Valentin, A., Slany, J. and Stöllberger, C. Stroke patients 

with atrial fibrillation have a worse prognosis than patients 

without: data from the Austrian Stroke registry 1734 

Stein, A. see Vogt, F. 1330 

Steinbeck, G. and Reithmann, C. Paroxysmal supraventricular 

tachycardia: preferential use of either adenosine or 

verapamil is dependent on the rate of tachycardia? 1277 

Stella, P.R., Elsman, P. and Doevendans, P.A. Remise in the 

treatment of in-stent restenosis 898 

Stellbrink, C., Breithardt, O.-A., Sinha, A.-M. and Hanrath, P. 

How to discriminate responders from non-responders to 

cardiac resynchronisation D101 

Stellbrink, C., Breithardt, O.A. and Hanrath, P. Technical 

considerations in implanting left ventricular pacing leads for 


Stellbrink, C. see Breithardt, O.A. D16 

Stephens, D. see Mikhail, G.W. 431 

Stephens, J.W. see Dhamrat, S.S. 468 

Steuer, J., Bjerner, T., Duvernoy, O., Jidéus, L., Johansson, L., 

Ahlström, H., Sta˚hle, E. and Lindahl, B. Visualization and 

quantification of peri-operative myocardial infarction after 

coronary artery by surgery with contrast-enhanced magnetic 

resonance imaging 1293 

Stevens, A. see Vanhees, L. 1120 

Stix, G., Borggrefe, M., Wolpert, C., Hindricks, G., Kottkamp, 

H., Böcker, D., Wichter, T., Mika, Y., Ben-Haim, S., 

Burkhoff, D., Wolzt, M. and Schmidinger, H. Chronic 

electrical stimulation during the absolute refractory period 

of the myocardium improves severe heart failure 650 

Stoel, M.G. see Mannaerts, H.F.J. 680 

Stokoe, G. see Rydén, 611 

Stöllberger, C. see Steger, C. 1734 

Störk, S. see Angermann, C.E. 1626 

Strasser, R.H. see Braun, M. 424 

Straus, S.M.J.M. see Bleumink, G.S. 1614 

Strauss, B.H. see Segev, A. 1029 

Stricker, B.H.Ch. 



Stumpf, M. see Argaud, L. 2019 

xxiv 

Sturkenboom, M.C.J.M. see Bleumink, G.S. 1614 

Stypmann, J. see Vahlhaus, C. 151 

Suarez, S.M. see Leone, O. 1237 

Sugeng, L. see Zamorano, J. 2086 

Sugiyama, T. see Baba, A. 1108 

Sulke, A.N. see Farwell, D.J. 1257 

Sullivan, L. see Sundström, J. 523 

Sundström, J., Evans, J.C., Benjamin, E.J., Levy, D., Larson, 

M.G., Sawyer, D.B., Siwik, D.A., Colucci, W.S., Wilson, 

P.W.F. and Vasan, R.S. Relations of plasma total TIMP-1 

levels to cardiovascular risk factors and echocardiographic 

measures: the Framingham heart study 1509 

Sundström, J., Sullivan, L., Selhub, J., Benjamin, E.J., 

D’Agostino, R.B., Jacques, P.F., Rosenberg, I.H., Levy, D., 

Wilson, P.W.F. and Vasan, R.S. Relations of plasma 

homocysteine to left ventricular structure and function: the 

Framingham Heart Study 523 

Suryapranata, H. 





Sutherland, G.R. 

see Breithardt, O.A. 535, D16 

see Celutkiene, J. 932 

see Merli, E. 1477 


Sutton, R. 

see Brignole, M. 2054 


Suyama, K. see Noda, T. 2149 

Svatikova, A., Wolk, R., Magera, M.J., Shamsuzzaman, A.S., 

Phillips, B.G. and Somers, V.K. Plasma homocysteine in 

obstructive sleep apnoea 1325 

Svensson, A.-M. see Björklund, E. 113 

Swedberg, K. 



see Meredith, P. H1 


see Schaufelberger, M. 300 

Swedberg, K. and McMurray, J.J.V. Angiotensin receptor 

blockers and heart failure: still CHARMing after VALIANT? 357 

Sweetnam, P.M. see Yarnell, J.W.G. 1049 

Szili-Torok, T. see Kimman, G.P. 2232 

Szucs, T. see Claude, J. 2195 

Taaffe, M. see Sievert, H. 361 

Takahashi, Y. see Yamamoto, K. 1221 

Takatsu, F. see Murase, Y. 970 

Tamani, M.H. see Yousufuddin, M. 377 

Tamargo, J. see Lópex-Sendón, J. 1341, 1454 

Tan, M. see Yan, A.T. 2006 

Tanabe, K. see Degertekin, M. 32 

Tanaka, K. see Iwakura, K. 1526 

Taneja, A.K., Collinson, J., Flather, M.D., Bakhai, A., de 

Arenaza, D.P., Wang, D., Adgey, J. and Fox, K.A.A. 

Mortality following non-ST elevation acute coronary 

syndrome: 4 years follow-up of the PRAIS UK Registry 

(Prospective Registry of Acute Ischaemic Syndromes in the 

UK) 2013 

Tardiff, B. see Roe, M.T. 313 

Tarricone, D. see Lombardi, F. 1242 

Tascón, J. see Alfonso, F. 1829 

Task Force 2 of the Cardiovascular Round Table see Rydén, 611 

Tavazzi, L 


Tavazzi, L. 



see Ghio, S. 571, F35 






Tavazzi, L. and Arbustini, E. A research project focusing on 

uncommon aspects and novel markers in congestive heart 

failure. Critical evaluation of multicentre research 

management F1 

Tavazzi, L. The ranolazine clinical experience I13 

Taylor, F.C. see Ascione, R. 765 

Taylor, P.R. see Törnwall, M.E. 1171 

Tebbe, U. 



Tendera, M. 

see Bassand, J.-P. 804 


Tenderich, G. 

see Angermann, C.E. 1626 

see Höcht-Zeisberg, E. 749 

Tenerz, Ä. see Bartnik, M. 1990 

TenVergert, E.M. see Hagens, V.E. 1542 

Terai, H. see Konno, T. 246 

Tessier, D. see Chetboul, V. 1934 

Teunissen, B.E.J., Jongsma, H.J. and Bierhuizen, M.F.A. 

Regulation of myocardial connexins during hypertrophic 

remodelling 1979 

The Task Force on Infective Endocarditis of the European Society 

of Cardiology: Horstkotte, D., Follath, F., Gutschik, E., 

Lengyel, M., Oto, A., Pavie, A., Soler-Soler, J., Thiene, G. 

and von Graevenitz, A. Guidelines on Prevention, Diagnosis 

and Treatment of Infective Endocarditis 267 

The Task Force on the Diagnosis and Management of Peridardial 

Diseases: Maisch, B., Seferovic, P.M., Ristic, A.D., Erbel, R., 

Rienmüller, R., Adler, Y., Tomkowski, W.Z., Thiene, G. and 

Yacoub, M.H. Guidelines on the Diagnosis and Management 

of Pericardial Diseases: Executive Summary 587 

The Task Force on the Use of Antiplatelet Agents in Patients with 

Atherosclerosic Cardiovascular Disease of the European 

Society of Cardiology, Patrono, C., Bachmann, F., Baigent, 

C., Bode, C., De Caterina, R., Charbonnier, B., Fitzgerald, 

D., Hirsh, J., Husted, S., Kvasnicka, J., Montalescot, G., 

Rodriguez, L.A.G., Verheugt, F., Vermylen, J. and 

Wallentin, L. Expert Concensus Document on the Use of 

Antiplatelet Agents 166 

Thelle, D.S. see Erikssen, G. 978 

Theodorakis, G. see Brignole, M. 2054 

Theuns, D.A.M.J. see Kimman, G.P. 2232 

Thibault, H. see Chetboul, V. 1934 

Thiene, G. 



see Maisch, 587 

Thiene, G., Corrado, D. and Basso, C. Cardiomyopathies: is it 

time for a molecular classification? 1772 

Thijs, V. More bad news about atrial fibrillation 1670 

Thomas, D. see Gackowski, A. 1788 

Thompson, J.R. see Tobin, M.D. 459 

Thoms, K. see Timmer, J.R. 926 

Thomsen, P.E.B. see Brignole, M. 2054 

Thomson, A. see Lowe, G.D.O. 252 

Thuaire, C. see Steg, P.G. 2187 

Thuillez, C. see Chetboul, V. 1934 

Thygesen, K. and Uretsky, B.F. Acute ischaemia as a trigger of 

sudden cardiac death D88 

Tijssen, J.G.P. 


see Nollen, G.J. 1146 

Tilling, K. see Martin, R.M. 778 

TIME investigators see Kaiser, C. 1036 

TIMI Study Group see Gibson, C.M. 1001, 1998 

Timmer, J.R., Ottervanger, J.P., Thoms, K., Hoorntje, J.C.A., 

de Boer, M.-J., Suryapranata, H. and Zijlstra, F. on behalf 

of the Zwolle myocardial infarction study group Long-term, 

xxv 

Author index 

cause-specific mortality after myocardial infarction in 

diabetes 926 

Tio, R.A. see Agema, W.R.P. 1163 

Tirouvanziam, A. see Steg, P.G. 2187 

Title, L.M. see Verma, S. 1754 

Tjan, T.D.T. see Vahlhaus, C. 151 

Tobin, M.D., Braund, P.S., Burton, P.R., Thompson, J.R., 

Steeds, R., Channer, K., Cheng, S., Lindpaintner, K. and 

Samani, N.J. Genotypes and haplotypes predisposing to 

myocardial infarction: a multilocus case-control study 459 

Togni, M., Balmer, F., Pfiffner, D., Maier, W., Zeither, A.M. and 

Neier, B. on behalf of the Working Group Interventional 

Cardiology and Coronary Pathophysiology of the European 

Society of Cardiology Percutaneous coronary intervention in 

Europe 1992-2001 1208 

Tognoni, G. see Latini, R. 292 

Toivonen, L. see Märkkäinen, S. 885 

Tomasi, C. see Solano, A. 1116 

Tomassini, M. see Martuscelli, E. 1043 

Tomkowski, W.Z. see Maisch, 587 

Tondi, P. see Gabrielli, M. 64 

Tonino, W.A.L. see Dirksen, M.T. 392 

Tonkin, A. see Colquhoun, D. 771 

Tonkin, A. The metabolic syndrome – a growing problem A37 

Topol, E.J. 


see Roffi, M. 190 

Torbicki, A. see Galiè, N. 2243 

Törnwall, M.E., Virtamo, J., Korhonen, P.A., Virtanen, M.J., 

Taylor, P.R., Albanes, D. and Huttunen, J.K. Effect of atocopherol 

and ß-carotene supplementation on coronary 

heart disease during the 6-year post-trial follow-up in the 

ATBC stydy 1171 

Torp-Pedersen, C. 

see Gustafsson, F. 129, 1711 


Torp-Petersen, C. see Kragelund, C. 1891 

Torti, S.R., Billinger, M., Schwerzmann, M., Vogel, R., Zbinden, 

R., Windecker, S. and Seiler, C. Risk of decompression illness 

among 230 divers in relation to the presence and size of 

patent foramen ovale 1014 

Toutouzas, K., Colombo, A. and Stefanidis, C. Inflammation and 

restenosis after percutaneous coronary intervention 1679 

Touzery, C. see Zeller, M. 308 

TRACE Study Group see Kragelund, C. 1891 

Trappe, H..J. see Fetsch, T. 1385 

Treese, N. see Fetsch, T. 1385 

Trenkwalder, P. Preventing the cardiovascular complications of 

hypertension H37 

Trevisi, N. see Bella, P.D. 1127 

Trial of Invasive versus Medical therapy in the Elderly (TIME) 

Investigators see Claude, J. 2195 

Tritto, M., De Ponti, R., Salerno-Uriarte, J.A., Spadacini, G., 

Marazzi, R., Moretti, R. and Lanzotti, M. Adenosine restores 

atrio-venous conduction after apparently successful ostial 

isolation of the pulmonary veins 2155 

Troseid, M., Lappega˚rd, K.T., Claudi, T., Dama˚s, J.K., M¢rkrid, 

L., Brendberg, R. and Mollnes, T.E. Exercise reduces plasma 

levels of the chemokines MCP-1 and IL-8 ib subjects with 

the metabolic syndrome 349 

Tschöpe, D. and Bode, C. Impaired glucose tolerance – a new 

risk factor? 1969 

Tsetsekou, E. see Panagiotakos, D.B. 492 

Tsuchimoto, K. see Baba, A. 1108 

Tulner, S.A.F. see Steendijk, P. D35 

Tundo, F. see Lombardi, F. 1242 

Tuomainen, P. see Märkkäinen, S. 885 

Tuomilehto, J. 

see Barengo, N.C. 2204 

see Hu, G. 2212 

Turolo, L. see Giannattasio, C. F30 

Turreni, F. see Padeletti, L. D79 



Author index 

Turschner, O., D’hooge, J., Dommke, C., Claus, P., Verbeken, 

E., De Scheerder, I., Bijnens, B. and Sutherland, G.R. The 

sequential changes in myocardial thickness and thickening 

which occur during acute transmural infarction, infarct 

reperfusion and the resultant expression of reperfusion 

injury 794 

Tuzcu, E.M. see Yousufuddin, M. 377 

Twardella, D., Küpper-Nybelen, J., Rothenbacher, D., 

Hahmann, H., Wüsten, B. and Brenner, H. Short-term 

benefit of smoking cessation in patients with coronary heart 

disease: estimates based on self-reported smoking data and 

serum cotinine measurements 2101 

Twisk, J. see Mannaerts, H.F.J. 680 

Tybærg-Hansen, A. see Frikke-Schmidt, R. 943 

Uchiyama, K. see Konno, T. 246 

Ueberfuhr, P. see Bengel, F.M. 1726 

Underwood, S.R., Bax, J.J., vom Dahl, J., Henein, M.Y., van 

Rossum, A.C., Schwarz, E.R., Vanoverschelde, J.-L., van der 

Wall, E.E. and Wijns, W. Imaging techniques for the 

assessment of myocardial hibernation. Report of a Study 

Group of the European Society of Cardiology 815 

Ungar, A. see Brignole, M. 2054 

Unger, T. Pharmacological aspects of candesartan, an effective 

angiotensin-type-1 receptor blocker H11 

Uretsky, B.F. see Thygesen, K. D88 

Utens, E.M.W.J. 

see Roos-Hesselink, J.W. 1057 

see van Rijen, E.H.M. 1605 

Utens, J. see Roos-Hesselink, J.W. 1264 

Vaes, J. see Conraads, V.M. 1797 

Vahanian, A. see Iung, B. 701 

Vahlhaus, C., Bruns, H.-J., Stypmann, J., Tjan, T.D.T., Janssen, 

F., Schäfers, M., Scheld, H.H., Schober, O., Breithardt, G. and 

Wichter, T. Direct epicradial mapping predicts the recovery of 

left ventricular dysfunction in chronic ischaemic myocardium 

151 

Val-HeFT investigators see Latini, R. 292 

Valdés, M. see Lopez-Palop, R. 2040 

Valentin, A. see Steger, C. 1734 

Valgimigli, M. see Agnoletti, L. F22 

Valsecchi, S. see Puglisi, A. 1063 

Van Belle, E. see de Groote, P. 656 

van Berio, J.H., Duboc, D. and Pinto, Y.M. Often seen but rarely 

recognised: cardiac complications of lamin A/C mutations 812 

Van Damme, L.C.A. see Verheye, S. 158 

Van de Veire, N. see Gillebert, T.C. 2185 

Van de Werf, F. 

see Goodman, N. 1382 

see Post, M.C. 1651 


van der Giessen, W.J. see Degertekin, M. 32 

van der Graaf, Y. see Olijhoek, J.K. 342 

van der Heide, J.A. see Mannaerts, H.F.J. 680 

van der Laarse, A. see Agema, W.R.P. 1163 

van der Meer, P., Voors, A.A., Lipsic, E., van Gilst, W.H. and van 

Veldhuisen, D.J. Eruthropoietin in cardiovascular diseases 285 

van der Steen, A.F.W. see Schaar, J.A. 1077 

van der Wall, E.E. 

see Agema, W.R.P. 1163 

see Nollen, G.J. 1146 



van Dijk, J.G. see Brignole, M. 2054 

van Domburg, R. see Roos-Hesselink, J.W. 1057, 1264 

van Domburg, R.T. see van Rijen, E.H.M. 1605 

van Duijn, C.M. see Schut, A.F.C. 2143 

van Exel, H. see Vanhees, L. 1120 

Van Gelder, I.C. see Hagens, V.E. 1542 

van Gilst, W. see Velazquez, E.J. 1911 

van Gilst, W.H. see van der Meer, P. 285 

xxvi 

van Hemel, N. Quinidine rehabilitated and more lessons from 

the PAFAC and SOPAT anti-arrhythmic drug trials for the 

prevention of paroxysmal atrial fibrillation 1371 

Van Hoof, V. see Conraads, V.M. 1797 

Van Langenhove, G. see Verheye, S. 158 

van Rijen, E.H.M. see Roos-Hesselink, J.W. 1057 

van Rijen, E.H.M., Utens, E.M.W.J., Roos-Hesselink, J.W., 

Meijboom, F.J., van Domburg, R.T., Roelandt, J.R.T.C., 

Bogers, A.J.J.C. and Verhulst, F.C. Medical predictors for 

psychopathology in adults with operated congenital heart 

disease 1605 

van Rijen, E.M.W.J. see Roos-Hesselink, J.W. 1264 

van Rossum, A.C. 

see Pennell, D.J. 1940 


Van Veldhuisen, D.J. 


see van der Meer, P. 285 

Van Veldhuissen, D.J. Unanswered questions in the treatment of 

heart failure I39 (2003) 

Van Wagoner, D.R. see Abdellhadi, R.H. 1089 

Vanderheyden, M. 

see Barbato, E. 2034 

see Rivero-Ayerza, M. I97 (2003) 

Vanhees, L., Kornaat, M., Defoor, J., Aufdemkampe, G., 

Schepers, D., Stevens, A., van Exel, H., can den Beld, J., 

Heidbüchel, H. and Fagard, R. Effect of exercise training in 

patients with an implantable cardioverter-defibrillator 1120 

Vanicek, T. see Reisinger, J. 1318 

Vanoli, E., Bacchini, S., Panigada, S., Pentimalli, F. and 

Adamson, P.B. Experimental models of heart failure F7 

Vanoverschelde, J.-L. 



van’t Hof, A.W.J. 




van’t Hof, A.W.J., Ernst, N., de Boer, M.-J., de Winter, R., 

Boersma, E., Bunt, T., Petronio, S., Marcel Gosselink, A.T., 

Jap, W., Hollak, F., Hoorntje, J..C.A., Suryapranata, H., 

Dambrink, J.-H.E. and Zijlstra, F. on behalf of the On-TIME 

study group Facilitation of primary coronary angioplasty by 

early start of a glycoprotein 2b/3a inhibitor: results of the 

ongoing tirofiban in myocardial infarction evaluation (On- 

TIME) trial 837 

Vantrimpont, P.J.M.J. see Lenzen, M.J. 1214 

Vardas, P.E. see Simantirakis, E.N. 1070 

Vartianinen, E. A lot more can be done to prevent cardiovascular 

diseases 457 

Vasan, R.S. see Sundström, J. 523, 1509 

Vasovagal Syncope and Pacing trial Investigators see Raviele, A. 

1741 

Vassalli, G. and Winkelmann, B.R. Molecular genetics of 

myocardial infarction: many genes, more questions than 

answers 451 

Vassalli, G. see Simeoni, E. 1438 

Vázquez, N. see Alfonso, F. 1829 

Velazquez, E.J., Francis, G.S., Armstrong, P.W., Aylward, P.E., 

Diaz, R., O’Connor, C.M., White, H.D., Henis, M., 

Rittenhouse, L.M., Kilaru, R., van Gilst, W., Ertl, G., 

Maggioni, A.P., Spac, J., Weaver, W.D., Rouleau, J.-L., 

McMurray, J.J.V., Pfeffer, M.A. and Califf, R.M. An 

international perspective on heart failure and left 

ventricular systolic dysfunction complicating myocardial 

infarction: the VALIANT registry 1911 

Ven de Werf, F. see Morrow, D.A. 1139 

Venge, P. see Björklund, E. 113 

Ventura, R. see Willems. S. 1249 

Verbeek, X.A.A.M. see Pescher, M. D61 

Verbeken, E. see Turschner, O. 794 

Verges, B. see Zeller, M. 308 



Verheugt, F. see Patrono, C. 166 

Verheugt, F.W.A. and Antman, E.M. Introduction to Supplement 

B B1 

Verheugt, F.W.A. see Schellekens, S. 2164 

Verheye, S., De Meyer, G.R.Y., Krams, R., Kockx, M.M., Van 

Damme, L.C.A., Gourabi, B.M., Knaapen, M.W.M., Van 

Langenhove, G. and Serruys, P.W. Intravascular 

thermography: Immediate functional and morphological 

findings 158 

Verhulst, F.C. see van Rijen, E.H.M. 1605 

Verma, S., Wang, C.-H., Lonn, E., Charbonneau, F., Buithieu, J., 

Title, L.M., Fung, M., Edworthy, S., Robertson, A.C. and 

Anderson, T.J. for the FATE investigators Cross-sectional 

evaluation of brachial artery flow-mediated vasodilation and 

C-reactive protein in healthy individuals 1754 

Vermeulen, K.M. see Hagens, V.E. 1542 

Vermylen, J. see Patrono, C. 166 

Vernooy, K. see Pescher, M. D61 

Vicini, I. see Puglisi, A. 1063 

Vigano, M. see Rinaldi, M. F81 

Viles-Gonzalez, J.F., Fuster, V. and Badimon, J.J. 

Atherothrombosis: A widespread disease with unpredictable 

and life-threatening consequences 1197 

Villain, E., Denjoy, I., Lupoglazoff, J.M., Guicheney, P., 

Hainque, B., Lucet, V. and Bonnet, D. Low incidence of 

cardiac events with ß-blocking therapy in children with long 

QT syndrome 1405 

Vincenzi, A. see Giannattasio, C. F30 

Violante, A. see Briguori, C. 206, 1822 

Violi, F. see Serneri, G.G.N. 1845 

Virmani, R. see Schaar, J.A. 1077 

Virtamo, J. see Törnwall, M.E. 1171 

Virtanen, K.S. see Lepäntalo, A. 476 

Virtanen, M.J. see Törnwall, M.E. 1171 

Visser, C.A. see Mannaerts, H.F.J. 680, 2073 

Visseren, F.L.J. see Olijhoek, J.K. 342 

Vitale, C., Wajngaten, M., Sposato, B., Gebara, O., Rossini, P., 

Fini, M., Volterrani, M. and Rosano, G.M.C. Trimetazidine 

improves left ventricular function and quality of life in 

elderly patients with coronary artery disease 1814 

Vitali, E. see Puglisi, A. 1063 

Vliegenthart, R. see Oei, H.-H. 48 

Voci, P., Pizzuto, F. and Romeo, F. Coronary flow: a new asset 

for the echo lab? 1867 

Voci, P., Pizzuto, F. and Romeo, F. The slippery slope 1480 

Vogel, M. see Cheung, M.M.H. 2238 

Vogel, R. see Torti, S.R. 1014 

Vogt, A. see Zeymer, U. 322 

Vogt, F., Stein, A., Rettemeier. G., Krott, N., Hoffmann, R., 

vom Dahl, J., Bosserhoff, A.-K., Michaeli, W., Hanrath, P., 

Weber, C. and Blindt, R. Long-term assessment of a novel 

biodegradable paclitaxel-eluting coronary polylactide stent 

1330 

Vogt, J. 




see Lamp, B. D5, D128 


Vogt, J., Heintze, J., Hansky, B., Güldner, H., Buschler, H. and 

Horstkotte, D. Implantation: tips and tricks – the 

cardiologist’s view D47 

Vogt, J., Heintze, J. Lamp, B., Hansky, B. and Horstkotte, D. 

Standard haemodynamic measurements D29 

Vogt, J., Lamp, B., Hansky, B., Heintze, J., Faber, L., Güldner, 

H., Körfer, R. and Horstfotte, D. The Bad Oeynhausen 

Experience D122 

Voigt, J.-U., Nixdorff, U., Bogdan, R., Exner, B., 

Schmieddehausen, K., Platsch, G., Kuwert, T., Daniel, W.G. 

and Flachskampf, F.A. Comparison of deformation imaging 

and velocity imaging for detecting regional inducible 

ischaemia during dobutamine stress echocardiography 1517 

xxvii 

Volterrani, M. see Vitale, C. 1814 

vom Dahl, J. 



von Beckerath, N. see Gorchakova, O. 1898 

von Graevenitz, A. see Horstkotte, D. 267 

von Leitner, E.-R. see Zahn, R. 1550 

von Schulthness, G.K. see Giang, T.H. 1657 

Voors, A.A. see van der Meer, P. 285 

Vos, M.A. see Pescher, M. D61 

Vrints, C.J. see Conraads, V.M. 1797 

Author index 

Waagstein, F. 

see Deedwania, P.C. 1300 


Wagner, A. see Butter, C. D106 

Wagner, F.M. see Angermann, C.E. 1626 

Wagner, O. see Schillinger, M. 742 

Wagoner, L.E. see Javaheri, S. 260 

Wahl, A., Paetsch, I., Gollesch, A., Roethemeyer, S., Foell, D., 

Gebker, R., Langreck, H., Klein, C., Fleck, E. and Nagel, E. 

Safety and feasibility of high-dose dobutamine-atropine stress 

cardiovascular magnetic resonance for diagnosis of myocardial 

ischaemia: experience in 1000 consecutive cases 1230 

Wa˚hlander, H. see Friberg, P. 987 

Wajngaten, M. see Vitale, C. 1814 

Walker, M. 

see Emberson, J. 484 

see Lowe, G.D.O. 252 

Wallentin, L. 

see Björklund, E. 113 



see Rosengren, A. 663 

Wallentin, L. Oral direct thrombin inhibition for anticoagulation 

in coronary artery disease – forus on the ESTEEM trial B9 

Walley, T. see Hill, R.A. 902 

Waltenberger, J. see Agema, W.R.P. 1163 

Walters, S.J. see Channer, K.S. 144 

Wang, C.-H. see Verma, S. 1754 

Wang, D. 

see Taneja, A.K. 2013 

see Yousufuddin, M. 377 

Wang, K. see Melo, L.G. E24 

Wartiovaara, U. see Lepäntalo, A. 476 

Wassmann, S. and Nickenig, G. The role of the AT 1 receptor in 

the cardiovascular continuum H3 

Watarai, M. see Murase, Y. 970 

Waters, D.D. and Khush, K.K. Management of the acute coronary 

syndrome patient C49 

Watkins, H.see Channon, K.M. 900 

Watts, G.F. Treating low HDL-cholesterol in 

normocholesterolaemic patients with coronary disease: 

statins, fibrates or hourses for courses? 716 

Waurick, P. see Kleber, F.X., D1 

Weaver, W.D. see Velazquez, E.J. 1911 

Weber, C. 



Weber, H., Allikmets, K. and Kornfeld, G. Treating electrical 

instability in sudden cardiac death survivors – are we 

looking at the right side of the coin? 623 

Weber, M.A. see Zeymer, U. 322 

Weerasooriya, R. see Scavée, C. 963 

Weinert, L. see Zamorano, J. 2086 

Weiß, S. see Ortlepp, J.R. 514 

Weiss, C. see Willems. S. 1249 

Welch, K.M.A. Statins for the prevention of cerebrovascular 

disease: the rationale for robust intervention C34 

Wellens, H.J. 

see Farré, J. 1083 

see Priori, S.G. 437 



Author index 

Wellnhofer, E. see Butter, C. D106 

Wensel, R. see Scott, A.C. 1806 

Werner, G. see Barbato, E. 219 

West, J.N. see Channer, K.S. 144 

Wheeler, J.G., Mussolino, M.E., Gillum, R.F. and Danesh, J. 

Associations between differential leucocyte count and 

incident coronary heart disease: 1764 incident cases from 

seven prospective studies of 30,374 individuals 1287 

Whincup, P. see Emberson, J. 484 

Whincup, P.H. see Lowe, G.D.O. 252 

White, H. see Colquhoun, D. 771 

White, H.D. 



Wichter, T. 


see Stix, G. 650 

see Vahlhaus, C. 151 

Wielepp, P. see Baller, D. D91 

Wieling, W. see Brignole, M. 2054 

Wiener, M. see Steendijk, P. D35 

Wiesinger, G.F. see Nuhr, M.J. 136 

Wietze, L. see Abizaid, A. 107 

Wijns, W. 

see Barbato, E. 2034 

see Steg, P.G. 2187 


Wiklund, O. see Eriksson, A.-L. 386 

Wikstrand, J.C.M. see Deedwania, P.C. 1300 

Wilding, J.P.H. see Coughlin, S.R. 735 

Wilhelmsen, L. 

see Pocock, S. 1974 

see Rosengren, A. 56 

Willekens, F. see Mamun, A.A. 409 

Willems, R. and Sipido, K.R. Nonexcitatory stimulation as a 

novel treatment for heart failure: cause for excitement? 626 

Willems. S., Rostock, T., Shenasa, M., Weiss, C., Risuis, T., 

Ventura, R., Hoffmann, M. and Meinertz, T. Sub-threshold 

stimulation in variants of atrioventricular nodal re-entrant 

tachycardia: electrophysiological effects and impact for 

guidance of slow pathway ablation 1249 

Willenheimer, R. see Andersson, P. 1776 

Wilson, I. see Channer, K.S. 144 

Wilson, P.W.F. see Sundström, J. 523, 1509 

Wiman, B. see Edfeldt, 1447 

Winbeck, G. see Butter, C. D106 

Windecker, S. 


see Torti, S.R. 1014 

Winkelmann, B.R. 

see März, W. 2109 


see Vassalli, G. 451 

Winnicki, M. and Palatini, P. Obstructive sleep apnoea and 

plasma homocysteine: an overview 1281 

Winterhalter, M. see Kleber, F.X. D1 

Wise, R.J.S. see Rosen, S.D. 952 

Witteman, J.C.M. 


see Oei, H.-H. 48 


Wittes, J. see Pocock, S. 1974 

Wiviott, S.D. 



Wlodarska, K. see Basso, C. 531 

Wojta, J. see Gyöngyösi, M. 2125 

Wolf, J.-E. see Zeller, M. 308 

Wolk, R. see Svatikova, A. 1325 

Wolpert, C. see Stix, G. 650 

Wolzt, M. see Stix, G. 650 

Woodward, M. see Imhof, A. 2092 

xxviii 

Working Group Interventional Cardiology and Coronary 

Pathophysiology see Togni, M. 1208 

Wuelfert, E. 



Wulf, G. see Höcht-Zeisberg, E. 749 

Wüsten, B. see Twardella, D. 2101 

Wuyts, F.L. see Conraads, V.M. 1797 

Yacoub, M.H. 

see Maisch, 587 

see Mikhail, G.W. 431 

Yajima, J. see Sahara, M. 2026 

Yamada, Y. see Murase, Y. 970 

Yamaguchi, M. see Konno, T. 246 

Yamamoto, K., Takahashi, Y., Mano, T., Sakata, Y., Nishikawa, 

N., Yoshida, J., Oishi, Y., Hori, M., Milwa, T., Inoue, S. and 

Masuyama, T. N-Methylethanolamine attenuates cardiac 

fibrosis and improves diastolic function: inhibition of 

phospholipase S as a possible mechanism 1221 

Yan,A.T.,Yan,R.T.,Tan,M.,Chow,C.-M.,Fitchett,D.,Stanton, 

E., Langer, A. and Goodman, S.G. for the Canadian Acute 

Coronary Syndrome (ACS) Registry Investigators Troponin is 

more useful than creatine kinase in predicting one-year 

mortality among acute coronary syndrome patients 2006 

Yan, R.T. see Yan, A.T. 2006 

Yan, Z.-Q. see Edfeldt, 1447 

Yarnell, J.W.G., Patterson, C.C., Sweetnam, P.M. and Lowe, 

G.D.O. Haemostatic/inflammatory markers predict 10-year 

risk of IHD at least as well as lipids: the Caerphilly 

collaborative studies 1049 

Yeo, W.W. see Channer, K.S. 144 

Ylä-Herttuala, S. and Dzau, V.J. Introduction to Supplement E E1 

Ylitalo, K. see Märkkäinen, S. 885 

Yo, M.-H. see Chen, Y.-H. 39 

Yokata, M. see Murase, Y. 970 

Yokoyams, I., Inoue, Y., Moritan, T., Ohtomo, K. and Nagai, R. 

Impaired myocardial vasodilation during hyperaemic stress is 

improved by simvastatin but not by pravastatin in patients 

with hypercholesterolaemia 671 

Yongzhong, W. see Goetze, J.P. 759 

Yoshida, J. see Yamamoto, K. 1221 

Yoshikawa, T. see Baba, A. 1108 

Young, J. see Nordmann, A.J. 69 

Young, J.B. 


see Yousufuddin, M. 377 

Yousufuddin, M., Haji, S., Starling, R.C., Tuzcu, E.M., Ratliff, 

N.B., Cook, D.J., Abdo, A., Saad, Y., Karnik, S.S., Wang, D., 

McCarthy, P.M., Young, J.B. and Tamani, M.H. Cardiac 

angiotensin II receptors as predictors of transplant coronary 

artery disease following heart transplantation 377 

Yucel, E.K. see Pennell, D.J. 1940 

Yusuf, S. 


see Östergren, J. 17 

Zahn, R., Mark, B., Niedermaier, N., Zeymer, U., Limbourg, P., 

Ischinger, T., Haerten, K., Hauptmann, K.E., von Leitner, E.- 

R., Kasper, W., Tebbe, U. and Senges, J., for the 

Arbeitgemeinschaft Leitende Kardiologische 

Krankenhausärzte (ALKK) Embolic protection devices for 

cardiac artery stenting: better results than stenting without 

protection? 1550 

Zahn, R. see Zeymer, U. 322 

Zakarkaite, D. see Celutkiene, J. 932 

Zamorano, J., Perez de Isla, L., Sugeng, L., Cordeiro, P., 

Rodrigo, J.L., Almeria, C., Weinert, L., Feldman, T., 

Macaya, C., Lang, R.M. and Antolin, R.H. Non-invasive 

assessment of mitral valve area during percutaneous balloon 

mitral valvuloplasty: role of real-time 3D echocardiography 

2086 



Zani, C. see Covolo, L. 1534 

Zanierato, M. see Mojoli, E. F74 

Zannad, F., Nippert, M., Sadoul, N. and Aliot, E. Case study: 

therapeutic options in a patient with heart failure, 

ventricular tachycardia and atrial fibrillation I105 (2003) 

Zazzeron, C. see Giannattasio, C. F30 

Zbinden, R. see Torti, S.R. 1014 

Zehender, M. see Brunner, M. 88 

Zeither, A.M. 

see Fichtlscherer, S. 1412 

see Rössig, L. 1620 

see Togni, M. 1208 

Zeller, M., Cottin, Y., Brindisi, M.-C., Dentan, G., Laurent, Y., 

Janin-Manificat, L., L’Huillier, I., Beer, J.-C., Touzery, C., 

Makki, H., Verges, B. and Wolf, J.-E., on behalf of RICO survey 

working group Impaired fasting glucose and cardiogenic shock 

in patients with acute myocardial infarction 308 

Zellweger, M.J., Hachamovitch, R., Kang, X., Hayes, S.W., 

Friedman, J.D., Germano, G., Pfisterer, M.E. and Berman, 

D.S. Prognostic relevance of symptoms versus objective 

evidence of coronary artery disease in diabetic patients 543 

Zellweger, M.J., Osterwalder, R.H., Langewitz, WQ. and 

Pfisterer, M.E. Coronary artery disease and depression 3 

Zerkowski, H.-R. see Kaiser, C. 1036 

Zerres, K. see Ortlepp, J.R. 514 

xxix 

Author index 

Zeymer, U. see Zahn, R. 1550 

Zeymer, U., Vogt, A., Zahn, R., Weber, M.A., Tebbe, U., 

Gottwik, M., Bonzel, T., Senges, J. and Neuhaus, K.-L., for 

the Arbeitgemeinschaft Leitende Kardiologische 

Krankenhausärzte (ALKK) Predictors of in-hospital mortality 

in 1333 patients with acute myocardial infarction 

complicated by cardiogenic shock treated with primary 

percutaneous coronary intervention (PCI). Results of the 

primary PCI registry of the Arbeitgemeinschaft Leitende 

Kardiologische Krankenhausärzte (ALKK) 322 

Zijlstra, F. 



see Petrie, M.C. 540 



Zrenner, B., Dong, J., Schreieck, J., Deisenhofer, I., Estner, H., 

Luani, B., Karch, M. and Schmitt, C. Transvenous cryoablation 

versus radiofrequency ablation of the slow pathway for the 

treatment of atrioventricular nodal re-entrant tachycardia: 

a prospective randomized pilot study 2226 

Zwinderman, A.H. see Agema, W.R.P. 1163 

Zwolle Myocardial Infarction Study Group 





Subject index 

a-tocopherol on coronary heart disease 1171 

abciximab: five-year outcome of acute myocardial infarction 

1562, 1635 

abdominal adiposity and metabolic syndrome A37 

abdominal aortic aneurysm: metabolic syndrome associated 

with vascular damage 342 

abnormal glucose metabolism in myocardial infarction 1969, 

1990 

absolute refractory period of severe heart failure, electrical 

stimulation during 626, 650 

acarbose and risks of myocardial infarction 10 

acetylcysteine prevention of contrast-induced nephropathy 188, 

212 

action potential duration in canine heart D61 

acute coronary syndromes 

anticoagulation in coronary disease B2 

association of revascularisation with low mortality 1471, 1494 

BNP in 1284 

creatine kinase-MS elevation after percutaneous coronary 

intervention 313 

enoxaparin and heparin in 1667, 1688 

glomerular filtration rate in 1998 

low-risk patients with chest pain 329 

management of C49 

and management of chronic angina I17 

percutaneous intervention in diabetic patients 190 

relative value of N-terminal probrain natriuretic peptide 859 

statin therapy, improving outcomes through A28 

statins’ role in early management of A32 

terminology for high-risk and vulnerable plaques 1077 

troponin in 2006 

acute heart failure: comparison of echocardiography and plasma 

ß-type natriuretic peptide 1763, 1788 

acute myocardial infarction 

admission Troponin T and measurement of ST-segment 

resolution at 60 min 113 

assessing myocardial perfusion with transthoracic Doppler 

technique 1480, 1526 

impaired fasting glucose and cardiogenic shock in 308 

ITF-1697 on reperfusion in patients undergoing primary 

angioplasty 392 

long-term: low-dose warfarin added to aspirin 232 


occluded artery angioplasty after 2177, 2187 

predictors of in-hospital mortality 322 

ProANP on 416 

regional denervation after 551 

ST-elevation, severity of 1702 

acute pulmonary edema: respiratory fatigue in F74 

adenosine 

heart rate and symptomatic paroxysmal supraventricular 

tachycardia 1277, 1310 

restores atrio-venous conduction 2155 

adenovirus 

AGENT programme E18 

design and preclinical testing of Ad5FGF-4 E12 

adults: predictors for psychopathology with congenital heart 

disease 1605 

age/ageing 

and clinical presentation of acute coronary syndromes 663 

cost-effectiveness of invasive versus medical management in 

chronic angina 2180, 2195 

medical and revascularisation therapy and 1036 

aged 80 and over: mortality in congestive heart failure 1711 

AGENT clinical trials programme E18 

Subject index 

xxx 

alcohol 

intake, role of lifestyle 1153 

and systemic markers of inflammation 2075, 2092 

aldosterone: prognostic value of neurohormones at baseline in 

heart failure 281, 292 

algorithm: imaging techniques for the assessment of myocardial 

hibernation 815 

alpha-adrenergic receptor blockade in intermediate coronary 

stenoses 1970, 2034 

ALPINE study H31 

alveolar ventilation in acute cardiogenic pulmonary edema F74 

amiodarone therapy with supporting DC cardioversion 144 

amyloid deposition as a cause of atrial remodelling 1185, 1237 

anaemia 

decision making in managing the ‘difficult’ patient with 

chronic heart failure I88 (2003) 

aneurysm 

aortic stiffness and diameter predict progressive dilatation in 

Marfan syndrome 1146 

endoluminal stent – graft replacement for acute rupture of 

descending thoracic aorta 694 

angina 

C-reactive protein elevation and disease activity in 401 

chronic, unmet needs in I1 

cost-effectiveness of invasive versus medical management of 

2180, 2195 

management of and ACS I17 

medical and revascularisation therapy in the elderly 1036 

metabolic manipulation in 634 

statins’ role in early management of acute coronary syndrome 

A32 

angina pectoris 

endothelial progenitor cells in 999, 1003 

myocardial bridging and alterations in coronary vasoreactivity 

2134 

angiogenesis 



angiography 

increases plasma pro-B-type natriuetic peptide 759 

oestrogen receptor alpha gene polymorphism and coronary 

artery disease 240 

angioplasty 

antiplatelet effect of 300 mg clopidogrel in 454, 476 

embolic protection devices for cardiac artery stenting 1550 

fractional flow reserve in evaluation of in-stent restenosis 

1970, 2040 

inflammation and restenosis after 1679 

mortality after myocardial infarction in diabetes 926 

predictors of in-hospital mortality in acute myocardial 


statin administration before 1822 

versus stents in non-acute coronary artery disease 69 

angiotensin converting enzyme (ACE) inhibitors 

decision making in managing the ’difficult’ patient with 

chronic heart failure I88 

(2003) 

expert consensus document on 1454 

gender and long-term survival of ischaemic heart disease 101, 

129 

polymorphism and risk of heart failure 2143 

and proven therapy in heart failure H43 

recent drug studies in chronic heart failure I28 (2003) 

short and long-term mortality in congestive heart failure 1711 

therapeutic options in a patient with heart failure I105 (2003) 



therapeutic strategies in heart failure I69 (2003) 

in treatment of heart failure I39 (2003) 

angiotensin II 

candesartan in H11 

and progression of left ventricular dysfunction to end-stage 


receptors as predictors of transplant coronary artery disease 

377 

angiotensin receptor blockers 

candesartan on heart failure 1920 

and heart failure 357 

and recent drug studies in chronic heart failure I28 (2003) 


angiotensin-type-1 receptor blockers: candesartan as H11 

ankle blood pressure: ramipril in peripheral vascular disease 1, 

17 

anti-cytokine molecules in chronic heart failure F16 

antiarrhythmics 

in heart failure and sudden death I108 (2003) 

suppression of paroxysmal atrial tachyarrhythmias 1371, 1395 

therapy in cardiac arrest survivors 623, 642 

anticoagulation 

atrial fibrillation, recent trials in B15 

in coronary artery disease B9 

antidepressant therapy and coronary artery disease 3 

antihypertensive therapy: modern strategies in H23 

antiplatelet agents 

in coronary disease B2 

Expert Concensus Document on the Use of 166 

antiplatelet therapy 

and 2-year mortality in diabetics with peripheral arterial 

disease 1769, 1845 

atherothrombosis, consequences of 1197 

percutaneous coronary intervention in diabetic patients 190 

in primary coronary angioplasty 807, 837 

antithrombin/antithrombotic agents 

in acute coronary syndromes 1667, 1688 

in coronary disease B2 

therapy: atherothrombosis, consequences of 1197 

aorta 

endoluminal stent - graft replacement for rupture of 694 

stiffness and diameter predict dilatation in Marfan syndrome 

1146 

aortic arch geometry after repair of coarctation of the aorta 

1853 

aortic dissection in evolution of aortic intramural haematoma 81 

aortic intramural haematoma 81 

aortic stenosis 

B-type natriuretic peptide as predictor of 1972, 2048 

risk stratification by echocardiography 185, 199 

value and limitations of valve resistance 787 

aortic stiffness in Marfan syndrome 1146 

aortic valve resistance, value and limitations of 787 

aortocoronary surgery 1836 

apolipoprotein E polymorphism and circulating C-reactive 

protein 2109 

apoptosis 

eruthropoietin in cardiovascular diseases 285 



serum activity in heart failure 1620 

arrhythmia 



exercise training with implantable cardioverter-defibrillator 

1120 

findings from MADIT-II substudies I34 (2003) 

implantable loop recorders in diagnosis and management of 

syncope 1257 

syncope, detection with implantable loop-recorder 1116 

arrhythmogenic right ventricular cardiomyopathy 531 

arterial duct and anticipate abnormal left lung perfusion 1927 

xxxi 

Subject index 

arterial stiffness in heart failure patients F30 

articial pacemaker: long-term survival after implantation 88 

aspirin 

and 2-year mortality in diabetics with peripheral arterial 

disease 1769, 1845 


antiplatelet effect of 300 mg clopidogrel with 454, 476 


asynchrony: indications for cardiac resynchronisation therapy 

D128 

AT1 receptor blockers 

in cardiovascular continuum H3 

on cardiovascular structure and function H17 

CHARM in relation to clinical trials with H55 

haemodynamic and neurohormonal effects of H49 

and hypertension management H23 

preventing cardiovascular complications of hypertension 

H37 

atherogenic risk: non-high-density lipoprotein cholesterol as A43 

atheroprotection: statins on HDL-cholesterol C58 

atherosclerosis 

CagA-positive cytotoxic H. pylori strains in 64 

consequences of 1197 

depressive symptomatology in cardiovascular disease-free 

people 492 

evaluation of brachial artery flow-mediated vasodilation 1754 

exercise reduces plasma levels of the chemokines MCP-1 and 

IL-8 349 

haemoglobin A1c and markers of inflammation 2120 

intravascular thermography on 158 

and metabolic syndrome 342 

risk factors for 48 


athletes, syncope in 1749 

atorvastatin 1898 

atrial arrhythmias 

in Brugada syndrome 879 

and paroxysmal atrial fibrillation 1242 

atrial fibrillation 

adenosine on atrio-venous conduction 2155 

amiodarone supporting DC cardioversion 144 

amyloid deposition as a cause of 1185, 1237 

autoantobodies against M2-muscarine acetylcholine receptor 

1091, 1108 

Bad Oeynhausen experience in D122 

and C-reactive protein concentrations during glucocorticoid 

therapy 1089, 1100 

flecainide versus ibutilide for immediate cardioversion of 

1274, 1318 

management of in cardiac resynchronisation therapy D106 

post-operative, impairment of left atrial function predicts 

1836 

prevention of after cardioversion 1385 

rate control is more cost-effective than rhythm control 1542 

recent trials in B15 

stroke patients with have a worse prognosis than patients 

without 1670, 1734 


therapeutic options in I105 (2003) 

atrial flutter, catheter ablation of 963 

atrial function: predicts post-operative atrial fibrillation 1836 

atrial remodelling 

amyloid deposition as a cause of 1185, 1237 

predicts post-operative atrial fibrillation 1836 

atrioventricular nodal re-entrant tachycardia 

comparing transvenous cryothermal and radiofrequency 

ablation in 2232 

sub-threshold stimulation of 1249 

transvenous cryoablation versus radiofrequency ablation for 

2226 

autoantobodies against M2-muscarine acetylcholine receptor 

1091, 1108 



Subject index 

automated external defibrillators: recommendations for the use 

of 437 

autonomic nervous system 

in heart failure 952 

paroxysmal atrial fibrillation on 1242 


1473, 1502 

availability of medical technology to patients across Europe 611 

B-type natriuretic peptide 

increased by angiography 759 

as predictor of outcome in aortic stenosis 1972, 2048 

Bad Oeynhausen experience D122 

bare metallic stent: soft plaque as predictor of in-stent 

restenosis 2026 

beating heart 

against cardioplegic arrest studies (BHACAS 1 and 2) 765 

surgery 2077 

beer and systemic markers of inflammation 2075, 2092 

beta-adrenergic receptors I14 (2003) 

beta-blockers 

cardiac events in children with long QT syndrome 1405 



and proven therapy in heart failure H43 



therapeutic strategies in heart failure I69 (2003) 


beverage preferences: role of lifestyle 1153 

biomarkers 

creatine kinase-MB elevation after percutaneous coronary 


role and importance in clinical cardiology 1187 

biventricular pacing/ICD 

in cardiac resynchronisation D53 

complications of D117 

decision making in managing the ’difficult’ patient with 


lead selection and implantation technique for D112 

blood flow 


2134 

natural history of myocardium awaiting revascularisation 500 

blood pressure 

impact of ramipril on peripheral arterial disease 1, 17 

and increased left ventricular mass in obese adolescents 987 

obstructive sleep apnoea and prevalence of metabolic 

syndrome 709, 735 

bone marrow: therapies for cardiovascular diseases E24 

brachytherapy: treatment of in-stent restenosis 898, 920 

bradyarrhythmias with sleep apnoea 1070 

bradykinin on muscle hyperactivity in chronic heart failure 1806 

brain function and heart failure 952 

brain natriuretic peptide 

in acute coronary syndromes 1284 

evaluation of right ventricular performance F61 

prognostic value of neurohormones at baseline in heart failure 

281, 292 

in pulmonary hypertension F35 

breastfeeding and cardiovascular mortality 778 

breathlessness in heart failure 952 

bridge to transplant, left ventricular assistance in F81 

British medicine, continental doctors take leadership in 1568 

Brugada syndrome 

incidence, clinical implications and prognosis of atrial 

arrhythmias in 879 

prevalence and prognosis of subjects with 810, 874 

ß-adrenergic receptor blockers, expert consensus on 1341 

ß1-adrenoceptor polymorphisms in heart failure 1534 

ß2-adrenoceptor polymorphisms in heart failure 1534 

ß-blockade 

efficacy, safety and tolerability of 1300 

xxxii 

ß-carotene 

on coronary heart disease 1171 

ß-type natriuretic peptide 

monitoring response to treatment in acute heart failure 1763, 

1788 

bundle branch block: QRS prolongation on CHF D79 

bypass: visualization and quantification of myocardial infarction 

1279, 1293 

C-reactive protein 

and apolipoprotein E polymorphism 2109 

concentrations during glucocorticoid therapy and recurrent 

atrial fibrillation 1089, 1100 

determining nitric oxide bioavailability with 1412 

elevation of and disease activity in coronary artery disease 

401 

and endothelial progenitor cells in unstable angina 999, 1003 

in healthy individuals 1754 

identifying patients at risk of coronary vascular disease C21 

pre-procedural plasma levels of and restenosis 1029 


CagA-positive cytotoxic H. pylori strains in atherosclerosis 64 

calcium/calcification 

in aortic valves is influenced by gender and genetic 

polymorphisms 514 

risk factors for coronary calcification in older subjects 48 

sodium current, late, inhibition of I3 

candesartan 

on cardiovascular structure and function H17 

CHARM in relation to clinical trials with H55 

glucose metabolism disturbances induced by antihypertensive 

drugs H31 


and hypertension management H23 

pharmacological aspects of H11 

preventing cardiovascular complications of hypertension H37 

treatment with preserved systolic function H61 

cardiac arrest: programmed ventricular stimulation in 623, 642 

cardiac arrhythmias: reverse remodelling by drugs I44 (2003) 

cardiac artery stenting: embolic protection devices 1550 

cardiac dyssynchrony: technical issues I83 (2003) 

cardiac hypertrophy 



cardiac imaging for assessment of myocardial hibernation 815 

cardiac intima-media thickness: identifying patients at risk C15 

cardiac markers in non-ST-elevation acute coronary syndromes 

859 

cardiac natriuretic hormones in systemic sclerosis F68 

cardiac progenitors: therapies for cardiovascular diseases E24 

cardiac regeneration 749 

cardiac resynchronisation therapy 


and CPET D5 

device therapy for congestive heart failure I75 (2003) 

discriminating responders from non-responders D101 

and Doppler imaging D10 

echocardiographic assessment of mitral regurgitation D25 

extended indications for D128 

in heart failure D83 


implantation of systems for D53 

indications for, extension of I97 (2003) 

lead selection and implantation technique D112 

management of atrial fibrillation in D106 

myocardial oxygen consumption and perfusion D91 

pressure-volume measurements in D35 

selection of patients for D98 

strain rate imaging in CRT candidates D16 

technical considerations in D43 

technical issues I83 (2003) 





ventricular remodelling and chamber dyssynchrony I54 

(2003) 

cardiac rhythm disturbances: severe bradyarrhythmias in 1070 

cardiac surgery: amyloid deposition 1185, 1237 

cardiogenic shock 

in acute myocardial infarction 308 


severity of heart failure with ST-elevation myocardial 


cardiomyocyte function: sodium current, late, inhibition of I3 

cardiomyopathy 

and asymptomatic myocardial abnormalities 1865, 1934 

molecular classification in 1772 

cardiopulmonary bypass on the beating heart 2077 

cardiopulmonary exercise testing (CPET) 

and cardiac resynchronisation therapy D5 


cardiovascular continuum: role of the AT1 receptor in H3 

cardiovascular disease 

breastfeeding and 778 

eruthropoietin in 285 

expert consensus document on ACE inhibitors in 1454 

flu vaccination in 25 

identifying patients at risk C21 

isoprostanes in 1675 

physical activity, body mass index, waist circumference and 

waist-to-hip ratio on 2183, 2212 

physical activity as a predictor for 2183, 2204 

primary prevention of 457, 484 

ramipril on patients with 1, 17 

risk factors and type 2 diabetes G3 

risk of, and evolution of statin therapy A3 

smoking and duration of life 409 


cardiovascular events 

acarbose and risk of myocardial infarction 10 

preventing complications of hypertension H37 

cardiovascular magnetic resonance (CMR), clinical indications 

for 1940 

cardiovascular morbidity: chronic psycosocial stress predicts 867 

cardiovascular risk factors 

alcohol intake and diet in lifestyle 1153 

calcium-deficient hexagonal hydroxyapatite and gene 

polymorphism 514 

and coronary heart disease in Japan A8 

management in peripheral arterial disease C43 

cardioversion 

flecainide versus ibutilide for 1274, 1318 

management of atrial fibrillation in cardiac resynchronisation 

therapy D106 

supporting with amiodarone therapy 144 

carotid arteries: embolic protection devices 1550 

case-control study: ß1- and ß2-adrenoceptor polymorphisms 

1534 

case study: patients with heart failure, ventricular tachycardia 

and atrial fibrillation I105 (2003) 

catechol-O-methyltransferase (COMT) and myocardial infarction 

386 

catheter: intravascular thermography by 158 

catheter ablation 


on atrioventricular nodal re-entrant tachycardia 2226, 2232 

of cavotricuspid isthmus-dependent atrial flutter 963 

radiofrequency, outcome of ventricular tachycardia 1127 

CCR5 gene polymorphism with increased risk of coronary 

arteriosclerosis 1438 

cellular cardiomyopathy: therapies for cardiovascular diseases 

E24 

cerebral blood flow in heart failure 952 

cerebral ischaemia: transcatheter closure of patent foramen 

ovale (PFO) 361, 424 

cerebrovascular disease: statins for prevention of C34 

xxxiii 

Subject index 

chemokines: exercise reduces plasma levels of 349 

chest pain observation unit 329 

chimerism: cellular repopulation of myocardial infarction 749 

cholesterol lowering: evolution of statin therapy A3 

chronic heart failure 

combined endurance/resistance training reduces NT-proBNP 

levels in 1797 

decision making in managing the ’difficult’ patient with I88 

(2003) 

disease management program F91 

haemoglobin predicting survival in 1021 

indications for, extension of I97 (2003) 

questions in treatment of I39 (2003) 

recent drug studies in I28 (2003) 

telemonitoring systems in F99 


chronic renal failure: reduction of cyclosporine after 

mycophenolate mofetil 1626 

chronic stable angina: therapeutic options E2 

chronotropic agent: heart rate reduction during myocardial 

ischaemia 579 

circadian rhythm and ventricular tachycardia or fibrillation I22 

(2003) 

circulating endothelial cells: assessment of endothelial damage 

371 

clinical indications for cardiovascular magnetic resonance (CMR) 

1940 

clinical outcome 

of atrial arrhythmias in Brugada syndrome 879 

mortality after myocardial infarction in diabetes 926 

clinical trials 


CHARM in relation to trials with ARBs H55 

prevention of atrial fibrillation after cardioversion 1385 

Risk Score Profile in 1139 

substudy: pravastatin on coronary events 716, 771 

treatment of heart failure with preserved systolic function 

H61 

clopidogrel 

antiplatelet effect of and aspirin therapy 454, 476 

antiplatelet effects of 1898 

high loading dose during coronary stenting 1903 

therapy after percutaneous coronary intervention 720 

CO2 removal in acute cardiogenic pulmonary edema F74 

coagulation in cardiovascular disease-free people 492 

coarctation of the aorta 1853 

coil occlusion: Doppler flow on abnormal left lung perfusion 

1927 

collagen: N-methylethanolamine on 1221 

collateral circulation 

preconditioning during coronary angioplasty 2019 

in ST-segment-elevation myocardial infarction 854 

collateral coronary arteries: design and testing of Ad5FGF-4 

E12 

community patients: management in general practice and the 

hospital 1718 

commuting: physical activity as a predictor for total and 

cardiovascular disease mortality 2183, 2204 

complications 

N-acetylcysteine to prevent contrast agent nephrotoxicity 

188, 206 

statin administration before percutaneous coronary 


stroke patients with atrial fibrillation have a worse prognosis 

than patients without 1670, 1734 

conductance catheter: pressure-volume measurements by D35 

congenital heart defects 

outcome after surgical closure of 1057 


repair 1264, 1863 

congenital heart disease: medical predictors for 

psychopathology 1605 



Subject index 

congestive heart failure 


device therapy for I75 (2003) 

diabetes mellitus on long-term survival 629, 656 

immune activation in F22 


therapy D106 

patient differences related to management in general 

practice and the hospital 1718 

uncommon aspects and novel markers in F1 

connexins: myocardial, regulation of during hypertrophic 

remodelling 1979 

conservative strategy in unstable angina 1559, 1641 

continental doctors take leadership in British medicine 1568 

continuous positive airway pressure 

in acute cardiogenic pulmonary edema F74 

in obstructive sleep apnoea 1281, 1325 

contractility and myocardial performance index 2185, 2238 

contrast media: nephrotoxicity, standard vs double dose of Nacetylcysteine 

188, 206, 212 

conventional coronary angiography: thin-slice computed 

tomography in 1043 

coronary allograft atherosclerosis: obstructive sleep apnoea in 

260 

coronary angiographic restenosis 1029 

coronary angiography 

nephropathy following, acetylcysteine for the prevention of 

188, 212 

sex, age and clinical presentation of acute coronary 

syndromes 663 

coronary angioplasty 

in Europe 1992-2001 1208 

preconditioning during 2019 

coronary artery bypass graft 

on the beating heart 2077 

impairment of left atrial function predicts post-operative 

atrial fibrillation after 1836 

quality of life after 765 

coronary artery disease 

abnormal glucose regulation in 1861, 1880 

acute ischaemia in D88 

C-reactive protein 

and apolipoprotein E polymorphism 2109 

elevation and disease activity in 401 

levels determine nitric oxide bioavailability 1412 

and depression 3 

exercise versus recovery electrocardiography in predicting 

mortality 558 


1970, 2040 

obstructive sleep apnoea in 709, 728 

oestrogen receptor alpha gene polymorphism in 240 

oral direct thrombin inhibition for anticoagulation in B9 

perfusion in: effect of metoprolol 537, 565 

RANTES G-403A gene polymorphism 1438 

relationship with reduced elasticity of extracardiac vessels 

508 

safety and feasibility of high-dose dobutamine-atropine stress 

cardiovascular magnetic resonance 1183, 1230 

stents versus balloon angioplasty in 69 

thin-slice computed tomography on detection of 1043 

trimetazidine on left ventricular function and quality of life in 

the elderly 1765, 1814 

validation of flow reserve measurements 219 

coronary artery spasm: genetic risk 900, 970 

coronary artery stenting: effects of clopidogrel 1898 

coronary circulation: myocardial vasodilation, simvastatin on 

671 

coronary collateral flow in coronary artery disease 537, 565 

coronary disease 

angiography increases plasma pro-B-type natriuetic peptide 

759 

xxxiv 


2180, 2195 

deformation and velocity imaging for detecting ischaemia 

1477, 1517 

detection of by magnetic resonance imaging 1657 

medical and revascularisation therapy in the elderly 1036 


risk factors for calcification 48 

social support and social class 56 

coronary flow 

echocardiography on 1867 


1970, 2040 

validation of measurements 219 

coronary heart disease 

a-tocopherol and ß-carotene supplementation in 1171 

Bad Oeynhausen experience of D122 

evolution of statin therapy A3 

guidelines and management of risk C5 

and high density lipoprotein A19 

in Japan A8 

leucocyte count and 1271, 1287 

and low-density lipoprotein cholesterol A12 

managing dyslipidaemia A23 

metabolic syndrome associated with vascular damage 342 

mortality, exercise capacity of healthy men and 978 

non-high-density lipoprotein cholesterol as risk factor 

A43 

overweight and obesity in patients with 121 

prediction of cardiorespiratory fitness 1374, 1428 

risk and markers of oxidative stress in diabetic men 468 

and smoking cessation 2101 


therapeutic options for E2 

tissue plasminogen activator antigen and 252 

in women 1672, 1695 

coronary microcirculation 

assessing myocardial perfusion with the transthoracic Doppler 

technique 1480, 1526 



coronary revascularization and gender 1559, 1641 

coronary risk factors: genetic risk and gene-environment 

interaction 900, 970 

coronary sinus access: implantation tips and tricks D47 

coronary stenting 

high clopidogrel loading dose during 1903 

percutaneous intervention in Europe 1992-2001 1208 

coronary vein leads 

implantation tips and tricks D47 

left ventricular, implanting D43 

cost-benefit analysis of invasive versus medical management of 

chronic angina 2180, 2195 

cost effectiveness of implantable loop recorders 1257 

costs of rate control and rhythm control for persistent atrial 

fibrillation 1542 

cotinine: smoking cessation and coronary heart disease 2101 

creatine kinase 

elevation after percutaneous coronary intervention 313 

and troponin in acute coronary syndrome 2006 

visualization and quantification of peri-operative myocardial 

infarction 1279, 1293 

cyclosporine: reduction of 1626 

data monitoring in the MOXCON trial 1974 

decision making: data monitoring experience in the MOXCON 

trial 1974 

decompression illness, risk of 1014 

degenerative calcific aortic stenosis 514 

depression 

in cardiovascular disease-free people 492 

coronary artery disease and 3 

destination therapy: left ventricular assistance to F81 



diabetes 

and cardiovascular risk factors G3 

and coronary heart disease risk in Japan A8 


and metabolic syndrome A37 

mortality after myocardial infarction in 926 

percutaneous coronary intervention in 190 

picotamide on 1769, 1845 


and sirolimus-eluting stents 99, 107 

diabetes mellitus 

abnormal glucose regulation in 1861, 1880 

cardiovascular risk and markers of oxidative stress in 468 

impaired fasting glucose and cardiogenic shock in acute 

myocardial infarction 308 

long-term survival in congestive heart failure 629, 656 

relevance of symptoms versus objective evidence of coronary 


diabetes risk factors and metabolic syndrome A37 

diabetic dyslipidaemia, treating C28 

diagnosis with biological markers in clinical cardiology 1187 

diastolic dysfunction 

after reperfused acute myocardial infarction 1376, 1419 

arterial stiffness in heart failure patients F30 

diastolic function 

N-methylethanolamine on 1221 

ProANP on 416 

diet and role of lifestyle 1153 

dilated cardiomyopathy 

autoantibodies against M2-muscarine acetylcholine receptors 

1091, 1108 


lamin A/C gene in 812, 885 

rescreening of "healthy" relatives of patients with F54 

skeletal muscle damage in F40 

disease management programmes in reducing hospital readmission 

with heart failure 1570 

disease progression of mild and moderate aortic stenosis 185, 

199 

diuretics and pharmacotherapy for chronic heart failure I64 

(2003) 

diving: risk of decompression illness and size of patent foramen 

ovale 1014 

DNA banking: arrhythmogenic right ventricular cardiomyopathy 

531 

dobutamine stress echocardiography 

deformation and velocity imaging for detecting ischaemia 

during 1477, 1517 

post-systolic motion to detect induced ischaemia 932 

Doppler echocardiography: assessing myocardial perfusion with 

1480, 1526 

Doppler flow 

on abnormal left lung perfusion 1927 

velocity, coronary collateral perfusion 537, 565 

Doppler myocardial imaging 932 

doses in pharmacotherapy for chronic heart failure I64 (2003) 

drug-eluting stent 

inhibit neointimal hyperplasia in diabetic patients 99, 107 

systematic review 895, 902 

treatment of in-stent restenosis 898, 920 

drug therapy 

CHARM in relation to other heart failure trials with ARBs H55 

reperfusion in patients undergoing primary angioplasty 392 

Duchenne’s cardiomyopathy 1865, 1934 

duration of therapy: amiodarone supporting DC cardioversion 

144 

dyslipidaemia 

cardiovascular disease and type 2 diabetes G3 

emerging insights into G8 

managing A23 

trials on future management of G13 

dyspnea: CPET in heart failure D1 

xxxv 

Subject index 

dyssynchrony 

pressure-volume measurements by conductance catheter D35 

and ventricular remodelling I54 (2003) 

echocardiography 

on abnormal left lung perfusion 1927 

for assessment of myocardial hibernation 815 

on asymptomatic myocardial abnormalities 1865, 1934 

brain natriuretic peptide as marker of right ventricular 

overload F35 

on coronary flow 1867 

indications for cardiac resynchronisation therapy: extension 

of I97 (2003) 

Interventricular and intraventricular dyssunchrony in heart 

failure 535, 571 

on left ventricular remodelling after myocardial infarction 

680 

monitoring response to treatment in acute heart failure 1763, 

1788 

myocardial performance index 2185, 2238 

and myocardial performance index 2185, 2220 

myocardial thickness and thickening 714, 794 

non-invasive assessment of mitral valve 2073, 2086 

relation of plasma homocysteine to left ventricular 

hypertrophy 523 

relations of plasma total TIMP-1 levels to cardiovascular risk 

factors 1475, 1509 

risk stratification of aortic stenosis 185, 199 



repair 1264, 1863 

economic burden of chronic heart failure D57 

efficacy of hypertension management H23 

Eisenmenger syndrome 1651 

ejection fraction 

in myocardial infarction 224 


sleep apnoea and periodic limb movements in heart 

transplantation 260 

elasticity 

of aorta in Marfan syndrome 1146 

reduced, of extracardiac vessels 508 

elderly 

management programmes in reducing hospital re-admission 

1570 


tolerability of ß-adrenergic blockade with metroprolol CR/XL 

in 1300 

trimetazidine improves left ventricular function and quality of 

life in 1765, 1814 

see also age/ageing 

electrical stimulation 

during refractory period of heart failure 626, 650 

of thigh muscles in patients with chronic heart failure 104, 

136 

electrocardiogram in assessment of myocardial hibernation 

815 

electrocardiography 

direct mapping predicts recovery of left ventricular 

dysfunction 151 

for identification of preclinical carriers of hypertrophic 


predicting mortality in uncomplicated myocardial infarction 

558 

Troponin T and measurement of ST-segment resolution at 60 

min 113 

electrodes: implanting left ventricular pacing leads D43 

electromechanical imaging for assessment of myocardial 


electron-beam-computed tomography: identifying patients at 

risk C15 

electronic medical records: heart failure clinics and outpatient 

management 1565, 1596 



Subject index 

Electrophysiological perspectibes – what has ranolazine taught 

us? 

electrophysiological perspectives of ranolazine I9 

electrophysiological stimulation in cardiac arrest survivors 623, 

642 

electrophysiology 

regional denervation after acute myocardial infarction 551 

reverse remodelling by drugs I44 (2003) 

embolism: transcatheter closure of patent foramen ovale (PFO) 

361, 424 

emergency room: low-risk patients with chest pain and without 


emotional support in coronary disease 56 

end-organ protection and cardiovascular complications of 

hypertension H37 

end-stage heart failure and right ventricular performance F61 

endocardial mapping of atrioventricular nodal re-entrant 


endomyocardial biopsy in patients with dilated cardiomyopathy 

F40 

endothelial cells: pro-apoptotic serum activity in heart failure 

1620 

endothelial dysfunction 

and AT1-receptor blockade H17 

hypertension and dyslipidaemia synergies G8 


2134 

endothelial function and C-reactive protein in healthy 

individuals 1754 

endothelial progenitor cells 

and inflammation in unstable angina 999, 1003 

therapies for cardiovascular diseases E24 

endothelin: prognostic value of neurohormones at baseline in 


endothelin receptor antagonists: in chronic heart failure I28 (2003) 

endothelium 

anti-cytokine therapy in chronic heart failure F16 

C-reactive protein levels determine nitric oxide 

bioavailability 1412 

progenitor cells in angina pectoris 999, 1003 

enoxaparin in acute coronary syndromes 1667, 1688 

enzymatic infarct size 

collateral circulation in ST-segment-elevation myocardial 


epidemiology 

burden of heart failure I3 (2003) 

of chronic heart failure D57 

haemostatic/inflammatory markers on IHD 1049 

and prevention of atherosclerosic stroke 64 

psycosocial stress on long-term cardiovascular morbidity and 

mortality 867 

quantifying the heart failure epidemic 1614 

of syncope in young competing athletes 1749 

eplerenone in chronic heart failure I28 (2003) 


ESTEEM trial B9 

estrogen and myocardial infarction in a hypertensive population 

386 

etanercept in chronic heart failure I28 (2003) 

etomoxir in ischaemic heart disease 634 

EuroHeart Failure survey H43 

EuroHeart Survey 1181, 1214 

Europe: guidelines and management of risk in coronary heart 

disease C5 

European Society of Cardiology 

hotline sessions 2164 

major changes in the statutes of 804 

evaluation of arrhythmogenic right ventricular cardiomyopathy 

531 

event recording 



xxxvi 

evidence-based medicine: pharmacotherapy for chronic heart 

failure I64 (2003) 

exercise/exercise testing/exercise training 

with an implantable cardioverter-defibrillator 1120 

electrical stimulation of thigh muscles in patients with 

chronic heart failure 104, 136 

and heart failure 952 



558 

prediction of for cardiovascular events 1374, 1428 

prognosis of healthy men 978 

prostaglandin and bradykinin on muscle hyperactivity 1806 

reduces NT-proBNP levels in chronic heart failure 1797 

reduces plasma levels of the chemokines 349 

EXP-3174: pharmacological aspects of H11 

experimental models of heart failure F7 

Expert Concensus Document on the Use of Antiplatelet Agents 

166 

expert consensus document on ß-adrenergic receptor blockers 

1341 

extracardiac vessels, reduced elasticity of 508 

familial hypercholesterolaemia A23 

family screening of "healthy" relatives of patients with dilated 


fasting glucose: obstructive sleep apnoea and prevalence of 

metabolic syndrome 709, 735 

feasibility of high-dose dobutamine-atropine stress 


fibrate 


pravastatin on coronary events 716, 771 

fibrinogen: C-reactive protein and apolipoprotein E 


fibrinolysis 

with ST-elevation myocardial infarction 1702 

tissue plasminogen activator antigen and coronary heart 

disease 252 

fibroblast growth factor 



flecainide for cardioversion of atrial fibrillation 1274, 1318 

follow-up studies 

exercise capacity of healthy men 978 

outcome after surgical closure of ventricular septal defect 

1057 


repair 1264, 1863 

force frequency relation in canine heart D61 

fractional flow reserve: validation of measurements by 

thermodilution 219 

fractional flow reserve and complex coronary pathologic 

conditions 723 

Future directions in the management of chronic angina and ACS - 

the MERLIN-TIMI 36 trial 

gap junction: regulation of myocardial connexins 1979 

gender 

clinical presentation of acute coronary syndromes 663 

and long-term survival after pacemaker implantation 88 

and long-term survival in congestive heart failure 101, 129 

on unstable angina or non-ST-elevation myocardial infarction 

1559, 1641 

gene polymorphism: calcium-deficient hexagonal 

hydroxyapatite in aortic valves 514 

genes and angiographic restenosis after coronary stenting 39 

genetic polymorphism: ß1- and ß2-adrenoceptors in heart failure 

1534 

genetics 

5A/6A polymorphism of the stromelysin-1 gene and restenosis 

335 

ACE polymorphism and risk of heart failure 2143 

cardiomyopathy, molecular classification in 1772 



cardiovascular risk in and markers of oxidative stress in 

diabetic men 468 

gene-environment interaction in coronary artery spasm 900, 

970 

genotypes and haplotypes predisposing to myocardial 


identification of preclinical carriers of hypertrophic 


impact of matrix metalloproteinase gene polymorphism in 


toll-like receptor 4 variants and risk of myocardial infarction 

1378, 1447 

geographical variation: alcohol intake and systemic markers of 

inflammation 2075, 2092 

glucocorticoid therapy: C-reactive protein concentrations 1089, 

1100 

glucose 

hyperinsulinaemia following acute myocardial infarction 1891 

impaired fasting, and cardiogenic shock in acute myocardial 


metabolism disturbances induced by antihypertensive drugs 

H31 

glycoprotein IIb/IIIa 

inhibitors in acute coronary syndromes 1667, 1688 

use of abciximab prior to primary angioplasty 2125 

glycoproteins: percutaneous coronary intervention in diabetic 

patients 190 

glycosylated haemoglobin: hyperinsulinaemia following acute 


grafting: coronary artery bypass on the beating heart 2077 

guidelines 

consensus document on ß-adrenergic receptor blockers 1341 

on diagnosis and management of pericardial diseases 587 

on diagnosis and treatment of pulmonary arterial 

hypertension 2243 

ESC-ERC recommendations for the use of automated external 

defibrillators (AEDs) in Europe 437 

expert consensus document on angiotensin converting 

enzyme inhibitors in cardiovascular disease 1454 

on Management (Diagnosis and Treatment) of syncope 2054 

and management of global risk: the European perspective C5 

on Prevention, Diagnosis and Treatment of Infective 

Endocarditis 267 

proven therapy in heart failure H43 

haemodynamics: value and limitations of aortic valve resistance 

787 

haemoglobin: predicting survival in chronic heart failure 1021 


haemorrhagic stroke: atrial fibrillation, recent trials in B15 

haemostasis: markers on ischaemic heart disease 1049 

health care economy 611 

health care provision 611 

health economics and burden of heart failure I3 (2003) 

health technology assessment on drug-eluting stents 895, 902 

healthy men, exercise capacity of 978 

heart defect: outcome after surgical closure of 1057 

heart disease: primary hyperparathyroidism and 1776 

heart failure 

ACE polymorphism and risk of 2143 

acute ischaemia as trigger of sudden cardiac death D88 

angiography transiently increases plasma pro-B-type 

natriuetic peptide 759 

and angiotensin receptor blockers 357 

anti-cytokine therapy in F16 

arterial stiffness in F30 

burden of I3 (2003) 

cardiac resynchronisation therapy in D83 

cardiopulmonary exercise testing and patient selection D5 

central nervous system processing in 952 

clinics and outpatient management 1565, 1596 

CPET in D1 

data monitoring experience in the MOXCON trial 1974 

xxxvii 

Subject index 

decreasing one-year mortality and hospitalization rates 283, 

300 

differences between preserved and depressed left ventricular 

function 1181, 1214 

discriminating responders from non-responders to cardiac 

resynchronisation D101 

echocardiographic assessment of mitral regurgitation D25 

effects of AT 1-receptor blockers H49 

electrical stimulation during 626, 650 

epidemiology and economic burden of D57 


experimental models of F7 

extended indications for cardiac resynchronisation therapy 

D128 

future use of antiarrhythmic drugs I108 (2003) 


631, 688 

implementation of proven therapy in H43 

Interventricular and intraventricular dyssunchrony in 535, 571 

left ventricular assistance in F81 

and left ventricular systolic dysfunction 1911 

low-frequency stimulation of thigh muscles 104, 136 


1570 


myocardial performance index and 2185, 2220 

N-methylethanolamine on 1221 

and obesity F87 

pharmacotherapy for I64 (2003) 

plasma homocysteine and left ventricular structure and 

function 523 

prevalence, incidence rate, lifetime risk and prognosis of 

1614 

pro-apoptotic serum activity in 1620 

prognostic value of plasma neurohormones at baseline 281, 

292 

progression of left ventricular dysfunction I14 (2003) 

prostaglandin and bradykinin on muscle hyperactivity in 1806 

QRS prolongation in D79 

reverse remodeling in D66 

ß1- and ß2-adrenoceptor polymorphisms in 1534 

ß-adrenergic blockade with metroprolol CR/XL 1300 

with ST-elevation myocardial infarction 1702 

standard haemodynamic measurements D29 


therapeutic strategies in I69 (2003) 

thoracatomy as alternative to transvenous implant 1063 

TIMP-1 levels and cardiovascular risk factors 1475, 1509 

tissue Doppler imaging in D10 

treatment of with preserved systolic function H61 

heart rate 

increased, and reduced heart-rate variability and subclinical 


reduction during exercise-induced myocardial ischaemia and 

stunning 579 

and symptomatic paroxysmal supraventricular tachycardia 

1277, 1310 

heart-rate variability 

and paroxysmal atrial fibrillation 1242 

reduced, associated with subclinical inflammation 359, 363 


1473, 1502 

heart septal defects: transcatheter closure of patent foramen 

ovale (PFO) 361, 424 

heart transplantation 

angiotensin II receptors predict transplant coronary artery 

disease 377 

cellular repopulation of myocardial infarction in 749 

cyclosporine reduction after mycophenolate mofetil and 

chronic renal 

dysfunction 1626 

and left ventricular assistance F81 



Subject index 

sympathetic reinnervation, exercise performance and effects 

of ß-adrenergic blockade 1726 

heme oxygenase-1 gene promoter polymorphism 39 

heme oxygenase therapies for cardiovascular diseases E24 

heparins: re-emergence of anticoagulation in coronary disease 

B2 

high density lipoprotein cholesterol and the cardiovascular 

system A19 

high density lipoprotein (HDL) 


statins on HDL-cholesterol C58 

high-risk plaques, terminology for 1077 

HIV infection: primary pulmonary hypertension in F35 

homocysteine in obstructive sleep apnoea 1281, 1325 

hydrochlorothiazide and glucose metabolism disturbances H31 

hyperaemia: fractional flow reserve and 723 

hyperaemic response in intermediate coronary stenoses 1970, 

2034 

hypercholesterolaemia 

and coronary heart disease risk in Japan A8 


non-high-density lipoprotein cholesterol as risk factor A43 

reducing low-density lipoprotein cholesterol A12 

simvastatin on 671 


hypertension 

ACE polymorphism and risk of heart failure 2143 

after successful repair of coarctation of the aorta 1853 


modern strategies in management of H23 

sleep apnoea and periodic limb movements in heart 

transplantation 260 


hypertriglyceridaemia, treating C28 

hypertrophic cardiomyopathy: abnormal Q waves for 

identification of 246 

hypertrophy 

in canine heart in AV-block and LBBB D61 

regulation of myocardial connexins during 1979 

ibutilide for cardioversion of atrial fibrillation 1274, 1318 

imaging 

by intravascular thermography 158 


immune system 

activation in severe heart failure F22 


1378, 1447 

impaired glucose tolerance, regulation of 1861, 1880 

implantable cardioverter-defibrillator 

atrial arrhythmias in Brugada syndrome 879 


effect of exercise training with 1120 




programmed ventricular stimulation in cardiac arrest 

survivors 623, 642 

questions in treatment of heart failure I39 (2003) 


and ventricular tachycardia or fibrillation I22 (2003) 

implantable loop-recorder 

in diagnosis and management of syncope 1257 

syncope, detection with 1116 

implantation technique for biventricular pacing D112 

IMPROVEMENT survey H43 

in-stent restenosis: soft plaque as predictor of 2026 

in vitro studies on candesartan H11 

incidence 

of cardiovascular disease 2183, 2212 

of heart failure 1614, I3 (2003) 

one-year mortality and hospitalization rates for heart failure 

283, 300 

xxxviii 

induced ischaemia during dobutamine stress echocardiography 

932 

infant nutrition: breastfeeding and cardiovascular mortality 778 

infarct-related artery: use of abciximab prior to angioplasty 

2125 

infarct reperfusion: changes in myocardial thickness and 

thickening 714, 794 

infection: biventricular pacing, complications of D117 

infective endocarditis: guidelines on prevention, diagnosis and 

treatment 267 

inflammation 

after percutaneous coronary intervention 1679 

C-reactive protein and apolipoprotein E polymorphism 

2109 

C-reactive protein concentrations during glucocorticoid 

therapy and recurrent atrial fibrillation 1089, 1100 

C-reactive protein elevation in coronary artery disease 401 

C-reactive protein levels determine nitric oxide 

bioavailability 1412 

cardiovascular risk and markers of oxidative stress in diabetes 

468 

depressive symptomatology in cardiovascular disease-free 

people 492 

and endothelial progenitor cells in unstable angina 999, 1003 

exercise reduces plasma levels of the chemokines 349 

and glycosylated haemoglobin A 1c 2120 


increased heart rate and reduced heart-rate variability 

associated with 359, 363 



markers on ischaemic heart disease 1049 

statins on peripheral artery disease 712, 742 

inflammatory markers and risk of coronary vascular disease C21 

inflammatory molecules in chronic heart failure F16 

infliximab in chronic heart failure I28 (2003) 

influenza vaccination in acute coronary syndromes 25 

insertable loop recorder on bradyarrhythmias with sleep apnoea 

1070 

insulin: hyperinsulinaemia following acute myocardial infarction 

1891 

insulin resistance and metabolic syndrome A37 

interleukin-6: pre-procedural plasma levels of and restenosis 

1029 

intermediate coronary stenoses: alpha-adrenergic receptor 

blockade and hyperaemic response 1970, 2034 

intermittent claudication 

assessment of endothelial damage 371 

and peripheral arterial disease C43 

interventional cardiology: drug-eluting stents 895, 902 

interventional strategy in unstable angina or non-ST-elevation 

myocardial infarction 1559, 1641 

interventional therapy in peripheral arterial disease C43 

intravascular ultrasound 

angiotensin II receptors predict coronary artery disease after 

heart transplantation 377 


soft plaque as predictor of in-stent restenosis 2026 

and thermography 158 

intraventricular conduction delay: echocardiographic 

assessment of D25 

ion channels: cardiomyopathy, molecular classification in 1772 

ischaemia 

changes in autonomic nervous system activity 1473, 1502 

detection of with deformation imaging and velocity imaging 

1477, 1517 

diabetes mellitus on long-term survival 629, 656 

exercise-induced, heart rate reduction during 579 

experimental models of heart failure F7 


1970, 2040 




safety and feasibility of high-dose dobutamine-atropine stress 


as trigger of sudden cardiac death D88 

validation of coronary flow reserve measurements 219 

ischaemic cardiomyopathy, stepwise approach in I102 (2003) 

ischaemic chest pain: assessment of endothelial damage 

371 

ischaemic heart disease 


gender and long-term survival 101, 129 

haemostatic/inflammatory markers on 1049 

metabolic manipulation in 634 

trimetazidine on 1765, 1814 

ischaemic time: primary angioplasty on acute myocardial 


isoprostane F2a -III on reflow after myocardial infarction 847 

isoprostanes in cardiovascular diseases 1675 

Japanese coronary heart disease risk A8 

Joint Task Force European Guidelines: reducing low-density 

lipoprotein cholesterol A12 

kidney disease: glomerular filtration rate 1998 

kidneys: standard vs double dose of N-acetylcysteine on contrast 

agent associated nephrotoxicity 188, 206 

Killip class: heart failure and left ventricular dysfunction 

1911 

lamin A/C gene in familial dilated cardiomyopathy 812, 885 

large arteries: AT 1-receptor blockade in H17 

lead selection for biventricular pacing D112 

left bundle branch block 

in canine heart D61 

and cardiopulmonary exercise testing D5 




extended indications for cardiac resynchronisation therapy 

D128 


of I97 (2003) 


therapy D106 

left ventricular dysfunction 


heart failure and 1911 

and myocardial performance index 2185, 2220 

tissue Doppler imaging in D10 

left ventricular function, trimetazidine on 1765, 1814 

left ventricular hypertrophy 

and AT1-receptor blockade H17 

relation of plasma homocysteine to 523 


left ventricular remodelling 


of I97 (2003) 

ProANP on 416 

relation of plasma homocysteine to 523 

left ventricular systolic dysfunction 1718 

left ventricular systolic function 1181, 1214 

treatment of heart failure H61 

leisure time: physical activity as a predictor for mortality 2183, 

2204 

leucocytes and incident coronary heart disease 1271, 1287 

LIFE study H37 

lifestyle 

alcohol intake and diet in 1153 

smoking and duration of life with and without cardiovascular 

disease 409 

lifetime risk of heart failure 1614 

lipid-lowering therapy 

in dyslipidaemia C28 

in management of acute coronary syndrome C49 

in peripheral arterial disease C43 


xxxix 

Subject index 

lipids 

disorders and metabolic syndrome A37 

obstructive sleep apnoea 709, 735 

profiles and glucose metabolism disturbances H31 

logistic regression in strategies for primary prevention of 

cardiovascular disease 457, 484 

long QT syndrome 

cardiac events with ß-blocking therapy in children with 1405 

and Torsade de pointes 2149 

long-term recording in CHF F99 

long-term survival after pacemaker implantation 88 

losartan, pharmacological aspects of H11 

low-density lipoprotein cholesterol 



low-density lipoprotein cholesterol, reducing A12 

low-density lipoprotein (LDL) 

and the cardiovascular system A19 

evolution of statin therapy A3 



receptor, and stroke 943 

statins on HDL-cholesterol C58 

treating dyslipidaemia in C28 

low molecular weight heparin 1667, 1688 

lung scintigraphy on abnormal left lung perfusion 1927 

magnetic resonance imaging 

aortic stiffness and diameter predict progressive dilatation in 

Marfan syndrome 1146 

for assessment of myocardial hibernation 815 

detection of coronary artery disease by 1657 

in evolution of aortic intramural haematoma 81 

high-dose dobutamine-atropine stress cardiovascular, safety 

and feasibility of 1183, 1230 

hypertension and aortic arch geometry after coarctation of 

the aorta repair 1853 


increased left ventricular mass in obese adolescents 987 

persistent diastolic dysfunction after reperfused acute 

myocardial infarction 1376, 1419 

visualization and quantification of peri-operative myocardial 


management 

of chronic angina I1 

and ACS I17 

patient differences related to in general practice and the 

hospital 1718 

mapping 


predicts recovery of left ventricular dysfunction 151 

transvenous cryoablation versus radiofrequency ablation 

2226 

mass spectroscopy: calcium-deficient hexagonal hydroxyapatite 

in aortic valves 514 

matrix metalloproteinase gene polymorphism in heart failure 

631, 688 

MCP-1 gene polymorphism with risk of coronary arteriosclerosis 

1438 

mechanical support in heart failure F81 

mechanistic studies of AT 1-receptor blockers H49 

medical technology: patient access to across Europe 611 

medical therapy for chronic heart failure I64 (2003) 

medical variables: predictors for psychopathology with 

congenital heart disease 1605 

Mercury I: reducing low-density lipoprotein cholesterol A12 

meta-analysis 

of acarbose and risk of myocardial infarction 10 

leucocyte count and coronary heart disease 1271, 1287 


1570 

of primary angioplasty in Denmark 540 

of stents versus balloon angioplasty 69 



Subject index 

tissue plasminogen activator antigen and coronary heart 

disease 252 

metabolic syndrome 

associated with advanced vascular damage 342 

cardiovascular risk factors and type 2 diabetes G3 

exercise reduces plasma levels of the chemokines 349 


and obstructive sleep apnoea 709, 735 

as risk factors A37 

metabolism 

chamber dyssynchrony and effects of cardiac 

resynchronisation I54 (2003) 

manipulation of in ischaemic heart disease 634 


relation of plasma homocysteine to left ventricular 

hypertrophy 523 

metalloproteinases: TIMP-1 levels and cardiovascular risk 

factors 1475, 1509 

metoprolol on coronary artery disease 537, 565 

mitral regurgitation: echocardiographic assessment of D25 

mitral stenosis, non-invasive assessment of 2073, 2086 

mitral valve 

commissurotomy, temporal trends in 701 

non-invasive assessment of 2073, 2086 

morbidity: chronic psycosocial stress on 867 

mortality 

chronic psycosocial stress on 867 

data monitoring experience in the MOXCON trial 1974 

decreasing, in heart failure 283, 300 

five-year outcome of acute myocardial infarction 1562, 1635 

following non-ST elevation acute coronary syndrome 2013 

hyperinsulinaemia following acute myocardial infarction 1891 

management in general practice and the hospital 1718 

medical and revascularisation therapy in the elderly with 

angina 1036 

physical activity as predictor for 2183, 2204 

prediction of cardiorespiratory fitness 1374, 1428 

QRS prolongation on the natural history of CHF D79 

risk factors of populations enrolled in clinical studies 1139 

rupture of descending thoracic aorta 694 

smoking with and without cardiovascular disease 409 

statins on peripheral artery disease 712, 742 

multi-centre study: stroke patients with atrial fibrillation 1670, 

1734 

multislice spiral computed tomography in detection of coronary 

stenosis 1043 

muscles: stimulation of in chronic heart failure 104, 136 

mustard repair: ventricular function and clinical condition after 

1264, 1863 

mycophenolate mofetil: reduction of cyclosporine 1626 


2134 

myocardial hibernation: imaging techniques 815 

myocardial infarction 

abnormal glucose tolerance in 1969, 1990 

biochemical markers in 1187 

cellular repopulation of 749 

changes in myocardial thickness and thickening during 714, 

794 

collateral circulation in the acute phase of ST-segmentelevation 

854 

in diabetes, long-term, cause-specific mortality after 926 

exercise versus recovery electrocardiography in predicting 

mortality in 558 


five-year outcome of patients with 1562, 1635 

flu vaccination in 25 

genetic risk and gene-environment interaction in 900, 970 

genotypes and haplotypes predisposing to 451, 459 

hyperinsulinaemia and long-term mortality following 1891 

isoprostane F 2a -III on reflow after 847 

left ventricular remodelling after 680 

xl 

and left ventricular systolic dysfunction 1911 

low activity genotype of catechol-O-methyltransferase and 

386 

low-risk patients with chest pain 329 

managing: reverse remodelling by drugs I44 (2003) 

natriuetic peptides in 1486 

oral direct thrombin inhibition for anticoagulation in B9 

peri-operative, visualization and quantification of 1279, 

1293 

persistent diastolic dysfunction after 1376, 1419 

prediction of cardiorespiratory fitness for cardiovascular 

events 1374, 1428 

risk factors of populations enrolled in clinical studies 1139 

risk of in type 2 diabetic patients 10 

sex, age and clinical presentation of 663 

ST segment elevation at 72 hours in 224 

statin administration before percutaneous coronary 


statins’ role in management of A32 

time-to-treatment by primary angioplasty 1001, 1009 

and toll-like receptor 4 variants 1378, 1447 

myocardial ischaemia 



eruthropoietin in 285 

therapeutic options for E2 

myocardial oxygen consumption and cardiac resynchronisation 

therapy D91 

myocardial performance index: comparison with conductance 

catheter measurements 2185, 2238 

myocardial perfusion: time-to-treatment by primary angioplasty 

1001, 1009 

myocardial perfusion SPECT 543 

myocardial repair, promise of 1483 

myocardial stunning 

heart rate reduction during exercise-induced 579 

persistent diastolic dysfunction 1376, 1419 

myocardial viability: direct mapping predicts the recovery of 

left ventricular dysfunction 151 

myocarditis: molecular classification in 1772 

myocardium 

increased left ventricular mass in obese adolescents 987 

molecular classification in 1772 

n-3 polyunsaturated fatty acids in chronic heart failure I28 

(2003) 

N-methylethanolamine on cardiac fibrosis and diastolic function 

1221 

N-terminal proatrial natriuretic peptide (Nt-proANP) 416 

N-terminal probrain natriuretic peptide 859 

natriuretic peptides 

exercise training reduces levels in chronic heart failure 1797 

in unstable coronary artery disease 1486 

natural history of mild and moderate aortic stenosis. 185, 199 

neointimal hyperplasia: sirolimus-eluting stents inhibiting in 

diabetic patients 99, 107 

nephrotoxicity: N-acetylcysteine to prevent 188, 206 

neurohormones at baseline, prognostic value of in heart failure 

281, 292 

neutral endopepidase inhibitors 


New York Heart Association (NYHA) functional class 1920 

niacin and high density lipoprotein A19 

nitric oxide 

C-reactive protein levels determine availability of 1412 


as predictor for survival with congenital heart defects 1651 


non-ST elevation acute coronary syndrome: mortality following 

2013 

non-ST elevation myocardial infarction 

and gender 1559, 1641 

mortality in 1471, 1494 



non-valvular atrial fibrillation 

new advances B20 


noninvasive imaging: atherothrombosis, consequences of 

1197 

nonsustained ventricular tachycardia 1093 

noradrenaline in systemic sclerosis F68 

norepinephrine: prognostic value of neurohormones in heart 


nurse case management in heart failure patients 1565, 1596 

obesity 

and coronary heart disease 121 

and increased left ventricular mass in adolescents 987 

and risk of cardiovascular disease 2183, 2212 

obstructive sleep apnoea 

in coronary artery disease 709, 728 

and prevalence of metabolic syndrome 709, 735 

occupational activity as predictor for total and cardiovascular 

disease mortality 2183, 2204 

oestrogen receptor alpha gene polymorphism 240 

off-pump coronary by grafting: quality of life after 765 

onset of Torsade de pointes in long QT syndrome 2149 

oral direct thrombin inhibition 

in coronary artery disease B9 

re-emergence of anticoagulation in coronary disease B2 

stroke prevention in atrial fibrillation B20 

oral glucose tolerance test 1861, 1880 

oral vitamin K antagonists 



outcome 

of Bad Oeynhausen experience D122 

neurohormones at baseline, prognostic value of in heart 


nitric oxide is a predictor for survival with congenital heart 

defects and pulmonary hypertension 1651 



oxidative stress and cardiovascular risk in diabetic men 468 

oxygen consumption: exercise training with implantable 

cardioverter-defibrillator 1120 

pacing/pacemakers 



detection of syncope 1116 



Interventricular and intraventricular dyssunchrony in heart 




technical considerations in implanting left ventricular pacing 

leads D43 

treatment of recurrent tilt-induced vasovagal syncope 1741 

paclitaxel: treatment of in-stent restenosis 898, 920 

paclitaxel-eluting coronary polylactide stent, assessment of 

1330 

paediatric arrhythmia: cardiac events with ß-blocking therapy 

1405 

paediatrics: increased left ventricular mass in obese adolescents 

987 

paroxysmal atrial tachyarrhythmias, suppression of 1371, 1395 

patent foramen ovale (PFO) 

risk of decompression illness 1014 

transcatheter closure of 361, 424 

patient access to medical technology across Europe 611 

percutaneous coronary intervention 


335 

creatine kinase-MS elevation after 313 

in diabetic patients 190 

in Europe 1992-2001 1208 

xli 

Subject index 

inflammation and restenosis after 1679 

long-term clopidogrel therapy after 720 


percutaneous transluminal angioplasty 

5A/6A polymorphism of the stromelysin-1 gene 335 

after acute myocardial infarction 2177, 2187 

effect of metoprolol 537, 565 

in Europe 1992-2001 1208 

practice and clinical outcomes in The Netherlands 1163 

perforation: biventricular pacing, complications of D117 

perfusion 

before and after cardiac resynchronisation therapy D91 

detection of coronary artery disease by MRI 1657 

perhexiline in ischaemic heart disease 634 

pericardial diseases: guidelines on diagnosis and management of 

587 

peripheral arterial disease 

and diabetes, picotamide on 1769, 1845 



statin therapy improves outcomes 712, 742 

peripheral atherosclerosis: assessment of endothelial damage 

371 

peripheral vascular disease: ramipril on 1, 17 

pharmacology: antiplatelet effects of clopidogrel 1898 

physical activity 

as predictor for total and cardiovascular disease mortality 

2183, 2204 

and risk of cardiovascular disease 2183, 2212 

picotamide: 2-year mortality in diabetics 1769, 1845 

plaque 

compexity, C-reactive protein elevation and 401 

intravascular thermography on 158 

plasma aldosterone: arterial stiffness in heart failure patients 

F30 

platelets 

clopidogrel and aspirin therapy on 454, 476 

effects of a loading dose of clopidogrel 1898 

function: high clopidogrel loading dose during coronary 

stenting 1903 

pleiotropic effects: statins for prevention of cerebrovascular 

disease C34 

policy on drug-eluting stents 895, 902 

polymers: assessment of paclitaxel-eluting coronary polylactide 

stent 1330 

polymorphism 

of COMT, and myocardial infarction in a hypertensive 

population 386 

genetic risk and gene-environment interaction in coronary 

artery spasm 900, 970 

of matrix metalloproteinase in heart failure 631, 688 

of RANTES G-403A gene 1438 

population-based studies: alcohol intake and markers of 


positron emission tomography 

on central nervous system processing in heart failure 952 

effects of ß-adrenergic blockade 1726 

on myocardial oxygen consumption and perfusion D91 

myocardial vasodilation, simvastatin on 671 

post-systolic motion: detecting induced ischaemia 932 

post-systolic thickening during acute transmural infarction 714, 

794 

pravastatin 

on coronary events 716, 771 

on myocardial vasodilation 671 

pre-participation screening in young competing athletes 

1749 


prediction 

exercise capacity of healthy men 978 

for psychopathology with operated congenital heart disease 

1605 



Subject index 

premature ventricular contraction and Torsade de pointes 

initiation 2149 

preserved left ventricular function: differences with preserved 

function 1181, 1214 

pressure-sensing guidewire on fractional flow reserve 723 

pressure-volume loops during cardiac resynchronisation therapy 

D35 

pressure-volume relations and cardiac resynchronisation 

therapy D35 

prevalence of heart failure 1614, I3 (2003) 

prevention 

of nephrotoxicity using N-acetylcysteine 188, 206 

therapeutic options for chronic myocardial ischaemia E2 

see also primary prevention; secondary prevention 

primary angioplasty 

collateral circulation in 854 

in Denmark 540 

glycoprotein 2b/3a inhibitor in 807, 837 

time-to-treatment in acute myocardial infarction 1001, 1009 

primary hyperparathyroidism and heart disease 1776 

primary percutaneous coronary angioplasty: use of abciximab 

2125 

primary percutaneous intervention: ITF-1697 on reperfusion 392 

primary prevention 

of cardiovascular disease 457, 484 

guidelines and management of risk in coronary heart disease 

C5 

statins for prevention of cerebrovascular disease C34 

primary pulmonary hypertension: right ventricular overload in 

F35 

pro-BNP: increased by angiography 759 

prognosis 

abnormal glucose tolerance in myocardial infarction 1969, 

1990 

B-type natriuretic peptide as predictor of outcome in aortic 

stenosis 1972, 2048 

clinical and morphologic findings in aortic intramural 

haematoma 81 

coronary artery disease and depression 3 

CPET in heart failure D1 

creatine kinase-MS elevation in acute coronary syndromes 313 

diabetes mellitus on long-term survival in congestive heart 


echocardiography and ß-type natriuretic peptide in acute 


glomerular filtration rate in non-ST-segment elevation acute 

coronary syndrome 1998 

heart failure and left ventricular systolic dysfunction 1911 

low-risk patients with chest pain and without myocardial 


mortality following non-ST elevation acute coronary 

syndrome 2013 

natriuetic peptides in unstable coronary artery disease 1486 

in non-ST-elevation acute coronary syndromes 859 

of populations enrolled in clinical studies 1139 


558 

pro-apoptotic serum activity in heart failure 1620 

quantifying the heart failure epidemic 1614 



ß-adrenergic blockade with metroprolol CR/XL in heart failure 

1300 

smoking cessation and coronary heart disease 2101 

of subjects with Brugada-type ECG pattern 810, 874 

troponin and mortality in acute coronary syndrome 2006 

Troponin T and measurement of ST-segment resolution at 60 

min 113 

of warfarin and aspirin in the long-term after acute 


prospective study: smoking cessation and coronary heart disease 

2101 

xlii 

prostaglandin on muscle hyperactivity in chronic heart failure 

1806 

protection devices for cardiac artery stenting 1550 

protective gene therapy for cardiovascular diseases E24 

pseudobipolar anodal stimulation: implantation tips and tricks 

D47 

psychological stress and social class and coronary heart disease 

56 

psychology 

medical predictors for psychopathology with congenital heart 

disease 1605 

women with coronary heart diseases and cardiac syndrome X 

1672, 1695 

psychopathology: predictors for with operated congenital heart 

disease 1605 

pulmonary arterial hypertension 2243 

pulmonary hypertension 

effects of sildenafil in 431 

evaluation of right ventricular performance F61 

nitric oxide is a predictor for survival 1651 

in systemic sclerosis F68 

pulmonary vein: adenosine on atrio-venous conduction 2155 

pulse pressure responder: standard haemodynamic 

measurements D29 

QRS duration in CHF D79 

quality of care: heart failure clinics and outpatient management 

1565, 1596 

quality of life 

beating heart against cardioplegic arrest studies 765 

medical and revascularisation therapy in the elderly with 

angina 1036 

trimetazidine on 1765, 1814 

quinidine 


suppression of paroxysmal atrial tachyarrhythmias 1371, 

1395 

RAAS and progression of left ventricular dysfunction to endstage 


radioisotopes in regional denervation after acute myocardial 


radionuclide angiocardiography for assessment of myocardial 


radionuclide imaging for assessment of myocardial hibernation 

815 

ramipril in peripheral arterial disease 1, 17 

randomisation: ITF-1697 on reperfusion 392 

randomized controlled trials: data monitoring experience in the 

MOXCON trial 1974 

ranolazine 

clinical experience of I13 

electrophysiological perspectives of I9 

in ischaemic heart disease 634 

RANTES G-403A gene polymorphism 1438 

rate control in persistent atrial fibrillation 1542 

re-admission to hospital, management programmes in reducing 

1570 

real-time 3D echocardiography: non-invasive assessment of 

mitral valve area 2073, 2086 

recanalization after acute myocardial infarction 2177, 2187 

regional contractility: ST-segment elevation at 72 hours after 


regional myocardial function: post-systolic motion to detect 

induced ischaemia 932 

registry: percutaneous coronary intervention in Europe 1992- 

2001 1208 

regression dilution bias in strategies for prevention of 

cardiovascular disease 457, 484 

remodelling 



by drugs in managing heart failure and sudden death I44 

(2003) 



left ventricular, after myocardial infarction 680 

of matrix metalloproteinase gene polymorphism in heart 


regulation of myocardial connexins 1979 


renal insufficiency: acetylcysteine for the prevention of 

nephropathy 188, 212 

renin: prognostic value of neurohormones in heart failure 281, 

292 

renin-angiotensin-aldosterone system in systemic sclerosis F68 

renin-angiotensin system 

AT1 receptor in H3 


reperfusion 

glycoprotein 2b/3a inhibitor in 807, 837 

isoprostane F2a -III on reflow after myocardial infarction 847 

reperfusion injury 

changes in myocardial thickness and thickening 714, 794 

in patients undergoing primary angioplasty 392 

rescreening of "healthy" relatives of patients with dilated 


research on uncommon aspects and novel markers in congestive 

heart failure F1 

resistance training reduces NT-proBNP levels in chronic heart 

failure 1797 

RESOLVD study H49 

respiratory fatigue in acute cardiogenic pulmonary edema 

F74 

restenosis 

5A/6A polymorphism of the stromelysin-1 gene and 335 

after percutaneous coronary intervention 1679 

assessment of biodegradable paclitaxel-eluting coronary 

polylactide stent 1330 

current PTCA practice and clinical outcomes in The 

Netherlands 1163 

and heme oxygenase-1 gene promoter microsatellite 


in-stent, fractional flow reserve in evaluation of 1970, 

2040 

in-stent, therapeutic implications of 1829 

in-stent, therapeutic implications of located at the stent edge 

1829 

in-stent, treatment of 898, 920 

plasma levels of C-reactive protein and interleukin-6 on 1029 

and sirolimus-eluting stents 99, 107 

ultrasound evaluation after sirolimus-eluting stent 

implantation 32 

restless leg syndrome 260 

resynchronisation 

implantation tips and tricks D47 

and standard haemodynamic measurements D29 


revascularization 

association of with low mortality in non-ST elevation actue 

coronary syndrome 1471, 1494 


2180, 2195 

in elderly patients with angina 1036 

natural history of myocardium awaiting 500 

severity of heart failure after fibrinolysis 1702 

reverse remodeling 

of the canine heart D61 


rheumatic heart disease 

amyloid deposition as a cause of atrial remodelling 

1185, 1237 

temporal trends in percutaneous mitral commissurotomy 701 

rhythm control in persistent atrial fibrillation 1542 

right bundle branch block: indications for cardiac 


right ventricular failure in systemic sclerosis F68 

right ventricular function: evaluation of F61 

xliii 

Subject index 

risk factors 

for coronary calcification in older subjects 48 

current PTCA practice and clinical outcomes in The 

Netherlands 1163 

evaluation of brachial artery flow-mediated vasodilation and 

C-reactive protein 1754 

genotypes and haplotypes predisposing to myocardial 


guidelines and management in coronary heart disease C5 

identifying patients at risk of coronary vascular disease 

C21 

impact of ramipril in patients with peripheral arterial disease 

1, 17 

increased heart rate and reduced heart-rate variability 

associated with subclinical inflammation 359, 363 

mortality following non-ST elevation acute coronary 

syndrome 2013 

oestrogen receptor alpha gene polymorphism in coronary 


of populations enrolled in clinical studies 1139 

prediction of cardiorespiratory fitness for cardiovascular 

events 1374, 1428 

risk models: haemostatic/inflammatory markers on IHD 

1049 

risk reduction: acarbose on myocardial infarction 10 

risk stratification 

of aortic stenosis by echocardiography 185, 199 

in non-ST-elevation acute coronary syndromes 859 

safety of high-dose dobutamine-atropine stress cardiovascular 

magnetic resonance 1183, 1230 

scintagraphy for assessment of myocardial hibernation 815 

SCOPE study H37 

SDF-1ß gene polymorphism with increased risk of coronary 

arteriosclerosis 1438 

secondary prevention 

guidelines and management of risk: in coronary heart disease 

C5 

managing heart failure and sudden death: reverse remodelling 

by drugs I44 (2003) 

overweight and obesity in coronary heart disease 121 

statins for prevention of cerebrovascular disease C34 

serum activity and apoptosis in heart failure 1620 

signalling pathways: regulation of myocardial connexins during 

hypertrophic remodelling 1979 

sildenafil: effect of in pulmonary hypertension 431 

silent ischaemia: relevance of symptoms versus objective 

evidence 543 

simvastatin 

antiplatelet effects of clopidogrel 1898 

on myocardial vasodilation 671 

single nucleotide polymorphism 

low-density lipoprotein receptor and risk of stroke 943 

and risk of myocardial infarction 1378, 1447 

sirolimus-eluting stents 

inhibit neointimal hyperplasia in diabetic patients 99, 107 

intravascular ultrasound evaluation after 32 

skeletal muscle biopsy in dilated cardiomyopathy F40 

sleep apnoea 

in CHF F99 

and heart transplantation 260 

plasma homocysteine in 1281, 1325 

severe bradyarrhythmias with 1070 

slow pathway ablation in atrioventricular nodal re-entrant 


smoking 

cessation and coronary heart disease 2101 

and duration of life with and without cardiovascular disease 

409 

social class and coronary heart disease 56 

social integration and coronary disease 56 

sodium current, late, inhibition of I3 

soft plaque as predictor of in-stent restenosis 2026 



Subject index 

sotalol 



spironolactone 


therapeutic options in patients with heart failure I105 

(2003) 

SPORTIF III: stroke prevention in atrial fibrillation B20 

ST-elevation myocardial infarction 

severity of and outcomes 1702 

use of abciximab prior to primary angioplasty 2125 

stable angina 



statins 

administration before percutaneous coronary intervention 

1822 

antiplatelet effects of clopidogrel 1898 

on HDL-cholesterol C58 



improving outcomes through therapy A28 

in management of acute coronary syndrome C49 

management of hypertension and dyslipidaemia G13 



on peripheral artery disease 712, 742 


for prevention of cerebrovascular disease C34 


reducing low-density lipoprotein cholesterol A12 

role in early management of acute coronary syndrome A32 

therapy, evolution of A3 

stem cells: cellular repopulation of myocardial infarction 749 

stent/stenting 


335 

versus balloon angioplasty in non-acute coronary artery 

disease 69 

biodegradable, long-term assessment of 1330 

drug-eluting, systematic review 895, 902 

endoluminal graft replacement for rupture of descending 

thoracic aorta 694 

five-year outcome of patients with myocardial infarction 

1562, 1635 


1970, 2040 

and heme oxygenase-1 gene promoter microsatellite 


percutaneous coronary intervention in diabetic patients 190 

plasma levels of C-reactive protein and interleukin-6 on 

restenosis 1029 

predictors of in-hospital mortality in acute myocardial 


statin administration before intervention 1822 

therapeutic implications of in-stent restenosis located at the 

stent edge 1829 

treatment of in-stent restenosis 898, 920 

ultrasound evaluation after implantation 32 

stimulation mode and standard haemodynamic measurements 

D29 

stimulation site and standard haemodynamic measurements D29 


strain rate mapping: detecting regional inducible ischaemia 

1477, 1517 

stress, psycosocial: on cardiovascular morbidity and mortality in 

middle-aged men 867 

stress testing 

high-dose dobutamine-atropine, safety and feasibility of 

1183, 1230 


558 

xliv 

stroke 

CagA-positive cytotoxic H. pylori strains in 64 

low-density lipoprotein receptor on 943 


modern strategies in hypertension management H23 

patients with atrial fibrillation have a worse prognosis than 

patients without 1670, 1734 

prevention and atrial fibrillation 

new advances B20 


statins for the prevention of cerebrovascular disease C34 

stromelysin-1 gene, polymorphism of and restenosis 335 

sub-threshold stimulation in variants of atrioventricular nodal 

re-entrant tachycardia 1249 

sudden death 

acute ischaemia as a trigger of D88 

cardiac events with ß-blocking therapy in children with long 

QT syndrome 1405 


supplementation in coronary heart disease of a-tocopherol and 

ß-carotene 1171 

supraventricular tachycardia: heart rate as predictor of 

successful treatment of 1277, 1310 

surgical technique: implantation of systems for cardiac 


survival 

abnormal glucose tolerance in myocardial infarction 1969, 1990 

analysis: findings from MADIT-II substudies I34 (2003) 

haemoglobin predicting in chronic heart failure 1021 

heart defect, outcome after surgical closure of 1057 




repair 1264, 1863 

sympathetic activition and paroxysmal atrial fibrillation 1242 

sympathetic nervous system 

and heart transplantation 1726 




sympathetic reinnervation and heart transplantation 1726 

symptomatic intracerebral haemorrhage with atrial fibrillation 

1670, 1734 

symptoms: CPET in heart failure D1 

syncope 

detection with implantable loop-recorder 1116 

guidelines on Management (Diagnosis and Treatment) of 2054 

use of implantable loop recorders in 1257 

in young competing athletes 1749 

syndrome X in women 1672, 1695 

systematic review 


of drug-eluting stents 895, 902 

systemic inflammation and alcohol intake 2075, 2092 

systemic sclerosis and right ventricular overload F68 

systolic function 

electrical stimulation during refractory period of heart failure 

626, 650 

gender and long-term survival of ischaemic heart disease 101, 129 

ProANP on 416 

tachycardia 

comparing transvenous cryothermal and radiofrequency 

ablation in 2232 

transvenous cryoablation versus radiofrequency ablation for 

2226 

tailored diet: obesity and heart failure F87 

technical issues in cardiac resynchronisation therapy I83 (2003) 

telemonitoring 

in CHF F99 

in heart failure management F91 

terminology for high-risk and vulnerable plaques 1077 

therapeutic sequence in heart failure I69 (2003) 



thermodilution: validation of coronary flow reserve 

measurements by 219 


three-dimensional confocal microscopy: cellular repopulation of 


three-dimensional echocardiography on non-invasive assessment 

of mitral valve area 2073, 2086 

thromboembolism: decision making in I88 (2003) 

thrombolytic therapy: sex, age and clinical presentation of 

acute coronary syndromes 663 

thrombosis: antiplatelet effect of clopidogrel and aspirin 

therapy 454, 476 

thromboxane A2 synthase: 2-year mortality in diabetics with 

peripheral arterial disease 1769, 1845 

tilt testing: cardiac pacing for treatment of vasovagal syncope 1741 

TIMI risk score 1998 

tirofiban 


in myocardial infarction evaluation 807, 837 

tissue Doppler echocardiography in congestive heart failure D10 

tissue Doppler imaging 

on asymptomatic myocardial abnormalities 1865, 1934 

detecting regional inducible ischaemia 1477, 1517 

tissue factor 

assessment of endothelial damage in atherosclerosic vascular 

disease 371 


tissue plasminogen activator antigen and coronary heart disease 

252 

TNF-a: immune activation in severe heart failure F22 

tolerability 

in hypertension management H23 

of ß-adrenergic blockade with metroprolol CR/XL 1300 


1378, 1447 

tomography 


risk factors for coronary calcification in older subjects 48 

Torsade de pointes 2149 

transcatheter closure of patent foramen ovale (PFO) 361, 424 

transoesophageal echocardiography 


impairment of 1836 

transplant coronary artery disease: cardiac angiotensin II 

receptors on 377 

transposition of the great arteries 1264, 1863 

transthoracic coronary Doppler ultrasound on coronary flow 

1867 

transvenous biventricular pacing, complications of D117 

treatment: options for chronic myocardial ischaemia E2 

tricuspid valve replacement: implantation of systems for cardiac 


trimetazidine 

improves left ventricular function and quality of life 1765, 

1814 

in ischaemic heart disease 634 

troponin 

and one-year mortality in acute coronary syndrome 2006 

role and importance in clinical cardiology 1187 

troponin T: measurement of ST-segment resolution at 60 min 113 

type-2 diabetes 

acarbose on risk of myocardial infarction 10 

and glucose metabolism disturbances H31 

treating dyslipidaemia in C28 

ultrasound: evaluation after sirolimus-eluting stent implantation 

32 

uncoupling protein 2 (UCP 2): cardiovascular risk and markers of 

oxidative stress 468 

unstable angina 

and gender 1559, 1641 

management of acute coronary syndrome C49 

natriuetic peptides in 1486 

xlv 

Subject index 

urinary albumin excretion: and hyperinsulinaemia 1891 

usual care in heart failure management F91 

vagal manoeuvres: heart rate and symptomatic paroxysmal 

supraventricular tachycardia 1277, 1310 

vagal mechanism and paroxysmal atrial fibrillation 1242 

valsartan 

CHARM in relation to other heart failure trials with ARBs H55 


VALUE study H37 

valve resistance, value and limitations of 787 

valvuloplasty temporal trends in 701 

variants of atrioventricular nodal re-entrant tachycardia 1249 

vasodilator: fractional flow reserve and complex coronary 

pathologic conditions 723 

vasospastic angina: genetic risk and gene-environment 

interaction in 900, 970 

vasovagal syncope, cardiac pacing for 1741 

VELVET study on AT1-receptor blockade H17 

ventilation: prostaglandin and bradykinin on muscle 

hyperactivity 1806 

ventricle: myocardial performance index 2185, 2238 

ventricular assistance devices in heart failure F81 

ventricular dilatation in myocardial infarction 224 

ventricular fibrillation 

and sudden cardiac death I22 (2003) 


ventricular function 

chamber dyssynchrony I54 (2003) 

heart rate reduction during exercise-induced myocardial 

ischaemia 579 

ventricular septal defects: outcome after surgical closure of 

1057 

ventricular tachycardia 

incessant, stepwise approach in I102 (2003) 

nonsustained 1093 

outcome of radiofrequency catheter ablation 1127 

and sudden cardiac death I22 (2003) 


verapamil 

heart rate and symptomatic paroxysmal supraventricular 

tachycardia 1277, 1310 


suppression of paroxysmal atrial tachyarrhythmias 1371, 

1395 

vessel fibrosis in heart failure patients F30 

viability: sequential changes in myocardial thickness and 

thickening 714, 794 

visceral fat: exercise reduces plasma levels of the chemokines 

349 

vitamin K antagonists: re-emergence of anticoagulation in 

coronary disease B2 

von Willebrand factor: assessment of endothelial damage 371 

vulnerable plaques, terminology for 1077 

wall stress in ventricular remodelling I54 (2003) 

warfarin: and aspirin in the long-term after acute myocardial 


Western medicine and coronary heart disease risk in Japan A8 

white blood cells: C-reactive protein and apolipoprotein E 


wine, and systemic markers of inflammation 2075, 2092 

women 

age and clinical presentation of acute coronary syndromes 663 

psychosocial differences between coronary heart diseases and 

cardiac syndrome X 1672, 1695 

see also gender 

X-ray angiocardiography for assessment of myocardial 


X-ray computed tomography for assessment of myocardial 


ximelagatran 

for anticoagulation in coronary artery disease B9

Comprising Volume 25 (2004) - European Heart Journal

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?